

Capacity Assessment and Recommendations for a National Cervical Cancer Screening Program in the Republic of Moldova

> Dr Philip Davies Dr Diana Valuta

Chişinău, February 2014

#### **Author Affiliations:**

Philip Davies, Director General, European Cervical Cancer Association, Belgium Diana Valuta, Gynae-Oncologist & Cervical Screening Coordinator, Institute of Oncology, Republic of Moldova Acknowledgements:

# This document represents the work of many organisations and people. The authors are particularly grateful for the contributions of Natalia Cojohari, Programme Analyst, United Nations Population Fund, Republic of Moldova and Irena Digol, Center for Reproductive Health and Medical Genetics, Republic of Moldova. In addition, the authors would like to express their sincere thanks to the people listed below who have participated in various aspects of this project:

• Parliament of the Republic of Moldova

- Liliana Palihovici, Deputy Speaker of the Parliament
  Valentina Stratan, Member of Parliament
- Ministry of Health of the Republic of Moldova
- Andrei Usatîi, Minister of Health
- Mihai Ciocanu, Vice Minister of Health
- Octavian Grama, Vice Minister of Health
- Rodica Scutelnic, Head, Dept. Emergency & Hospital Care
- Tatiana Zatîc, Head, Dept. of Primary Medical Care
- Carolina Cerniciuc, Head, Dept. of Public Health
- Eugenia Berzan, Head, Ext. Relations & EU Integration
- Galina Morari, Deputy Chief, Emergency & Hospital Care
- Luminița Avornic, Deputy Chief, Primary Medical Care
- Aliona Andronatii, Senior Consultant, Emergency & Hospital Care
- Veronica Ciobanu, MoH Oncology Specialist Committee
- National Health Insurance Company
- Mircea Buga, Director General
- Iurie Osoianu, Deputy Director
- Costel Şura, Head, Dept. of Information Systems
- Cornelia Nistor, Specialist Coordinator
- National Center for Health Management
- Petru Crudu, Deputy Director
- National Center for Public Health
- Tabuncic Nelea, Head, Dept. NCD Control
- State University of Medicine & Pharmacy "Nicolae Testemiţeanu"
- Olga Cerneţchi, Deputy Rector, Chief, Dept. of OB/GYN
- Uliana Tabuică, OB/GYN, Dept. OB/GYN
- Raisa Rotaru, OB/GYN, Gynaecology Clinic
- National College of Medicine & Pharmacy
- Ala Manolache, Director
- Institute of Oncology
- Victor Cernat, Director
- Jana Pungă, Deputy Director
- Dumitru Sofroni, Scientific Coordinator, Gyne Cytology
- Aliona Nicorici, Cytology Coordinator
- Institute of Mother and Child
- Ştefan Gaţcan, Member, Director; Member, MoH OB/GYN Specialist Committee
- Center for Reproductive Health & Medical Genetics
   Mihail Strătilă, Director; Member, MoH OB/GYN Specialist Committee
- Center for Continuous Training for Middle Level Health Workers
- Vera Loghin, Director
- Republican Clinical Hospital
- Svetlana Toderas, Researcher, Health Serv. Management, • Republican Diagnostic Centre
- Tatiana Cuzneţova, Chief, Cytology Service
- Territorial Health Administration "Centru"
- Olga Caras, Chief, Cytology Service,
- District Hospital, Cahul
- Botosan Gheorghe, Vice-Director, AMSA
- Constantin Cojas, Chief, Cytology Service
- District Hospital, Călărași
- Silvia Bobescu, Director

- District Hospital, Căuşeni
- Vasile Godoroja, Vice-Director Medical - Anastasia Ceban, Chief Cytology Service,
- District Hospital, Edinet
- Anatol Guţu, Director
- Valentina Colosova, Chief, Cytology Service
- District Hospital, Ialoveni
- Lidia Hanganu, Director
- District Hospital, Orhei
- Andrei Stratulat, Vice-Director Medical
- District Hospital, Ungheni
- Lidia Crăciun, Director
- Valentina Mamaliga, Chief, Cytology Service
- Municipal Clinical Hospital No. 1
- Iurie Dondiuc, Deputy Director; Member, MoH OB/GYN Specialist Committee
- Municipal Hospital, Bălți
  - Larisa Lungu, Chief, Cytology Service
- Tamara Alexandriuc, OB/GYN
- Carolina Frumusachi, OB/GYN, Perinatal Center
- Angela Nica, OB/GYN, Family Medical Center
- Municipal Hospital, Soroca
- Vera Pogorevici, Position, Cytology Service
- Women's Health Center "Dalila", Chisinau
- Vera Melenciuc, Position
- Family Medical Center, Cimişlia - Ludmila Capcelea, Director
- Svetlana Moroz, OB/GYN
- Family Medical Center, Comrat
- Svetlana Mavroghi, OB/GYNFamily Medical Center, Criuleni
- Alex lacub-Culava, OB/GYN
- Women's Health Center "Ana", Drochia - Svetlana Nicov, Director
- Family Medical Center, Edineţ • Tatiana Guţan, OB/GYN
- Family Medical Center, Făleşti - Ion Ionesii, Director
- Family Medical Center, Hînceşti - Vera Munteanu, Director
- Family Medical Center, Ocniţa - Cornelia Cozma, OB/GYN
- Family Medical Center, Străşeni
- Andrei laţişin, Director
  Family Medical Center, Ştefan Vodă
- Mariana Haret, Director
  Family Medical Center, Ungheni
- Lilia Scurtu, Director
- WHO, Republic of Moldova - Elena Boleea
- UNFPA Country Office for the Republic of Moldova - Ian McFarlane, Country Director
  - Boris Gîlcă, Assistant Country Representative
- Reproductive Health Training Center of the Republic of Moldova
- Rodica Comendant, Director
- Family Planning Association of Moldova
- Elena Sajina, Director

# Table of Contents:

1. Introduction	4
2. Methods	
3. Cancer Screening	
3.1 Principles of cancer screening	
3.2 Opportunistic vs organized screening	7
4. Cervical Cancer	
4.1 Background	8
4.2 Cervical screening	
4.3 HPV vaccination	
5. Analysis of the Current Situation in the Republic of Moldova	
5.1 Cervical cancer in RM	
5.2 Development strategies	10
5.2.1 National Reproductive Health Strategy 2006-2015	
5.2.2 National Program Against Oncological Diseases 2008-2012	
5.2.3 National Strategy for Prevention and Control of NCDs 2012-2020	
5.4 Estimated cervical screening population and service requirements	
5.5 Provision of cervical screening services	
5.5.1 Facilities for cervical screening	
5.5.2 PHC staff availability	
5.5.3 PHC staff training	
5.5.4 PHC staff certification for cervical screening	
5.5.5 Clinical guidelines and SOPs for cervical screening procedures conducted in PHC	15
5.5.6 Performance indicators, standards and CQI for cervical screening in PHC	
5.6 Cervical cytology (Pap test) screening and diagnosis	
5.6.1 Cervical cytology laboratories	
5.6.2 Cervical cytology laboratory staff availability	
5.6.3 Cervical cytology laboratory staff training	
5.6.4 Certification for cervical cytology screening 5.6.5 Laboratory guidelines and SOPs for cervical cytology screening	
5.6.6 Performance indicators, standards and CQI for cervical cytology screening	
5.7 Colposcopy for the follow-up of abnormal Pap tests and the treatment of CIN	10
5.7.1 Colposcopy clinics and staff	16
5.7.2 Colposcopy training and certification	
5.7.3 Clinical guidelines and SOPs for colposcopy	16
5.7.4 Performance indicators, standards and CQI for cervical screening in PHC	16
5.7.5 Health insurance coverage for colposcopy	16
5.8 Treatment of cervical cancer	
5.9 Quality assurance and CQI	
5.10 Cervical screening registry	
5.11 Cancer registry	
5.12 Private sector provision of health services	
6. Assessment of Current Capacities in the Republic of Moldova	
6.1 Provision of cervical screening services 6.2 Cervical cytology screening and diagnosis	
6.3 Colposcopy and the follow-up of women having abnormal screening results	
6.4 Treatment of cervical cancer	
6.5 Summary of capacity assessment findings	21
7. Recommendations for Implementing an Organised Cervical Screening Program	
7.1 Support for the implementation of a cervical screening program	
7.2 Cervical screening program administration	23
7.2.1 The screening coordination office	
7.2.2 Screening coordination office staff	
7.2.3 Advisory Committee	
7.2.4 Screening registry	
7.3 Primary health care	
7.3.1 PHC staff numbers	
7.3.2 PHC staff training and certification	
7.3.3 Outreach training for PHC staff 7.3.4 Regulatory changes	
7.3.5 Evidence-based clinical guidelines and standard operating procedures for PHC	
7.3.6 Facility and equipment specifications	

	7.4 Cervical cytology screening	
	7.4.1 Cervical cytology laboratory and staff numbers	
	7.4.2 Training and certification for cervical cytology screening	
	7.4.3 Designating cervical cytology screening as a distinct laboratory specialty	. 30
	7.4.4 Evidence-based laboratory guidelines and standard operating procedures	. 30
	7.4.5 Laboratory facility and equipment specifications	
	7.5 Colposcopy	
	7.5.1 Colposcopy clinic and staff numbers	
	7.5.2 Colposcopy training and certification	
	7.5.3 Designating colposcopy as a distinct medical specialty	
	7.5.4 Evidence-based clinical guidelines and standard operating procedures	
	7.5.5 Colposcopy facility and equipment specifications	
	7.6 Evidence-based performance indicators and standards	
	7.7 New technologies for cervical screening	
	7.7.1 The Pap Test	
	7.7.2 Liquid-Based Cytology (LBC)	
	7.7.3 HPV Testing	
	7.7.4 Economic considerations for the new technologies	
Q	Actions for Implementing an Organised Cervical Screening Program	
0.	8.1 Establish the Cervical Screening Coordination office	
	8.2 Establish relationships for training exchange programs	
	8.3 Initiate training exchange visits for SCO core staff 8.4 Establish the National Advisory Committee	. 30
	8.5 Maintain the involvement of the stakeholder group	
	8.6 Prepare & publish policy documents	
	8.7 Implement the cervical screening registry	
	8.8 Increase PHC capacity for cervical screening	
	8.9 Increase cervical cytology & cytopathology capacity	
	8.10 Increase colposcopy capacity	
_	8.11 Implementation actions Gantt chart	
	ferences:	62
Ap	pendicies:	
Ap	pendix 1: Legislation & orders affecting cervical screening	. 42
	pendix 2: Guidelines & protocols affecting cervical screening	
	pendix 3: Female population at 1 January 2011 & projected cervical screening requirement	
	pendix 4: Health facility staffing levels in 2011 (% of required staff levels)	
	pendix 5: Estimate eligible number vs. reported number of women screened/year	
	pendix 6: Cervical cytology laboratory staffing & results	
	pendix 7: Services & equipment for follow-up of abnormal Pap tests & cervical surgery	
	pendix 8: Screening registry data requirements and flows	
	pendix 9: SCO – Key staff positions, responsibilities & qualifications	
Ap	pendix 10: Minimum data reporting requirements	. 60
Ap	pendix 11: Performance indicators for cervical screening <sup>19</sup>	. 61
Та	bles:	
Та	ole 1: Harms inherent in breast & cervical screening programs	6
	ble 2: Fundamental elements of a cancer screening program	
	ble 3: Classification systems used for cervical cytology	
	ble 4: Summary of current recommendations with supporting legislation, orders & guidelines	
	ble 5: Structure of PHC services in RM	
	ole 6: Working practice recommendations for cervical cytology screening laboratories <sup>19</sup>	
Та	ole 7: Laboratories processing Pap tests	. 19
Та	ole 8: № of cytopathologists and cytotechnicians	. 19
Та	ole 9: Proportions of Pap test results reported during 2012	. 20
	ole 10: Colposcopy services and equipment	
	ble 11: Screening Coordination Office activities	
	ble 13: Educational modules for PHC staff	
	ble 14: Cervical screening clinical guidelines and SOPs relevant to PHC	
	ble 15: Estimated number of cytotechnicians & laboratories by level of population coverage	
	ble 16: Cervical cytology, cytopathology and histopathology laboratory guidelines and SOPs	
	ble 17: BSCCP Colposcopy Recommendations	
Та	ble 18 Estimated colposcopy clinic and staff requirements	
	ole 19: Colposcopy clinical guidelines and SOPs	

## Figures:

Figure 1: Cervical cancer cases by age group, 2011	10
Figure 2: Geographical distribution of operational cervical cytology laboratories in RM	
Figure 3: Proportions of Pap test results reported during 2012	20
Figure 4: Organisational structure of the cervical screening program	24
Figure 5: Screening Coordination Office staff organogram	25
Abbreviations:	

ADDIEV	
AMF	Asociației Medicilor de Familie / Association of Family Physicians
AMT	Asociația Medicală Teritorială / Territorial Medical Association
CBE	Clinical Breast Examination
CDR	Centrul Diagnostic Republican / Republican Diagnostic Centre
CIN	Cervical Intraepithelial Neoplasia
CME	Continuing Medical Education
CMF	Centrul Medicilor de Familie / Family Medicine Center
CNAM	Compania Naționala de Asigurări în Medicină / National Health Insurance Company
CNMF	Colegiul Național de Medicină și Farmacie / National College of Medicine and Pharmacy
CNMS	Centrul Național de Management în Sănătate / National Center for Health Management
CNSP	Centrul Național de Sănătate Publică / National Centre for Public Health
CNSRGM	Centrul Național de Sănătate a Reproducerii și Genetică Medicală / National Centre for Reproductive Health & Medical Genetics
CQI	Continuous Quality Improvement
CS	Centrul de Sănătate / Health Centre
ECCA	European Cervical Cancer Association / Asociația Europeană pentru Prevenirea Cancerul de Col Uterin
FIGO	International Federation of Obstetrics and Gynaecology
HPV	Human Papillomavirus / Virusul Papiloma Uman
IARC	International Agency for Research on Cancer / Agenția Internațională de Studiere a Cancerului
10	Institutului Oncologic / Oncology Institute
MS	Ministerului Sănătății / Ministry of Health
мно	Ordinul Ministerului Sănătății / Ministry of Health Order
OMF	Oficiul Medicilor de Familie / Family Physician Office
OS	Oficiu de Sănătate / Health Office
РНС	Primary Health Care
RM	Republica Moldova / Republic of Moldova
SCCSM	Societății "Combaterea Cancerului" din Moldova / Cancer Society of Moldova
SŞO	Societății Științifico-practice a Oncologilor din Republica Moldova / Scientific Society of Oncologists in Moldova
UNFPA	Fondul Natiunilor Unite pentru Populatie / United Nations Fund for Population Development
USMF	Universității de Stat de Medicină și Farmacie "Nicolae Testemițeanu"
WHO	Organizația Mondiala a Sănătății / World Health Organisation

## 1. Introduction

This study was undertaken to analyse the current situation with cervical cancer prevention in the Republic of Moldova (RM) and prepare recommendations for the implementation of a national cervical cancer screening program in the country.

The implementation of new health programs is challenging because health systems are complex adaptive networks composed of multiple interconnected components and with each component having multiple stakeholders. As the cooperation of these stakeholders will be essential to delivering the new program, the implementation process must do more than simply account for the medical or scientific aspects and instead use a holistic approach that accounts for the interests, motivations and alliances of all these stakeholders, and actively involves them in all aspects of the project.<sup>1,2,3</sup>

The implementation of cancer screening programs is particularly challenging because they require the coordinated interaction of multiple health services. Further, the optimal structure for these programs requires the screening tests to be delivered through facilities that are accessible and familiar to the screening population, with subsequent referral to secondary or tertiary care based on the screening test results. In RM, this means that screening should be delivered through the primary health care (PHC) facilities that constitute the largest health network in the country. Therefore, the number of stakeholders involved is very large and complex, as is the range of interests, motivations and alliances that must be accounted for. However, failure to account for this complexity will greatly reduce the chances of achieving the broad base of support that is required for the successful implementation and operation of the screening program.

Of direct relevance to the introduction of a complex health program, Atun and colleagues<sup>4</sup> evaluated primary health care reform in Bosnia and Herzegovina and identified a number of elements that enhanced the adoption and diffusion of these reforms:

- Regular interaction and communication between the innovators and adopters,
- Characterising the interests of the adopters and aligning program benefits with their interests,
- Characterising the interests of the public and aligning program benefits with their interests,
- Ensuring adopters fully understand the benefits that will accrue to all stakeholders,
- Allowing scope for reforms to be adapted to the local context (this was described as "critical" to the diffusion of reforms as it improved adopter ownership and reduced resistance.

These elements directly address the social and political dimensions of the health system by ensuring all stakeholders are fully involved in the design, planning and implementation of the project so:

- The stakeholders' collective knowledge of the realities of health service delivery in the country are fully accounted for so the new program as well as the implementation process are properly adapted to the local context,
- The stakeholders who must be involved in the implementation and operation of the new program have ownership and an interest in its success,
- Local champions can be identified and provide with support to advocate for proper resourcing of program implementation and operation.

Following this approach, the key steps undertaken in this project were:

- A systematic review of the literature relating to cervical cancer prevention in RM,
- A review of the laws, regulations, national strategy documents, clinical guidelines and protocols relating to the implementation or operation of a cervical screening program,
- Identification and recruitment of all stakeholders with a role to play in the design, planning, implementation or operation of the cervical screening program, and then work with thesm to:
  - Collect and analyse data about the organisation and capacity of all required services,
  - Estimate the health service capacities needed to operate a national cervical screening program,
  - Prepare a 5-year plan to develop the capacity of the required services.

# 2. Methods

A systematic review of the literature was conducted to identify all published data on the current status of cervical cancer and its prevention in RM. Given the limited amount of data, broad search terms were used ('cervical cancer, Moldova', 'cancer screening, Moldova' and 'gynecol\* oncology, Moldova' in English, Romanian and Russian) to search MEDLINE, the Cochrane Collection and Google. The electronic search was complemented by a manual review of relevant journals: Info-Med; Medical Courier; Bulletin of Perinatology, Public Health, Economics and Management in Medicine; Scientific Annals of the State University of Medicine and Pharmacy "N. Testemitanu"; Bulletin of the Academy of Sciences; Medical Sciences; Akademos. In addition to the literature review, the following sources were consulted for relevant data: the Statistical Yearbook of the Republic of Moldova; the National Center for Health Management; the World Health Organization; the WHO/ICO HPV Information Centre. This process identified 321 articles and reports of potential interest. The abstracts/ introductions/tables of contents for all were evaluated for relevance and 42 were selected for detailed review with relevant data extracted and summarised in this report.

All national strategy documents relating to the development of the health sector were obtained and evaluated to ensure the implementation of a national cervical screening program is consistent with government policy and identify opportunities for coordinating screening program implementation with other objectives to increase benefits for the overall health system.

An extensive analysis was undertaken to identify all organisations and people with a role to play in the design, planning, implementation or operation of the cervical screening program. Individual meetings were held with all stakehoders to introduce the project and obtain their recommendations for the design or implementation of the program, which were used to revise the project proposal. Subesquently, all stakeholders were invited to the 1st Stakeholder Meeting that was held in the Ministry of Health (MoH) on 23 March 2012 to present the revised project proposal, outline the steps that would be required and obtain further feedback within this group setting to refine the process.

Primary data on relevant health services were collected using 2 questionnaires:

- The Situation Analysis (SA): used to collect information about factors (policies, legislation, guidelines, recommendations, etc.) that will influence the delivery of these health services,
- The Capacity Assessment (CA): used to collect quantitative data on staff, facilities and equipment for these health services.

The questionnaires were distributed to all stakeholders, data were collected from June to November 2012, and data triangulation (stakeholder-stakeholder and stakeholder-literature) was used to identify discrepancies for further investigation.

The 2nd Stakeholder Meeting was held in the MoH on 11 December 2012 to review the results of the SA/CA and resolve inconsistencies or gaps in the dataset, with further work undertaken from January to November 2013 to complete and verify the data set. During this period, 2 people were selected from among the stakeholders to participate in training exchanges with the Irish organised cervical screening program 'CervicalCheck' to develop their knowledge of a) the organisation and management of an organised cervical screening program, and b) the organisation and management of colposcopy services within an organised cervical screening program.

A draft report containing the data summaries and preliminary analyses was prepared and circulated to all stakeholders at the beginning of November 2013 and the 3rd Stakeholder Meeting was held in the MoH on 21 November 2013. At this meeting, the stakeholders collectively reviewed and confirmed the outcomes of the SA/CA, and then divided into groups focused on key elements of the cervical screening program (administration; data collection and analysis; primary health care; pathology and colposcopy) to define the elements of a capacity building program to strengthen these services. The recommendations of the stakeholders are presented in Section 7 and the actions required to achieve them are presented in Section 8.

## 3. Cancer Screening

## 3.1 Principles of cancer screening

The objective of cancer screening is to identify the people within an asymptomatic target population who have pre-cancerous lesions that can be removed to prevent the cancers from developing or early stage cancers so their treatment can be started earlier to reduce morbidity and mortality. Therefore, cancer screening is a complex multistep process that includes:

- Identification and characterisation of the screening population,
- Education and promotion among the screening population to raise awareness about the benefits of screening and increase motivation to participate,
- Recruitment to screening,
- Counselling each individual and undertaking the screening test,
- Processing of the screening test,
- Using the screening test result together with the individual's clinical profile and personal history to assess the individual's risk of having a precancerous lesion or cancer,
- Based on the risk assessment, planning of subsequent care:
- Routine screening recall,
- Intensive surveillance,
- Referral to follow-up.
- If referred for follow-up, re-assessment of the individual's risk based on the follow-up results together with the screening test results, clinical profile and personal history to plan subsequent care:
  - Intense surveillance,
  - Referral for local treatment,
  - Referral for cancer treatment.

When considering the implementation of cancer screening programs, a common error is to focus too much on the screening test while neglecting the other parts of the screening process. However, screening programs will only provide substantial reductions in cancer incidence and/or mortality if a large proportion ( $\geq$ 75%) of the target population is screened, all the required services are of high quality and all of the services are efficiently coordinated.<sup>5,6</sup> Until these 3 criteria are achieved, the choice of screening test is largely irrelevant.

While cancer screening programs can provide substantial benefits, it is essential to recognise they can also produce a wide range of harms for the people being screened.<sup>7</sup> These harms are rare in wellorganised programs but screening is applied to populations so the absolute number of people affected can still be very large. The harms inherent in breast and cervical screening programs are summarised in Table 1 below.

Tab	le 1: Harms inherent in breast & cervical screening programs
1	False negative screening test results that provide false reassurance and lead to delays in diagnosis and the
	initiation of treatment
2	False positive screening test results leading to unnecessary stress, anxiety and invasive diagnostic procedures
	that carry a high risk of complications
3	Over-diagnosis through the identification of disease with no malignant potential or that would not become
	clinically relevant during the individual's lifetime
4	Over-treatment through the treatment of disease with no malignant potential or that would not become
	clinically relevant during the individual's lifetime
5	Substantial unnecessary costs arising from all of the above, which take resources away from services that could
	otherwise provide greater benefits for the population
6	Adverse pregnancy complications such as premature membrane rupture and premature delivery in women who
	have been treated for cervical epithelial neoplasia (CIN)
7	Radiation-induced carcinogenesis following mammography, particularly in situations where old and/or poorly
	maintained mammography machines are used

#### 3.2 Opportunistic vs organized screening

#### 3.2.1 Opportunistic screening

Opportunistic screening occurs when people are screened at their own request or while attending a doctor for other reasons, but there is no system in place to recruit people, monitor their attendance and follow-up, and ensure all the component services are of the highest possible quality.

Opportunistic screening can produce substantial disease reductions but these are seen only in highresource countries where a large proportion of the target population regularly interacts with the health system, there are established mechanisms for patient referral and follow-up, and the health services are all of high quality. However, opportunistic screening has been shown to screen women from higher socioeconomic groups too frequently although they are at lower risk of developing cancer while under-screening women from lower socioeconomic groups, minorities, etc. who are at higher risk. This is important because every screening test has an optimal screening age-range and interval that has been set to maximise the benefits and minimise the harms. Therefore, screening too frequently provides little additional protection but does increase the harms, while under-screening obviously provides less protection. As a result, opportunistic screening produces sub-optimal disease reductions, perpetuates or increases health inequalities and wastes health care resources.

## 3.2.2 Organised screening

In contrast to opportunistic screening, organised screening programs are specifically designed to maximise the benefits while minimising the harms for the population being screened. The principal element of an organised screening program is a central administration with the budget and authority to ensure:

- High and equitable coverage of the target population,
- Adherence to the recommended screening age-range and interval,
- Optimal quality and coordination of all the services involved in the screening program from recruitment to the follow-up and treatment of people having a positive screening test result.

As a result, organised cancer screening programs provide the optimal balance between the benefits and harms, ensure the benefits are equitably delivered across all social strata and deliver the most cost-effective disease reductions. For these reasons, the European Guidelines for Quality Assurance in Cervical Screening (European Guidelines) state that cervical screening should only be provided through organised programs. The fundamental elements of an organised cancer-screening program have been defined and are summarised in Table 2 below.5'6

Tabl	e 2: Fundamental elements of a cancer screening program									
1	A stable budget sufficient for the on-going costs of all of the services required to deliver the program									
2	A central administration with responsibility for screening policy & for coordinating of all elements in the									
	screening process including recruitment, recall, follow-up, monitoring & continuous quality improvement (CQI)									
3	Access to a current database of the target population for recruitment, monitoring & CQI									
4	A central screening registry or linked registries to record cervical cytology, colposcopy and histology that can be									
	used for call, recall, tracking of screen positives & CQI									
5	Access to a cancer registry for CQI & program audit									
6	Evidence-based training standards, clinical guidelines & performance indicators									
7	An comprehensive CQI policy covering the entire screening process from initial recruitment to the follow-up &									
	management of people with disease									
8	Education programs for the general public & for healthcare professionals									
9	Mechanisms to identify & recruit disadvantaged groups within the target population									
	These elements are all essential to the effective operation of cancer screening programs. Therefore,									

These elements are all essential to the effective operation of cancer screening programs. Therefore, the suboptimal performance of any one or more of them will reduce both the effectiveness and the efficiency of the program, even to the point where it has no measurable effect on cancer rates but still consumes substantial resources and produces a range of harms.

## 4. Cervical Cancer

## 4.1 Background

Globally, cervical cancer is the 3rd most common cancer among women with more than 530,000 new cases and 275 000 deaths every year.<sup>8</sup> Most cases occur in low and middle-income countries where there are no cervical cancer prevention programs. In Europe, about 60,000 women develop and 30,000 women die from cervical cancer every year. Eastern Europe and the Caucasus have substantially higher rates of cervical cancer than Western Europe and this is primarily due to the nationally organised screening programs or extensive opportunistic screening that is common in Western Europe.<sup>9</sup> Cervical cancer affects younger women than other adult onset cancers with the majority of cases occurring between 35-60 years of age. This is a time when the majority of women are working, caring for their families or doing both so the social impact of cervical cancer is greatly increased because it removes mothers from their families and workers from the economy.

Cervical cancer is caused by any one of  $\approx$ 15 carcinogenic (or 'high-risk') types of the Human papillomavirus (HPV).<sup>10</sup> HPV is a very common sexually transmitted virus and  $\leq$ 80% of adults will have had an HPV infection at some time in their lives. Most infections occur in young people during their first few years of sexual activity with the incidence and prevalence declining in older age groups.<sup>11-14</sup> Approximately 90% of new cervical HPV infections are cleared naturally by the immune system without any problems and it is only persistent infections that increase the risk of cervical cancer.<sup>15-17</sup>

Both transient and persistent HPV infections can lead to the development of dysplastic *pre-invasive* lesions called cervical intraepithelial neoplasia (CIN). CIN lesions will regress once the HPV infection has been cleared but if the infection persists, the CIN lesions can progress to cervical cancer over a period of  $\approx 10$  years.<sup>18-21</sup> There are no treatments for cervical HPV infections but the CIN caused by these infections can be removed using simple and effective outpatient procedures. However, CIN lesions do not cause any clinical symptoms and can only be identified through cervical screening.

#### 4.2 Cervical screening

Among all malignant tumours, cervical cancer is the one that can be most effectively prevented by screening. The primary objective of cervical screening is to identify women who have pre-invasive CIN lesions so these can be removed to prevent invasive cervical cancer from developing.<sup>22</sup> Cervical screening will also find asymptomatic cancers but these will be identified in earlier stages than cancers identified on the basis of clinical symptoms so treatment outcomes will be improved and mortality reduced. Well organised screening programs with a 3-5 year recall interval and appropriate mechanisms to follow-up and treat women having a positive screening test can reduce both the incidence and the mortality of cervical cancer by <80%.<sup>23</sup>

Currently, the majority of cervical screening is done using cervical cytology (either the conventional Pap test or liquid-based cytology/LBC) with a sample of cells gently scraped or brushed from the transformation zone of the cervix and the opening of the cervical canal. These cells are transferred to a glass microscope slide, stained to highlight cellular structures and examined microscopically to find abnormal cells indicating CIN or cancer.<sup>24</sup> Several systems are used to classify these cells (Table 3).<sup>25</sup>

Table 3:	Table 3: Classification systems used for cervical cytology										
System Normal											
Bethesda	Negative	Infection/ Reactive	ASCUS	LSIL	HSIL						
Bethesda (NEW)	Negative	Infection/ Reactive	ASC-US H-OSA	LSIL	HSIL		HSIL				
EU	Nega	Negative Border		line & Mild Dysplasia	Moderate	Severe	In Situ	Invasive			
Dutch	Pa	Pap 1 Pap 2		Pap 3a1	Pap 3a2 Pap 3b		Pap 4	Pap 5			
UK	Negative		Borderline/ HPV	Mild Dyskaryosis	Moderate Dyskaryosis	Severe D	yskaryosis				
WHO	Normal Atyp		rpia	Mild Dysplasia	Moderate Dysplasia	Severe Dysplasia	Carcinoma In Situ	Invasive Carcinoma			
Рар	p I II				IV		V				

When abnormal cells are identified, each woman must be followed-up by repeat cytology or colposcopy with biopsy to confirm the presence of CIN and establish its severity. Women with low-grade cytology (ASC-US) are usually re-screened with cytology in 6 months or immediately triaged with HPV testing (i.e. women with ASC-US cytology are tested for HPV and referred to colposcopy if positive). Women with higher-grade cytology (>ASC-US) are usually referred to colposcopy where the cervix is visualised and any suspicious areas are biopsied to confirm the presence and severity of CIN.

Although the vast majority of HPV infections and their associated CIN lesions, including  $\leq$ 70% of CIN3, will clear spontaneously, it is currently not possible to distinguish progressive from regressive lesions so all CIN must be carefully follow-up. Higher-grade CIN is thought to have a greater oncogenic potential and this has formed the basis of widely used clinical algorithms in which women with  $\leq$ CIN1 are re-screened with cytology in 6 months while those with  $\geq$ CIN2 are treated to remove the lesion. As a result, cervical cancer screening inevitably produces a substantial amount of overtreatment.<sup>26-32</sup> In the past, this has been seen as a relatively benign consequence of the screening process and a price worth paying to reduce cervical cancer rates. However, a growing body of evidence linking treatment for CIN to a range of pregnancy complications such as premature rupture of the membranes and pre-term deliveries has increased concern about the adverse health consequences of CIN treatments.<sup>33,34</sup> In addition, increased pressure on healthcare budgets has focused attention on the cost of these unnecessary treatments and their associated complications.

The recognition of these issues has had a strong influence on the design and operation of cervical screening programs in Western Europe and North America over the past 20 years. One priority area has been the replacement of opportunistic screening by organised screening programs to optimise the balance between the benefits and harms of screening while maximising cost-effectiveness.

Another priority area has been the refinement of colposcopy services with the development of evidence-based training curricula, clinical guidelines, standards and CQI procedures to optimise safety for the women and cost-effectiveness for the health system. This is a particularly important issue for Eastern Europe where colposcopy has not been a distinct medical speciality so training curricula and clinical guidelines have been rudimentary or absent. The safety, efficacy and cost-effectiveness of cervical screening are highly dependent on the quality of colposcopy so it is essential that all colposcopists are trained to current international standards and work in a strict CQI system.

#### 4.3 HPV vaccination

Cervical cancer risk can now also be reduced by vaccination against oncogenic Human papillomavirus (HPV) types 16 and 18. There are 2 commercially available HPV vaccines and both can reduce the risk of cervical cancer by ≈75% while simultaneously reducing the number of abnormal Pap tests, CIN lesions and follow-up procedures. The HPV vaccines are an important advancement in the prevention of cervical cancer but it is still necessary to recognise that:

- Neither vaccine protects against all the HPV types that can cause cervical cancer so cervical screening remains necessary to protect women against cancers caused by these other HPV types,
- The current vaccines provide their optimal protection when given to adolescents before the start of sexual activity and vaccine effectiveness is reduced when given to sexually active adults,
- The full benefits of a vaccination program will be achieved only once the majority (>75%) of the target population has been vaccinated.
- Reductions in abnormal Pap tests, CIN lesions and follow-up procedures will start to be seen when the first vaccinees enter the screening age range. For example, the effects of vaccinating successive age-cohorts of adolescent girls will start to be seen when the first vaccinated cohorts reach screening age with reductions in cervical cancer seen when these women reach their 30s.


Therefore, while each country needs to undertake a full cost-benefit analysis to identify the cervical cancer prevention strategy that is most appropriate for their specific circumstances, the optimal protection against cervical cancer would be provided by an organised program that effectively combines HPV vaccination for adolescent girls with cervical screening for women.

# 5. Analysis of the Current Situation in the Republic of Moldova

## 5.1 Cervical cancer in RM

The economic situation in RM over the past 2 decades has not allowed substantial investment in medical or health systems research so reliable data on cervical cancer and its prevention are scarce. Nonetheless, the data that are available indicate that cervical cancer incidence and mortality rates are very high at 17.2 and 7.4 per 100,000 (ASRw) respectively.<sup>35</sup> Meanwhile, a report prepared for the UNDP RM found the incidence of all cancers, including cervical cancer, had increased from 2005 to 2009,<sup>36</sup> with cervical cancer found to be the most common cancer among women in 2011, when it accounted for 39.3% of cancer cases. As in other countries, the majority of cervical cancers occur in middle-aged women with  $\approx$ 75% of cases occurring in women aged 30-60 (see Figure 1).

Very importantly, the proportion of cervical cancers diagnosed in the later stages (FIGO 3 & 4), when treatment is more complicated, more expensive and less successful, increased from 36.8% in 1990 to 56.1% in 2011, while the proportion of women surviving for 5 years or more decreased from 70.4% in 2000 to 61.5% in 2011.<sup>37</sup> These data are consistent with a lack of effective cervical screening and the consequent diagnosis of most cervical cancers on the basis of clinical symptoms that only appear in the late stages of this disease.



## 5.2 Development strategies

Cervical cancer prevention by screening has been consistently included as a priority in all relevant health sector strategy documents for the past decade, including the examples included below.

## 5.2.1 National Reproductive Health Strategy 2006-2015

This strategy includes goals to improve early detection and management of breast and cervical cancers by:

- Improve the regulatory framework for the early detection of breast and cervical cancers
- Improve population access to breast and cervical cancer prevention and diagnosis
- Increase provision of cytological screening for cervical cancer
- Train health care providers in the early detection of breast and cervical cancers
- Raise public awareness of breast and cervical cancer prevention through educational materials and the media promotion.

# 5.2.2 National Program Against Oncological Diseases 2008-2012

The principal objective of this program is to improve the early detection of cancers to decrease the related morbidity and morality. The program includes the following strategies: Strategy I. Primary prophylaxis

3. Include the assessment of individual cancer risk and risk-based patient management in PHC. Strategy 2. Secondary prophylaxis

3. Modernise and promote cytological screening for cervical cancer detection.

Strategy 3. Staff Management

- 1. Improve post-university and CME training in oncology (conforming to European guidelines)
- 2. Include oncology in the CME requirements for family physicians and paramedical personnel.
- 3. Introduce cancer screening and cancer risk monitoring in the training of medical staff
- 4. Collaborate with European and world centers to support the introduction of primary and secondary methods for cancer prevention and the implementation of new treatment methods.

#### 5.2.3 National Strategy for Prevention and Control of NCDs 2012-2020

The principal objective of this strategy is to reduce the incidence, morbidity and mortality of NCDs. The strategy includes the following:

28. Specific objectives:

- 6. Provision of the infrastructure needed to manage and care for NCDs,
- 7. Introduce evidence-based, cost-effective interventions for the primary and secondary prevention of NCDs, with an emphasis on PHC,
- 8. Increase health service accessibility.
- 39. Implementation of the Strategy:
- 1. Short-term strategic priorities (2012-2013)
  - c. Strengthen the skills of doctors and nurses and develop a CME program at all levels in the prevention and control of NCDs,
- 2. Medium-term strategic priorities (2012-2015)
  - b. Organize and implement national screening programs for the prevention and early detection of NCDs based on the models applied in the European Union and the USA.
- 55. International cooperation will be achieved by:
- 1. Acquisition and implementation of the *acquis communautaire* through the development of partnerships with EU countries to promote the exchange of data, knowledge and experience in the prevention and control of NCDs,
- 4. Intensification of international cooperation through participation in international fora and development of partnerships with states having relevant experience.

## 5.3 Legislation, orders and guidelines

A review of the laws, orders and guidelines governing the provision of and access to cervical screening (i.e. the provision of Pap tests) at the PHC level and the treatment of cervical cancer once it has been diagnosed shows they are clear and comprehensive. However, instruments governing the provision of services for the follow-up of women with an abnormal Pap test by colposcopy and biopsy, as well as the treatment of CIN do not exist and need to be implemented to ensure the required services are available and the referral pathways are clearly specified.

In keeping with WHO recommendations, RM legislation specifies that cervical screening and cancer treatment are provided free-of-charge to all women whether or not they are registered for national health insurance with Compania Naţionala de Asigurări în Medicină (CNAM). This is particularly important because cervical screening targets women who are healthy so they have no immediately obvious reason to attend for screening. Therefore, imposing a financial barrier would tend to restrict screening attendance to the wealthy (who can afford it) and the well educated (who will be better informed anout the future benefits) and thereby contravene government policies regarding the equitable provision of health services in RM.

However, this legislation also specifies that the follow-up of abnormal Pap tests and for the treatment of CIN will be provided free of charge only to women who are registered with CNAM and therefore creates a financial barrier for uninsured women. This situation is likely to be well-known to women with a proportion either defaulting from follow-up or choosing not to be screened in the first place because of fears about the cost of these services.

The primary objective of cervical screening is to identify <u>precancerous</u> lesions at a stage when they can be easily and safely removed using simple outpatient procedures to prevent cervical cancer from developing in the first place. Therefore, the provision of cervical screening in the absence of services to follow-up, diagnose and treat all women who have a positive screening test is both pointless and unethical.

The instruments affecting the delivery of cervical screening and the treatment of cervical cancers are summarised in Table 4 below with further details provided in Appendices 1 and 2.

Tab	le 4: Summary of current recommendation	ons with supporting legislation, orders & guidelines
Rec	ommendation	Law/regulation/guideline
	The current cervical screening recommendation is that all women aged 25-64 should be screened for cervical cancer using ecto and endocervical cytology once in every 2-year period.	<ul> <li>MHO Nº 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the unique program of compulsory health insurance for 2013."</li> </ul>
2	All women of screening age are entitled to free cervical screening through PHC services whether or not they are registered with CNAM.	<ul> <li>MHO № 627/163 of 9 September 2010, "Regulations on the registration of population health care facilities that provide PHC within the compulsory health insurance program."</li> <li>MHO/CNAM № 522/207 of 24 December 2009, "On approving Methodological Norms within the program of mandatory health insurance for 2010."</li> </ul>
3	(CBE) and cervical screening (Pap test).	<ul> <li>MHO № 252 of 1 April 2011, "On the Intensification of Prevention in PHC."</li> <li>MHO № 695 of 13 October 2010, "On Primary Health Care in Moldova."</li> <li>MHO № 504 of 25 December 2008, "Prophylactic Medical Examination of the Population."</li> <li>MHO № 1387 of 10 December 2007, "Approval of the Unique Programme of Obligatory Medical Insurance."</li> <li>MHO № 144/65A of 12 April 2007, "Equipment for PHC Institutions."</li> </ul>
	take samples for cervical screening.	<ul> <li>MHO № 695 of 13 October 2010, "On Primary Health Care in Moldova."</li> </ul>
	Clinical guidelines for taking cervical samples for cervical screening.	<ul> <li>MHO № 722 of 16 July 2012, "On improvement of cytological pathomorphologic services in Moldova."</li> </ul>
6	Guidelines for the referral and follow-up of women with an abnormal screening test.	<ul> <li>2013 - Precancerous conditions of the cervix: diagnostic issues and behaviour. Chişinău 2013. T Rotari, D Osadcii, N Ghidirim and L Rotaru.</li> <li>2012 - Methods of Instrumental Diagnostics in Gynecology. Chişinău, 2012. O Cernetchi and M Stemerg.</li> <li>2009 - National Guidelines for the Prevention of Cervical Cancer, Chişinău, 2009. NP Codreanu, VG Friptu, M Statitla and V Cernat.</li> </ul>
7	All women registered with CNAM and a family doctor who have abnormal cervical cytology (clinical group 1A) are entitled to free outpatient follow-up services including colposcopy & biopsy conducted in specialised outpatient facilities. Uninsured women must pay for these services.	<ul> <li>MHO № 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the program of compulsory health insurance for 2013."</li> <li>MHO/CNAM № 627/163-A of 9 September 2010, "On approval of the Regulation on population registration at health care facilities providing primary health care services under the mandatory health insurance program."</li> </ul>
8	All women registered with CNAM and a family doctor who have precancerous cervical disease (clinical group 1B) are legally entitled to free treatment in specialised outpatient facilities or inpatient services at the Oncology Institute. Uninsured women must pay for these services	<ul> <li>MHO № 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the program of compulsory health insurance, 2013."</li> <li>MHO/CNAM № 627/163-A of 9 September 2010, "On approval of the Regulation on population registration at health care facilities providing primary health care services under the mandatory health insurance program."</li> <li>MHO № 348/56A of 24 April 2011 "Approving Methodological Norms for 2011."</li> </ul>
		• MHO № 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the unique program of compulsory health insurance for 2013."
	All women registered with CNAM and a family doctor who have been successfully treated for a malignant disease (clinical group 3) are legally entitled to active monitoring by an oncologist/ gynaecologic oncologist and by a family physician on a quarterly, biannual or yearly basis. Uninsured women must pay for these services.	<ul> <li>MHO № 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the unique program of compulsory health insurance for 2013."</li> </ul>
11	All women registered with CNAM and a family doctor who are living with malignant disease (clinical group 4) are entitled to symptomatic palliative care and pain relief through the Oncology Institute and/or family medicine clinic as required. Uninsured women must pay for these services.	<ul> <li>MHO № 1239/253 of 19 December 2012, "Approving the Methodological Norms for services provided under the unique program of compulsory health insurance for 2013."</li> <li>MHO № 348/56-A of 24 April 2011, "On approving the Methodological Norms in 2011."</li> </ul>
12	The Oncology Institute has responsibility for the provision and supervision of cervical cytology and pathology services.	<ul> <li>MHO № 722 of 16 July 2012, "On improvement of activity and cytological pathomorphologic services in Moldova".</li> </ul>
13	Cytology/cytopathology work limits.	<ul> <li>MHO № 722 of 16 July 2012, "On improvement of cytological pathomorphologic services in Moldova."</li> </ul>
14	Colposcopy services	<ul> <li>MHO Nr. 1239/253 of 19 December 2012 "Approving the Methodological Norms 2013 a unique program of compulsory health."</li> <li>Ministry Health Order № 695 of 13 October 2010, "On Primary Health Care in Moldova"</li> </ul>
15	Performance indicators	<ul> <li>MHO/CNAM № 302/70A of 30 March 2012 "Approval of the regulation on the validation of performance indicators"</li> </ul>

#### 5.4 Estimated cervical screening population and service requirements

Current recommendations specify that all women aged 25 to 64 should be screened for cervical cancer once every 2 years. According to the 'Anuarul statistic al Republicii Moldova 2011', there were 1.85 million females in RM as of 1 January 2011, with  $\approx$ 1.031 million women aged 24-64 years. Therefore, using a 2 year screening interval with a maximum participation rate of 75%, a fully operational cervical screening program would require the capacity to screen  $\approx$ 386,711 women/year (1,031,230 ÷ 2 x 0.75 = 386,711) and a laboratory capacity to process  $\approx$ 444,720 Pap tests/year (+15% for additional Pap tests due to inadequate samples, follow-up testing, etc.)(see Appendix 3).

#### 5.5 Provision of cervical screening services

#### 5.5.1 Facilities for cervical screening

Effective cervical screening requires a high proportion (≥75%) of the target population to be regularly screened but this will only be achieved if the services are convenient and affordable for women in the target population. In RM, MHO/CNAM № 522/207 of 24 December 2009 specifies:

• All women [in the recommended screening age range] are entitled to free cervical screening through PHC services whether or not they are registered with CNAM.

And MHO № 695 of 13 October 2010 specifies:

- All PHC clinics are required to provide cervical screening services,
- All family physicians and nurses must be able to take cervical samples for Pap tests,
- Colposcopy services for the follow-up of women having an abnormal Pap test should be available through all AMTs, CMFs and CSs.

The PHC responsibilities relevant to the provision of cervical screening services at different levels of the health system in RM are set-out in Table 5.

Table 5: Structure of PHC services in RM								
Service	Location	Responsibilities						
Centrele Medicilor de Familie (CMF)	One per district, located in its capital: • Cat. 1: >80,000 people • Cat. 2: 40,001-80,000 • Cat. 3: ≤40,000	<ul> <li>Provides PHC services to the city and additional services to the district</li> <li>Coordinates all PHC services in the district including the services of the Health Centres, Family Physician Offices and Health Offices, and including services provided by autonomous organisations</li> <li>Responsible for collecting health data within the district</li> <li>Responsible for coordinating Continuing Medical Education (CME) for PHC</li> </ul>						
Asociația Medicală Teritorială (AMT)	There are 5 AMTs in Chişinău which each have the same status as a CMF: • AMT Botanica • AMT Buiucani • AMT Centru • AMT Ciocana AMT Rîşcani	<ul> <li>providers in the district</li> <li>Required to have a: <ul> <li>general medical examination room</li> <li>family physician's room (which cannot be used for primary screening)</li> <li>prophylactic gynaecology examination room for the follow-up of abnormal Pap smears (colposcopy, biopsy, etc.)</li> <li>reproductive health room (which, since 2010, is not to be used for cancer screening)</li> </ul> </li> </ul>						
Centrele de Sănătate (CS)	Located in rural areas: • Cat. 1: >11,500 people • Cat. 2: 9,001-11,500 • Cat. 3: 6,001-9,000 • Cat. 4: 4,500-6,000	<ul> <li>Can be sub-divisions of the CMF or autonomous units (coordinated by the CMF)</li> <li>Provides PHC services &amp; immediate emergency care within their catchment areas</li> <li>Staffed by ≥3 family physicians and ≥6 family nurses (2-3 family nurses/family physician)</li> <li>Coordinates the services of Family Physician Offices and Health Offices</li> <li>Recommended to have a: <ul> <li>family physician's room which can be used for primary screening</li> <li>prophylactic gynaecology examination room for the follow-up of abnormal Pap smears (colposcopy, biopsy, etc.)</li> </ul> </li> </ul>						
Oficiile Medicului de Familie (OMF)	Located in villages: • 901-3,000 people	<ul> <li>Are sub-divisions of the CMF or CS</li> <li>Provide PHC services &amp; emergency care within their catchment areas</li> <li>Staffed by 1-2 family physicians and ≥4 family nurses</li> <li>Recommended to have a: <ul> <li>family physician's room which can be used for primary screening</li> </ul> </li> </ul>						
Oficiile de Sănătate (OS)	Located in small villages: • ≤900 people	<ul> <li>Staffed by a family nurse</li> <li>Recommended to have a: <ul> <li>family physician's room which can be used for primary screening</li> </ul> </li> </ul>						

The network of PHC clinics in Moldova is extensive and easily accessed as evidenced by the number of outpatient contacts/person/year that exceeded the EU average in 2010<sup>38</sup> and by the decreasing number of people who failed to consult a doctor when ill.<sup>39</sup> However, cervical screening targets women who are healthy and with no immediately obvious need to go for screening so statistics on the behaviour of people when they are ill are unlikely to accurately predict the behaviour of women targeted for screening.

## 5.5.2 PHC staff availability

Staff shortages remain a problem in RM with PHC services currently able to recruit only 88.7% of their staffing needs at the national level but with more severe staff shortages seen in rural areas. Data from the Centrul Naţional de Management în Sănătate (CNMS) show that 48.6% of RM districts have <90% of the recommended staff and 21.6 have <80% (see Appendix 4).<sup>40</sup>

## 5.5.3 PHC staff training

The effect of PHC staff shortages on the delivery of cervical screening will be compounded by a lack of training among existing staff, as seen in the Căuşeni region where cervical screening cannot be provided in 12 villages because people with the required skills are not available.

The importance of staff training for cervical screening can be overlooked because cervical screening is often viewed only as the taking Pap tests and the taking of Pap tests is viewed as an inherently simple process. However, while the process is simple, it still requires strict adherence to the recommended protocol, with Pap test quality directly linked to the extent of staff training.<sup>41,42,43,44</sup> Good training will therefore directly affect program cost-effectiveness by reducing the number of women who need to be rescreened because of an inadequate Pap test. Cervical sampling is now included in training programs for family physicians and nurses but family physicians receive only theoretical information and the practical training is reserved for nurses.

Notwithstanding the importance of training PHC staff to take high quality Pap tests, the Pap test is only a very small part of a cervical screening program and PHC staff must understand all aspects of the program if they are to work effectively within it. Here, it is important to note the women who do develop cervical cancer in countries with screening programs can be divided into 3 ≈equal groups:

- Women who were not screened regularly or at all,
- Women who were screened but had a false negative result,
- Women who had a positive result but failed to complete the follow-up process.

Therefore,  $\approx 2/3$  of the cervical cancer cases in screened populations are due to poor recruitment and follow-up. PHC staff have the closest relationships with women in the screening population and can therefore play an essential role in maximising screening attendance and follow-up compliance. Further, because PHC is positioned as the gateway to all other health services in RM, PHC staff should be responsible for organising patient referrals to colposcopy and coordinating these services with each woman's on-going care at the PHC level.

To fulfil these roles, PHC staff must have a good understanding of the entire screening process and also know how to effectively counsel women about the importance of screening, the different Pap tests results, the follow-up procedures and the treatments. Currently, none of this information is included in the training programs or CME materials for either family physicians or nurses, and the monitoring of women as they progress through the screening program is not specified in the responsibilities of PHC staff.

## 5.5.4 PHC staff certification for cervical screening

Because of the importance of PHC staff to the effective operation of a cervical screening program, many countries with organised screening programs require PHC staff to be certified as having completed an approved training program before they can participate. Adopting this policy in RM

would ensure PHC staff understand the operation of the screening program, the referral criteria and pathways, and the counselling needed to maximise recruitment and follow-up compliance.

## 5.5.5 Clinical guidelines and SOPs for cervical screening procedures conducted in PHC

RM currently has no nationally approved clinical guidelines or SOPs for the cervical screening procedures conducted in PHC.

#### 5.5.6 Performance indicators, standards and CQI for cervical screening in PHC

RM currently has no nationally approved performance indicators or standards for the cervical screening services delivered through PHC, and there is no CQI program covering these services.

## 5.6 Cervical cytology (Pap test) screening and diagnosis

#### 5.6.1 Cervical cytology laboratories

MHO № 722 of 16 July 2012 assigns overall responsibility for cytology and cytopathology services to the IO and lists 16 cervical cytology screening laboratories (IO, Centrul Diagnostic Republican, 5 AMTs in Chişinău and 9 regional laboratories). However, as of 1 January 2013, only 12 of these were operational with the other laboratories contracting services from the operational ones.

## 5.6.2 Cervical cytology laboratory staff availability

RM currently has 15 cytopathologists and 17 cytotechnicians. This number of cytopathologists is likely sufficient to meet both current and future needs, although this will depend on the amount of work they are required to do for other health services. However, the number of cytotechnicians is sufficient to process only 50-60% of the current volume of Pap tests which leads to long delays in the reporting of results and compromises the quality of these services.

## 5.6.3 Cervical cytology laboratory staff training

For the training of cytopathologists, a mandatory cytopathology residency program was established in 1998 so the people subsequently entering the profession will have completed this residency while those entering at an earlier date will have undertaken an internship program.

For cytotechnicians, there is no formal training program or CME materials for cervical cytology screening and the people currently undertaking this activity in RM will have been trained in general laboratory techniques with subsequent on-the-job training in cytology. This is problematic because cervical cytology screening is highly subjective with the sensitivity and specificity dependent on the training and experience of the cytotechnicians. Therefore, a comprehensive initial training together with regular CME are essential to achieving and maintaining the performance levels required for cervical screening to be safe and cost-effective.

## 5.6.4 Certification for cervical cytology screening

RM currently does not recognise cervical cytology screening as a distinct laboratory speciality with a defined curriculum and certification criteria together with CME and recertification requirements. As a result, there is no mechanism to ensure the people undertaking this activity in RM have the required skills.

## 5.6.5 Laboratory guidelines and SOPs for cervical cytology screening

RM currently has no national laboratory guidelines or SOPs for cervical cytology screening. In addition, RM currently has no regulations governing the working practices of cytotechnicians. This is particularly problematic for cervical cytology screening because it is a mentally tiring process with performance decreasing as fatigue sets-in. Therefore, many countries have guidelines limiting the number of Pap tests cytotechnicians can screen per day, and while RM also set a limit in the past (MHO № 68 of 10 March 2005 set a limit of 67 Pap tests/cytotechnician/day or ≈14,500 Pap tests/cytotechnician/year), this order has replaced with recommendations that do not set a limit.

In addition to limits on the number of Pap tests screened/day, the European Guidelines<sup>23</sup> have working practice recommendations (see Table 6) that are designed to ensure cytotechnicians will be alert when they are screening cytology specimens so their performance is not compromised. These recommendations address basic human characteristics that will not vary by country so the lack of similar recommendations in RM will be adversely affecting the safety and cost-

Table 6: Working practice recommendations forcervical cytology screening laboratories

- Each period of continuous screening should be ≤2 hours,
- Total time spent on primary screening/day should be ≤6 hours,
- Each laboratory should process ≥15,000 Pap tests/year so cytotechnicians are regularly exposed to the full range of abnormal cytology,
- Each laboratory should have ≥4 cytotechnicians to enhance collaborative learning, ensure service provision during holidays, sick-leave, etc.

effectiveness of the cervical screening that is currently being undertaken in the country.

#### 5.6.6 Performance indicators, standards and CQI for cervical cytology screening

Currently, there are no performance indicators or standards for cervical cytology screening, and there is no CQI program covering this service.

#### 5.7 Colposcopy for the follow-up of abnormal Pap tests and the treatment of CIN

#### 5.7.1 Colposcopy clinics and staff

MHO № 695 of 13 October 2010 requires all AMTs, CMFs and CSs to have the facilities, staff and equipment to conduct:

- Preventive gynaecologic procedures (including breast and cervical screening),
- Related additional diagnostic procedures (colposcopy and biopsy),
- Related therapeutic interventions (LEEP, cryotherapy, laser or diathermic electro-conisation).

In common with the majority of Eastern European countries, RM does not recognise colposcopy as a distinct medical speciality. As a result, there is a limited number of colposcopists ( $\approx$  5) who are self-trained or obtained specialist training outside RM and all are based in Chisinau.

#### 5.7.2 Colposcopy training and certification

RM currently has no nationally approved training curriculum or certification requirements for colposcopists. High quality colposcopy is essential to ensure the safety and cost-effectiveness of cervical screening, although the quality of colposcopy is largely dependent upon highly subjective clinical judgements that take training, practice and experience to optimise.

As a result, many Western European countries have developed comprehensive training programs and certification criteria together with CME and recertification requirements to ensure colposcopists have the necessary skills. Certification with CME and periodic recertification are now prerequisites to practicing colposcopy in many countries where these requirements have produced enormous improvements in the outcomes of their cervical screening programs. The adoption of similar policies in RM will be required to ensure the quality of colposcopy supports the safe and cost-effective operation of a cervical screening program.

#### 5.7.3 Clinical guidelines and SOPs for colposcopy

RM currently has no nationally approved clinical guidelines or SOPs for the clinical procedures required to follow-up abnormal Pap tests or treat CIN.

#### 5.7.4 Performance indicators, standards and CQI for cervical screening in PHC

RM currently has no nationally approved performance indicators or standards for colposcopy, and there is no CQI program covering these services.

#### 5.7.5 Health insurance coverage for colposcopy

While cervical screening and cancer treatment are available free of charge to all Moldovan women whether they have health insurance or not, the follow-up of abnormal Pap tests and the treatment of

CIN is free of charge only for women who do have health insurance. As noted in Section 5.2, this will adversely affect referral compliance as well as screening recruitment while increasing disparities in health service provision because this effect will be greater among disadvantaged communities.

## 5.8 Treatment of cervical cancer

All cancer treatment in RM is undertaken at the IO in Chişinău. MHO № 1239/253 of 19 December 2012 specifies that all Moldovan citizens are entitled to free cancer treatment and palliative care whether or not they are registered with CNAM.

# 5.9 Quality assurance and CQI

Improving the quality and efficacy of medical services are specified priorities in the RM National Health Policy 2007-2021, the RM Health System Development Strategy 2008-2017 and the CNAM Institutional Development Strategy 2013-2017. However, CQI policies and programs have not yet been implemented for any of the services involved in cervical screening. This is of concern because many aspects of the cervical screening process are based on highly subjective clinical judgements and it will not be possible to ensure the quality of these services without an effective CQI program.

## 5.10 Cervical screening registry

RM currently has no cervical screening registry or mechanisms to collect and analyse the data that is required to effectively manage a cervical screening program. CNAM does have a database of all people registered for health insurance (currently ≈80% of the population of RM<sup>45</sup>) that includes the details needed to establish eligibility for cervical screening, together with mechanisms for the collection and analysis of data from all contracted health institutions. However, these data and analyses are for monitoring contractual obligations and calculating provider payments so much of the data needed for screening program management is not currently being collected.

## 5.11 Cancer registry

The Moldovan National Cancer Registry is based in the IO where it has access to data on all cancers diagnosed in RM because all suspect cancer cases are referred to the IO for diagnosis and treatment.

# 5.12 Private sector provision of health services

RM government policy encourages private sector provision of health services so private capital can be accessed for expanding health services, increasing consumer choice and introducing competition to stimulate improvements in service quality. However, private provision of cervical screening can be problematic because of the subjective nature of decisions about further investigations, follow-ups and treatments that will produce profits for the clinics. Therefore, the national clinical and laboratory guidelines, SOPs, performance indicators and standards, together with mandatory CQI participation for both public and private clinics will be even more essential to ensure the appropriateness as well as the quality of patient care.

A further consideration is that while some women will choose to be screened in the private sector, a proportion of these women will not be able to afford the more expensive follow-up procedures or treatments and will return to the public sector for these services. Therefore, strict application of the measures noted above to both the public and private sectors will be required to ensure women returning to the public sector meet the recommended referral criteria.

In addition, each woman's screening history will be required for follow-up or treatment decisions and additional costs will be incurred by the public sector if this information is not available. As there is little incentive for private clinics to provide this information, requiring all cytology, colposcopy and pathology results from both public and private clinics to be reported to the screening registry would ensure this information is readily available when it is needed by any clinician.

# 6. Assessment of Current Capacities in the Republic of Moldova

## 6.1 Provision of cervical screening services

The data collected in the capacity assessment indicate that 365,676 women were screened in RM during 2012, which equates to  $\approx$ 70.9% of the estimated 515,615 women who should be screened annually according to the current recommendations of biennial screening for women aged 25-64, with 137,280 of these women screened in Chişinău, which is  $\approx$ 117.7% of the estimated annual screening requirement for this municipality (see Appendix 5).

As coverage levels  $\geq$ 70% have been achieved only by a limited number of well organised screening programs in high-resource countries,  $\approx$ 70.9% is unlikely to reflect the true screening coverage in RM and these results are likely to have been influenced by one or more of the following:

- Women outside the target screening age range (25-64 years of age) are being screened,
- Women are being screened more frequently than the recommended 2-year screening interval,
- Women from other cities and towns are travelling to Chişinău to be screened due to:
  - Lack of local services
  - Patient preference (lack of trust in local services, belief the services in Chişinău are better, etc.)

These data also indicate that 91.0% of Pap tests were taken in CMFs (56.6%) and CSs (34.4%) with only 9.0% taken in OMFs and OSs. This is relevant because convenient access to screening services is key to achieving the high recruitment needed for screening to effectively reduce cancer rates. Therefore, fully utilising the existing network of clinics would greatly facilitate the operation of a screening program and the cause(s) of this imbalance need to be clarified.

The availability of equipment and facilities does not appear to be a substantial factor because much of the required equipment (vaginal speculums and cervical sampling kits) is provided as disposable plastic-ware and all PHC clinics reported they had sufficient supplies to meet demand. In addition, all clinics reported a sufficient number of gynaecology chairs, light sources and examination rooms. However, a number of clinics reported these were very old so poor quality equipment or facilities in the smaller clinics may be influencing patient choices.

PHC staff shortages are likely to be a factor as these are more severe in the rural and remote communities where OMFs and OSs predominate. Further, as noted above, the problem of staff shortages will have been compounded by a lack of training for the existing staff as seen in the Căuşeni region where a lack of people with the required skills in the villages requires women go to the Căuşeni CMF or to Chisinau for screening.

Patient preferences are also likely to be a factor as several nurses reported that women in smaller towns and villages do not want to be screened locally because of doubts about maintaining confidentiality within these small communities. As a result, they prefer to go to another town for cervical screening.

A particularly important finding of the capacity assessment is a substantial proportion of cervical samples are being taken using Volkmann curettes. This device is not recommended for cervical sampling as it does not sample the full cervical transformation zone and will therefore miss lesions that should be treated. A systematic review of cervical sampling devices was undertaken by Martin-Hirsh and colleagues who concluded the most effective method is an extended-tip spatula (not an Ayre's spatula) and an endocervical brush.<sup>46</sup> It is therefore strongly recommended that the use of Volkmann curettes be phased-out as quickly as possible and that PHC staff be trained to use the spatula/endocervical brush combination or the cervical brush.

# 6.2 Cervical cytology screening and diagnosis

Of the 16 cervical cytology laboratories listed in MHO № 722 of 16 July 2012 (IO, CDR, 5 Chişinău AMTs, and 9 regional laboratories), only 12 were operational as of 1 January 2013 (see Table 7,

Table 7: Laboratories processing Pap tests								
	Laboratory	Status	Volume					
1	10	Operational	63,238					
2	RDC	Operational	42,914					
3	AMT Botanica	Operational	26,840					
4	AMT Buiucani	Not operational → AMT Centru	-					
5	AMT Centru	Operational	40,054					
6	AMT Ciocani	Operational	20,400					
7	AMT Rîşcani	Operational	16,076					
8	Anenii Noi	Not operational → IO & RDC	-					
9	Bălți	Operational	42,130					
10	Basarabeasca	Not operational → IO & RDC	-					
11	Briceni	Stopped 2013. Now contracts services from Edineţ	-					
12	Cahul	Operational	35 128					
13	Căuşeni	ni Operational, based in the IMSP Spitalul Raional Căușeni						
14	Cimişlia	Not operational →IO	-					
15	Drochia	Not operational → RDC	-					
16	Edineţ CMF, IMSP Hospital	Operational, based in the IMSP Spitalul Raional Edineț	17 346					
17	Glodeni	Not operational <b>→</b> Bălţi	-					
18	Leova	Not operational→IO, RDC & Cahul	-					
19	Sîngerei	Not operational <b>→</b> Bălţi	-					
20	Soroca	Operational	25 158					
21	Ungheni	Operational	35 698					
22	Orhei	Not operational	-					
23	Hincesti	Not operational	-					
24	Comrat	Not operational	-					

Figure 2 and 6). Six of these laboratories are located within Chişinău with the rest located in other major centers.

The current number of cytopathologists and cytotechnicians in RM is presented in Table 8.

This number of cytopathologists is likely sufficient to meet both current and future needs, depending on the amount of work produced by other health services.

However, the number of cytotechnicians is not sufficient to meet current demand. If the limit of 67 Pap tests/cytotechnician/day previously set by MHO № 68 of 10 March 2005, was enforced together with the European Guideline recommendations set-out in Table 6 above, the





Table 8: № of cytopathologists and cytotechnicians										
	Laboratory	Volume	Cytopathologist	Cytotechnician						
1	10	63,238	4	5						
2	RDC	42,914	2	2						
3	AMT Botanica	26,840	1	1						
4	AMT Centru	40,054	1	1						
5	AMT Ciocani	20,400	1	1						
6	AMT Rîşcani	16,076	1	1						
7	Bălți	42,130	1	1						
8	Cahul	35 128	1	1						
9	Căuşeni	12,477	1	1						
10	Edineţ	17 346	1	1						
11	Soroca	25 158	1	1						
12	Ungheni	35 698	1	1						

screening of 365,676 women would require a minimum of 29 cytotechnicians working in a maximum of 7 laboratories.

Therefore, at best, RM has ≈60.0% of the staff required to process the current number of Pap tests with the majority of the cytotechnicians working alone in small laboratories that have neither the test volume nor the staff numbers required to ensure service quality. As a result, the current structure and staffing of the cervical cytology laboratory network in RM will be compromising the safety and cost-effectiveness of cervical screening.

No data were available to directly assess the quality of the cervical cytology services in RM. However, examination of the Pap test results from 11 of the 12 operational laboratories identified a number of issues that require further investigation (see Table 9 and Figure 3).

Table 9: Proportions of Pap test results reported during 2012												
	England	IO	RDC	Bălți	Botanica	Căuşeni	Centru	Ciocani	Edineţ	Rîșcani	Soroca	Ungheni
Normal	90.6%	77.25%	73.29%	82.70%	78.84%	97.61%	66.79%	98.47%	85.60%	84.57%	81.43%	81.43%
Inflammation	-	15.53%	26.18%	15.36%	20.19%	2.23%	27.00%	0.72%	14.21%	6.80%	25.68%	26.68%
LSIL + ASC-US	5.7%	5.92%	0.18%	1.44%	0.42%	0.01%	0.63%	0.11%	0.12%	8.40%	0.03%	0.03%
HSIL + ASC-H	1.1%	1.27%	0.29%	0.08%	0.36%	0.12%	0.27%	0.03%	0.03%	0.19%	0.08%	0.08%
Carcinoma	0.07%	0.03%	0.07%	0.42%	0.17%	0.002%	0.05%	0.01%	0.10%	0.04%	0.02%	0.05%



As illustrated in Figure 3, there are large variations between laboratories in their Pap test results. As this variation has no obvious biological basis, contributing factors are likely to include the lack of:

- A nationally approved cervical cytology training curriculum and certification criteria,
- Nationally approved cervical cytology laboratory guidelines and SOPs,
- A mandatory national cervical cytology CQI program.

Another issue is the high rate of inflammatory Pap tests that also varies widely between the laboratories. Inflammatory Pap tests can have a number of causes and high rates can be expected in some populations but the wide variation between laboratories that are serving similar populations indicates this is also likely to be related to education, guidelines/SOPs and CQI.

Finally, the HSIL rates are very low, even in comparison to well-screened Western European populations, and these rates also vary widely between laboratories. Inflammation can influence HSIL rates by masking diagnostic cells but this does not appear to be the only factor influencing these results as the laboratory with the lowest HSIL rate also has the lowest inflammatory rate. Therefore, other factors will be involved and a principal contributor is likely to be the use of Volkmann curettes for cervical sampling. As noted above, Volkmann curettes are not recommended for cervical sampling because they do not effectively sample the cervical transformation zone and will therefore miss clinically relevant lesions.

#### 6.3 Colposcopy and the follow-up of women having abnormal screening results

The capacity assessment found that 23 clinics offer colposcopy for the follow-up of abnormal Pap tests and 17 clinics offer cervical surgeries for the treatment of CIN. Together, these clinics have 37 colposcopes although only 27 were both operational and of recent manufacture (≥2000). For cervical surgeries, 8 LEEP, 1 cryotherapy and 18 DEC units were identified although only 8 of these were known to be of recent manufacture (see Table 10 and Appendix 7). Importantly, data on the serviceability of this equipment was not provided and needs to be obtained before the current colposcopy and cervical surgery capacities can be properly estimated.

However, even if all the equipment identified in the capacity assessment is operational, the current capacities for colposcopy follow-up of abnormal Pap tests and the treatment of CIN are guite limited so a large proportion of women having an abnormal Pap test in RM will not be able to obtain these services locally. Requiring women to travel to a distant colposcopy clinic is known to reduce attendance and this is likely to be a principal cause of the low follow-up rates seen in Cahul, Fălești and Strășeni where colposcopy services are not available and only 7.4%, 14.5% and 18.5% respectively of women referred to colposcopy attended.

Finally, no data were provided on the training and qualifications of the clinicians conducting cervical surgeries for the treatment of CIN. A number of studies have linked treatments for CIN to a range of adverse pregnancy complications such as premature rupture of membranes, preterm deliveries, etc.<sup>47,48</sup> which cause unnecessary morbidity for women and costs for the health system. The safety and efficacy of CIN treatments are directly linked to clinician training so it is essential to obtain further information about

	Colposcopy	Cervical Surgery	Colposcope	LEEP	Cryotherapy	DEC*
AMT Botanica	~	Х	?	0	0	0
CS Femeii "Dalila"	~	~	?	?	?	?
AMT Buiucani	~	~	1xDoM	?	?	?
AMT Centru	~	~	2x2010	0	0	?
AMT Ciocani	~	~	1x2002	0	0	?
AMT Rîşcani	~	~	1x1984 1x1987 1x2003 1x2010	0	0	1x1975 1x1978 1x1982 1x2010
Bălți CMF	~	х	1x2003			
CS Briceni	~		1x1989	0	0	0
Dondușeni (Auto) CS Sudarca	~	~	1x1998	0	0	1x2009
Drochia CMF	~	~	1xDoM			
Edineţ CMF	~	Х	1x2008	0	0	
CS Rîşcani	~	Х	1x2003	-	-	-
CS Sîngerei Noi	~	~	1x2003	?	0	1x1990
Soroca CMF	~	~	1x2005			1xDoM
Anenii Noi CMF	~	~	1x2004	1x1990	0	1x1990
Călărași CMF	~	~	3x2003	?	0	1x1976
Criuleni CMF	~	Х	1x2004	0	0	0
Ialoveni CMF	~	~	1xDoM			1xDoM
CS Nisporeni	~	~	1x2007		0	1xDoM
Rezina CMF	Х	~	1x2006	1x2011		
Ungheni CMF	~	~	1x2000	?	0	1xDoM
Cantemir CMF	~	Х	1x2006	0	0	0
CS Ştefan-Vodă	~	~	1x2005	1x2011	0	1x2009
Comrat CMF	~	~	1x2006	1x1979	0	

current training levels so educational programs can be designed to update clinical skills if required.

#### 6.4 Treatment of cervical cancer

While the treatment of cervical cancer is not part of this project, all participants indicated that women from their districts are referred to the IO for further work-up, diagnosis and treatment.

#### 6.5 Summary of capacity assessment findings

A key finding of this capacity assessment was that 365,676 women were screened in 2012. This is a very considerable number of women and it is essential to recognise this screening is being done without the organisation and quality assurance that is required for it to be safe and cost-effective. Therefore, the cervical screening currently undertaken in RM will produce suboptimal reductions in cancer rates but will still consume substantial health care resources. Further, it will produce an unnecessarily high degree of harm for the women being screened through an excessive number of false negative results leading to delayed diagnoses of cancer and false positive results leading to needless stress, follow-up procedures and treatments.

This situation is not due to any failure on the part of the people involved in the delivery of the screening services who are doing the best they can within the existing structures. Instead, it is because circumstances in RM since the collapse of the Soviet Union have prevented the health services from keeping pace with developments in screening program structures and systems that have occurred in other countries. Therefore, the solution is to move forward with implementing these structures and systems as quickly as possible but with the priority being the improvement of the existing services, not the recruitment of more women to screening.

## 7. Recommendations for Implementing an Organised Cervical Screening Program

A principal component of this project was the identification and active involvement of all relevant stakeholders to ensure the outcomes are well adapted to the RM health system and the people who will be responsible for delivering the cervical screening services have ownership of the program with an interest in its success.

As part of this process, the 3rd Stakeholder Meeting was held in the RM Ministry of Health on 21 November 2013 to review the outcomes of the capacity assessment and define the key elements of the capacity building program needed to strengthen the health services required for the delivery of cervical screening program. The key elements identified by the stakeholders at this meeting were:

- Establish an administrative structure with overall responsibility for the implementation and operation of the cervical screening program.
- Prepare and publish cervical screening policy documents and service specifications including:
  - Cervical screening service policy,
  - Cervical screening CQI policy.
  - Cervical screening service specification.
- Review and revise legislation and orders affecting the delivery of health services required for the delivery of a cervical screening program to ensure compatibility with screening program operaton.
- Design and implement the cervical screening registry:
  - Review and revise data collection by CNAM to include the data required for screening program management,
  - Review and revise data transfer mechanisms to meet the needs of the screening program.
- Increase PHC (family physicians and nurses) capacity for cervical screening:
  - Prepare a standard national cervical screening curriculum and certification criteria for PHC staff,
  - Review/revise/prepare clinical guidelines and SOPs for all cervical screening procedures conducted in PHC,
  - Review and revise facilities and equipment specifications,
  - Review/revise/define evidence-based performance indicators and standards,
  - Design and implement educational modules for university/college and CME programs,
  - Establish a PHC outreach training service for PHC staff in practice,
  - Design and implement a cervical screening CQI system for PHC.
- Increase cervical cytology laboratory capacity:
  - Undertake a full inventory of all cervical cytology screening laboratories,
  - Undertake external quality assessments of all cervical cytology screening laboratories,
  - Prepare a nationally approved curriculum and certification criteria for cervical cytology screening,
  - Review laboratory specialist classifications and revise to include cervical cytology screening,
  - Prepare laboratory guidelines and SOPs for all cervical cytology laboratory procedures,
  - Review and revise facilities and equipment specifications,
  - Define evidence-based performance indicators and standards,
  - Review and revise the structure of the existing laboratory network based on the inventory, external quality assessments, new guidelines, SOPs and standards,
  - Design and implement a training facility for cervical cytology screening,
  - Design and implement a cervical cytology CQI system.
- Increase colposcopy and cervical surgery capacity:
  - Prepare a nationally approved curriculum and certification criteria for colposcopy,
  - Revise medical specialist classifications to include colposcopy as a defined medical speciality,
  - Prepare clinical guidelines and SOPs for all procedures undertaken in the colposcopy clinic,
  - Review and revise facilities and equipment specifications,
  - Define evidence-based performance indicators and standards,
  - Design and implement a training facility for colposcopy and cervical surgery,
  - Design and implement a colposcopy CQI system.

## 7.1 Support for the implementation of a cervical screening program

A number of Western European (WE) countries have developed very high-quality cervical screening programs and the ECCA has established relationships with several of these programs to share their expertise for the development of cervical screening in Eastern Europe. To accommodate the complexity of screening program implementation and the time required for these programs to become embedded in the health system, these partnerships have been designed as long-term collaborations that include:

- Training exchange visits to the WE cervical screening program where the trainees will work directly with the people who are responsible for the day-to-day delivery of the services,
- The provision of program documentation including screening policies, service specifications, clinical/laboratory guidelines and SOPs, facility and equipment specifications, training curricula and certification criteria, CQI system specifications, etc. together with help to adapt these documents for use in the trainee's home country,
- Visits by WE trainers to the trainee's country to review service delivery in practice and work with local experts to refine program implementation or operation,
- On-going trainer-trainee interaction with monitoring of service performance and further intervention as required to address issues as they arise.

RM could obtain substantial support for the establishment of a cervical screening program through these collaborations. However, a potential problem is the majority of cervical cytology in RM is processed using the Romanowski technique and its use for this purpose is largely restricted to the countries of the former Soviet Union. Elsewhere in the world, including Western Europe, the majority of cervical cytology is processed using the Papanicolaou technique. This is an important point as the 2 techniques use different processes and interpretations so laboratories specialised in one technique would not be able to effectively train cervical cytology screeners from laboratories using the other technique.

Therefore, RM would need to switch to the Papanicolaou technique to take full advantage of these partnerships with Western European cervical screening programs, while remaining with the Romanowski technique would restrict opportunities for laboratory technical training exchanges to countries of the former Soviet Union where most of the cervical cytology services are similar to or worse than the services in RM.

An additional consideration with switching to the Papanicolaou technique is the laboratory processing is completely different so costs would be incurred for the purchase of laboratory equipment and the renovation of facilities. However, these costs are not substantial and a proportion of these costs would be required for updating the laboratory network regardless of which technique is being used.

The implementation of a cervical screening program in RM will require staff training, equipment purchases, facility refurbishment and the creation of a cervical cytology training capacity to meet initial and on-going requirements, with a substantial part of this expenditure directly linked to the laboratory technique. Therefore, deciding to switch technique at a later date would require the retraining of laboratory staff together with the replacement of laboratory equipment and facility alterations to accommodate the new technique.

#### 7.2 Cervical screening program administration

#### 7.2.1 The screening coordination office

RM does not currently have an organization with the expertise and authority to coordinate the health services involved in cervical screening or to monitor women as they move through the program.

These duties are the responsibility of the Screening Coordination Office (SCO) and the establishment of the SCO is therefore a prerequisite to the implementation of a screening program in RM. The principal actions undertaken by the SCO are set-out in Table 11.


Table 11: Screening Coordination Office activities

- Regularly review and update the cervical screening service specification and operational guidelines,
- Implement, operate and maintain the cervical screening registry,
- Send service providers the data they need to coordinate patient referrals and ensure referral compliance,
- Operate the CQI programs and intervene as required to continuously improve service quality,
- Work with the USMF and IO to coordinate CME programs so they effectively support the CQI process,
- Design and implement public educational programs to raise awareness of cervical cancer prevention and encourage screening program attendance,
- Undertake actions to identify under-screened/unscreened women and implement programs to increase attendance,
- Work with the Ministry of Health, CNAM, USMF and relevant professional groups to facilitate the regular review and updating of training standards, certification criteria, clinical guidelines and SOPs, performance indicators and standards for each of the services involved in the screening process,
- Regularly monitor and evaluate all aspects of screening program performance, and intervene as required,
- Prepare and publish reports on screening program performance for the MoH, CNAM and other interested organisations,
  Interact with other health services as required to ensure efficient program operation (i.e. cancer registry),
- Interact with other governmental departments and nongovernmental organisations as required to ensure intersectoral cooperation for cancer prevention (such as the Department of Education for the inclusion of cancer prevention in secondary school health curriculums).

As seen in Table 11, cervical screening program management is primarily an administrative exercise, although it still requires a thorough understanding of the clinical services that are required to deliver the program. In addition, the SCO requires a regular flow of data to and from all of the component health services (see Appendix 8) and therefore needs access to mechanisms for the secure transfer of these data. In RM, relevant expertise, responsibilities and facilities are split between 2 organisations:

- CNAM:
  - Responsible for contracting all public sector health services with contracts setting terms of service provision, performance indicators and performance-based payments,
  - Database of all people registered for health insurance (currently ≈80% of the population of RM<sup>49</sup>), including details required to establish eligibility for cervical screening,
  - Mechanisms for the collection and analysis of data from all contracted health institutions.
- Institute of Oncology:
  - Clinical expertise in cancer screening, treatment and palliative care,
  - Responsible for all cytology laboratories, including staff training and service quality,
  - Location of the largest cervical cytology screening laboratory in RM (≈65,000 Pap tests/year),
  - Location of the largest colposcopy clinic in RM (≈15,000 patients/year),
  - Location of the cancer registry.

Therefore, the functions of the SCO must also be shared between these 2 institutions with CNAM having responsibility for hosting the SCO, data transfers and facilitating screening program operation through the terms of health center contracts, while the IO would act in a consultative capacity to provide expertise as required for program operation (see Figure 4).




## 7.2.2 Screening coordination office staff

Effective management of a fully operational national organised cervical screening program in RM will require substantial human resources. However, many of these people will be employed by the health services involved in the delivery of the screening program rather than by the SCO, while staff

employed directly by the SCO can be increased as the program is expanded.

In the short-term, the immediate need is for the appointment of the SCO core staff, starting with the Cervical Screening Director (CSD) who would then take responsibility for recruiting the other staff.

The principal staff positions and relationships are set out in Figure 5, with short descriptions below and more detailed descriptions included in Appendix 9.



## 7.2.2.1 Cervical Screening Director

The Cervical Screening Director is the person who will have overall responsibility for costs, service delivery and quality of the cervical screening program when operating and should therefore also have overall responsibility for the implementation of the program.

This position requires a medically qualified professional with clinical experience in some or all of the health services involved in cervical screening (PHC, cytology, colposcopy and cervical surgery, gynaeoncology) the administration of a cancer screening service or similar public health program. This experience should be from RM as a detailed knowledge of the RM health system will be essential. In addition, fluency in English is required as the Cervical Screening Director will need to communicate with a wide range of organisations in WE to facilitate training exchanges.

#### 7.2.2.2 Director of Clinical Services

The Director of Clinical Services will have overall responsibility for coordinating the clinical services involved in cervical screening (i.e. colposcopy and the clinical procedures conducted by PHC staff for the cervical screening program), and ensuring these services comply with the Cervical Cancer Prevention Policy, Cervical Screening CQI Policy and relevant international recommendations.

This position requires a medically qualified professional with training and clinical experience in colposcopy, together with a detailed knowledge of the provision of clinical services within the RM health system. In addition, fluency in English is required as the Director of Clinical Services will need to communicate with a wide range of organisations in WE to facilitate training exchanges.

#### 7.2.2.3 Director of Quality and Risk Management

The Director of Quality and Risk Management will have overall responsibility for developing the cervical screening program CQI policy and ensuring it is fully and continuously implemented at all levels of the program.

This position requires professional qualifications in health service quality and/or risk management together with experience in the quality management of health services in RM.

#### 7.2.2.4 Head of IT and Screening Registry Management

The Head of IT and Screening Registry Management will have overall responsibility for the design, implementation and operation of the cervical screening registry and related IT systems.

This position will require specialist qualifications and experience in database design, operation and maintenance as well as the collection, verification and analysis of confidential personal health data.

#### 7.2.2.5 Head of Communications and Cervical Screening Promotion

The Head of Communications and Cervical Screening Promotion will have overall responsibility for informing, educating and encouraging women to participate in the cervical screening program.

This position will require specialist qualifications in health communications and/or health psychology, together with a detailed knowledge of the factors that may influence screening recruitment in RM.

#### 7.2.2.6 Coordinator of PHC Training

The Coordinator of PHC Training will be responsible for all CME training of PHC staff including the development of the curriculum and certification criteria for family physician residency, nurse training and CME programs. In addition, the Coordinator of PHC Training will be responsible for managing the PHC outreach training service staff required to train the 7,190 PHC staff currently practicing in RM.

This position requires a good knowledge of PHC service delivery within the RM health system, obtained through a nurse training program with subsequent PHC clinical experience in both urban and rural settings. Good communications skills or teaching experience together with personnel management experience is also required.

#### 7.2.2.7 Cervical Screening Coordinators

A cervical screening program requires the efficient coordination of 3 key services: PHC, cytology/ cytopathology and colposcopy. A Cervical Screening Coordinator is therefore required for each service to be their single point of contact with the screening program and to maintain regular communications with each service to identify and resolve performance issues as they arise.

Each of these positions requires a good knowledge of targeted service, obtained through nurse or laboratory technician training programs together with practical experience in the RM health system. Very good organisational, communications and problem solving skills are also required.

#### 7.2.3 Advisory Committee

The cervical screening program requires the effective coordination and quality management of the component health services but this will not be possible unless the program can continuously adapt to the changing needs of each service. In addition, the cervical screening program requires high coverage of the target population and this will not be achieved unless the program effectively addresses the needs and concerns of these women.

Therefore, an Advisory Committee should be established to facilitate communication with *and* between these stakeholders. The Advisory Committee should include representatives from:

- MoH
- CNAM
- National Center of Health Management
- National Center of Public Health
- National Council for Evaluation and Accreditation in Health
- •I0
- USMF
- League of Doctors of RM
- Sanatatea

- Assoc. of Gynaecologists of RM
- Assoc. of Pathologists of RM
- Assoc. of Family Physicians of RM
- Assoc. of Nurses of RM
- NGOs/CSOs representing health, women's health, cancer patients, etc.
- Development partners: WHO, UNFPA
- Representative(s) from an established cervical screening program.

The Advisory Committee should meet at least 4 times per year during the implementation of the cervical screening program and it should report directly to the Cervical Screening Director.

#### 7.2.4 Screening registry

Effective cervical screening program management requires the timely collection and analysis of data from all component services, together with prompt return of the information service providers need for patient management. The screening registry is the tool used to achieve this.

The screening registry should be located in CNAM as it already has established mechanisms for the collection of data from all contracted health care institutions together with the IT expertise that will be required for the development of the screening registry. However, the CNAM IT system was established primarily for monitoring contract compliance and calculating provider payments so much of the data required for screening program management is not currently collected and the software will need to be modified accordingly. The data, sources and analyses required for cervical screening program management, as recommended by the European Guidelines,<sup>23</sup> are set-out in Appendix 10.

Model specifications for cervical screening registries (and possibly the associated software) can be obtained from Western European screening programs together with support for adaptation to RM.

#### 7.3 Primary health care

#### 7.3.1 PHC staff numbers

In keeping with other evaluations of PHC services, this assessment found that PHC staff shortages remain a problem, particularly in rural and remote communities. PHC staff recruitment is not part of this project, which instead focuses on increasing PHC screening capacity by ensuring all PHC staff have the skills required to effectively support the operation of the cervical screening program.

#### 7.3.2 PHC staff training and certification

As noted in Section 5.5.3, PHC staff must have a good understanding of all aspects of the cervical screening process, but this information is not currently included in the training programs or CME materials for either family physicians or nurses. Therefore, family physician residency and CME programs, together with nurse training and CME programs need to be revised to include the full range of information required for these people to work effectively as members of the team required to deliver the cervical screening program (see Table 12).

Table 12: E	ducational modules for PHC staff
Module	Content
Cervical screening for PHC staff	<ul> <li>The cervical screening process &amp; the structure of cervical screening programs</li> <li>Operating the cervical screening registry (submitting data, checking patient records, receiving results, etc.)</li> <li>Patient reception, registration &amp; data recording</li> <li>Patient counselling, communications &amp; stress management techniques</li> <li>Patient confidentiality</li> <li>History taking and assessment of individual cervical cancer risk</li> <li>Routine vs high-risk cervical screening algorithms</li> <li>Anatomy, physiology &amp; pathology of the vulva, vagina and cervix</li> <li>Clinical examination the vulva, vagina and cervix</li> <li>Obtaining cervical samples, preparing microscope slides &amp; laboratory submission pathways (theoretical)</li> <li>Pap test results, interpretation, counselling, referral criteria &amp; colposcopy referral pathways</li> <li>Colposcopy/biopsy results, interpretation, counselling, referral criteria &amp; referral pathways for treatment</li> <li>Performance indicators and CQI</li> <li>Failsafe &amp; audit procedures</li> </ul>

Examples of training curricula with certification criteria can be obtained from Western European screening programs together with support for their adaptation to RM.

Because of the central role that PHC staff play in supporting the operation of the screening program and acting as the interface between the screening program and the public, PHC staff should be required to complete an accredited training course before they can participate in the program. However, the introduction of this requirement should be accompanied by incentives to motivate compliance such as additional payments, provision of IT equipment, facilities refurbishment, etc.

## 7.3.3 Outreach training for PHC staff

Data from the RM National Center for Health Management for 2011 show there are 1,853 family physicians and 5,337 family practice nurses working in 1,328 clinics (37 x CMF; 263 x CS; 623 x OMF; 405 x OS) across RM. However, none of these people have received formal training about the operation of organised cancer screening programs or their role within these programs, so they will all need training to ensure they have the knowledge and skills to support effective program operation.

As the majority of PHC staff will have neither the time nor the money to travel to a distant center, the training must be delivered through an outreach service that uses a combination of online or print materials and classes conducted in regional centers. The training program can then be scheduled to remain one step ahead of the phased implementation of the screening program to ensure the PHC staff have access to the training that is required for them to participate.

Here it is worth noting that, once established, this outreach training service could be used to deliver many other training programs to PHC providers and can therefore contribute to the strengthening of the overall health system.

#### 7.3.4 Regulatory changes

MHO № 695 of 13 October 2010 states only that family physicians and nurses are required to take Pap tests, so this order needs to be changed so the full range of duties noted above are clearly specified among the responsibilities of PHC staff.

#### 7.3.5 Evidence-based clinical guidelines and standard operating procedures for PHC

Evidence-based clinical guidelines and SOPs for each step in the screening process are essential to ensure each of the component services will produce the expected outcomes and are effectively integrated into the operation of overall screening program. Clinical guidelines and SOPs are also integral to the standard training curricula, certification criteria, performance standards and CQI processes. Clinical guidelines and SOPs relevant to cervical screening in PHC are set-out in Table 13.

 Table 13: Cervical screening clinical guidelines and SOPs relevant to PHC

Service provider operation of the cervical screening registry

- Counselling women about the benefits and drawback of cervical screening,
- Assessment of cervical cancer risk and identification of women at increased risk,

• Obtaining cervical samples, preparing the microscope slides and submitting them to the laboratory,

• Pap test results, interpretation, counselling, follow-up/referral criteria and colposcopy referral pathways,

• Colposcopy/biopsy results, interpretation, counselling, follow-up/referral criteria and treatment referral pathways.

Examples of clinical guidelines and SOPs can be obtained from Western European screening programs together with support for their adaptation to RM.

#### 7.3.6 Facility and equipment specifications

As cervical screening targets healthy women with no pressing need to attend for screening, good quality facilities that provide women with a pleasant experience are essential for achieving recruitment targets. Therefore, the RM cervical screening Director of Clinical Services should work with the National Council for Evaluation and Accreditation in Health to review the specifications for PHC clinics and revise them if required to support the effective operation of the program.

#### 7.4 Cervical cytology screening

#### 7.4.1 Cervical cytology laboratory and staff numbers

The capacity assessment found that RM has ≈60.0% of the staff required to process the current number of Pap tests, with the majority of these people working alone in small laboratories that do not have the Pap test volume or staff numbers required to ensure the quality of these services.

Therefore, the first priority for cervical cytology in RM must be to objectively assess the existing laboratory network and implement any measures that are required to ensure the quality of these services is sufficient to deliver safe and cost-effective cervical screening. These actions include:

- Prepare an inventory of each laboratory to characterize the quantity and quality of their facilities, equipment and staffing levels relative to the number of Pap tests being processed,
- Conduct an external assessment of the quality of cytology services in each laboratory,

Then, the inventory data and external assessment outcomes can be used to:

- Prepare a plan for restructuring the laboratory network to have a smaller number of larger laboratories that each have the Pap test volume and staff numbers required to provide a high-quality service. In addition, this process will allow the laboratory network to be structured to accommodate the future introduction of new technologies such as liquid-based cytology, HPV testing, HPV vaccination, etc. and thereby facilitate their implementation as and when they are found to be cost-effective within the RM health system,
- Design and implement targeted training programs as required to improve the skills existing staff.

In parallel with the laboratory evaluations and staff training, measures should be taken to enforce compliance with the recommended screening age-range and interval to bring the number of Pap tests more into line with the current laboratory capacity, while simultaneously concentrating the existing resources on the women who will benefit most from cervical screening. The simplest way to achieve this is to restrict payments for PHC clinics and cytology laboratories to Pap tests taken from women who comply with the recommendations. This approach was used in Norway when they launched their organised cervical screening program and the volume of Pap tests declined by 35% within the first year. However, enforcing the screening age-range and interval must be accompanied by information to PHC staff explaining why these restrictions are required so they can provide clear advice to women in their catchment areas.

The number of Pap tests could be further reduced by restricting the screening age range to 30-59 years or by lengthening the screening interval to 3 years. However, once strict compliance with the age range and interval recommendations has been achieved, changing them in the future and achieving strict compliance with the new recommendations will be very difficult. Therefore, RM should just focus on ensuring the current recommendations are followed.

The actions outlined above will help to improve the quality of cervical cytology services in the short term but the number of cytotechnicians will still need to be increased in the longerterm. Based on the limit of 67 Pap tests/cytotechnician/day and the European Guidelines,<sup>23</sup> the estimated number of cytotechnicians and laboratories for different coverage levels is setout in Table 15.

Table 14: Estimated number of cytotechnicians & laboratories by level of population coverage					
Coverage	Est. № Pap	Min №	Max №		
%	Tests/Year	Cytotechnicians	Laboratories		
35	198,512	14	4		
45	255,229	17	5		
55	311,947	21	6		
65	368,665	25	7		
75	425,382	29	8		

However, these estimates for the number of cytotechnicians are based on the recommended *minimum* numbers for a program with well-trained and experienced staff, working in well-resourced laboratories that have clearly defined laboratory and administrative procedures. Therefore, until the laboratories in RM reach a similar position, the number of staff required will be considerably higher.

Further, the estimates for the number of laboratories are maximums so a smaller number of larger laboratories would still comply with the recommendations. In this regard, concentrating cervical cytology serves into 3-4 laboratories would simplify CQI, provide economies of scale and facilitate the introduction of new technologies. However, decisions about the number of laboratories also need to consider the effect of specimen transport on reporting times, clinician-laboratory interaction and security of supply if unforeseen events force the closure of one or more laboratories.

#### 7.4.2 Training and certification for cervical cytology screening

Because cervical cytology screening relies on the subjective assessments of the cytotechnicians, comprehensive initial training together with CME and strict CQI are essential to achieving and maintaining a safe and cost-effective service. Therefore, in addition to the priority actions listed above, the implementation of a cervical screening program in RM will require:

- Preparation of a cervical cytology screening training curriculum with certification criteria,
- Designation of cervical cytology screening as a distinct laboratory specialty with a defined training curriculum and certification criteria together with CME and re-certification requirements,
- Design and implementation of a comprehensive cervical cytology CQI program,
- Establishment of a cervical cytology screening training facility that will:
  - Run refresher courses for the existing cytotechnicians,
  - Train new cytotechnicians to meet the needs of the screening program as it expands and the on-going needs of the program as people retire, change jobs, etc.
  - Run CME courses to maintain workforce skills,
  - Support the cervical cytology CQI program with targeted training interventions.

In RM, the USFM has jurisdiction over setting medical training curricula and related examination/ certification criteria, while the IO has jurisdiction over cervical cytology services, including responsibility for staff training and service quality. Further, the IO has the largest cervical cytology screening laboratory in RM (≈65,000 Pap tests/year) with the greatest concentration of cytology expertise. Therefore, a cervical cytology screening training facility would need to be established as a partnership of these 2 institutions with the USFM responsible for the curriculum and certification, and the IO responsible for delivering the program.

If RM changes to the Papanicolaou technique, a partnership could be established between the USFM, IO and a foreign cervical cytology screening training facility as described in Section 7.1 and **Error! Reference source not found.** Language differences could be a problem with foreign training exchanges but should be manageable as much of the training focuses on visual recognition while communication could be facilitated by selecting one or more bilingual trainees who can interpret for the group.

#### 7.4.3 Designating cervical cytology screening as a distinct laboratory specialty

The quality of the cervical cytology service will directly influence the safety and cost-effectiveness of the screening program so it is essential to ensure all staff have the required training and skills. Therefore, cervical cytology screening should be designated as a distinct laboratory speciality with a defined curriculum, CME requirements, certification/recertification criteria and certification being mandatory to work in the field. Doing this would not only ensure the quality of cervical cytology services in RM, but also increase the credibility of these services in the eyes of the public, thereby helping to attract people to work in this field and facilitate the recruitment of women to be screened.

#### 7.4.4 Evidence-based laboratory guidelines and standard operating procedures

Evidence-based laboratory guidelines and SOPs for each step in the processing and analysis of Pap tests are essential to ensure the cervical cytology services produce the expected outcomes and are effectively integrated into the operation of the screening program. Laboratory guidelines and SOPs are also integral to the standard training curricula, certification criteria, performance standards and CQI processes. The laboratory guidelines and SOPs relevant to cervical cytology screening, cytopathology and histopathology are set out in Table 15.

Table 15: Cervical cytology, cytopathology and histopathology laboratory guidelines and SOPs

- Sample receipt and laboratory processing of cervical cytology,
- Service provider operation of the cervical screening registry

- Sample receipt and laboratory processing of cervical biopsy specimens
- Evaluation of cervical biopsy specimens
  Clinico-Pathological Correlation (CPC)/Multidisciplinary Team (MDT) Meeting Guidelines.

<sup>•</sup> Primary screening of cervical cytology,

Diagnosis of the cytological abnormalities identified in screening,

<sup>•</sup> CQI of cervical cytology,

Examples of clinical guidelines and SOPs can be obtained from Western European screening programs together with support for their adaptation to RM. However, this should be coordinated with the cytology training described in Section 7.4.2 so the techniques and procedures taught to the trainees will be the same as the ones that will be adapted for use in RM.

### 7.4.5 Laboratory facility and equipment specifications

The laboratory environment and equipment are also important factors influencing the quality of cervical cytology screening. Therefore, the RM National Council for Evaluation and Accreditation in Health should be supported to review the facility and equipment requirements for cytology laboratories and revise them if required to comply with the European Guidelines.<sup>23</sup>

## 7.5 Colposcopy

#### 7.5.1 Colposcopy clinic and staff numbers

Currently, 23 clinics offer colposcopy for the follow-up of abnormal Pap tests and 17 clinics offer treatment for CIN. In addition, data for 2011 indicate there were 562 gynaecologists registered in RM. However, in common with most Eastern European countries, RM does not recognise colposcopy as a distinct medical speciality so there is a limited number of colposcopists (≈ 5) who are self-trained or obtained specialist training outside RM, and all are based in Chisinau.

Estimates for the colposcopy clinic and staff requirements for a cervical screening program in RM can be based on the guidelines prepared by the English National Health Service and the British Society for Colposcopy and Cervical Pathology (BSCCP) regarding the practice of colposcopy (see Table 16).<sup>50,51</sup>

Using these recommended timings and a mix of appointment types, each colposcopy clinic should be able to accommodate  $\leq 20$  colposcopies per day (2 sessions of 3-3.5 hours per day with 10 colposcopies per session). This equates to an annual capacity of  $\approx 4,400$  colposcopies per clinic based on 220 working days per year.

Based on these calculations, estimates of the facility and staff requirements for RM are presented in Table 17.

	Colposcopy Recommendations
Colposcopy clinic facilities	<ul> <li>A private area with changing facilities,</li> <li>Toilet facilities specific for the clinic,</li> <li>A room specifically for colposcopy procedures,</li> <li>A recovery area that is separate from the waiting room.</li> </ul>
Colposcopy clinic staff	<ul> <li>A designated colposcopy clinical lead,</li> <li>A second colposcopist,</li> <li>2 nurses: <ul> <li>1 registered nurse (RN) with training in colposcopy procedures and patient counselling and who is without other outpatient duties,</li> <li>1 nurse for support of the patient</li> </ul> </li> <li>1 clinical assistant who is present in the colposcopy room throughout every procedure (can be the RN noted above)</li> <li>Adequate clerical support for the effective operation of the clinic.</li> </ul>
Minimum appointment times	<ul> <li>New referral: 20 min</li> <li>New high-grade referral: 30 min</li> <li>Return for treatment: 20 min</li> <li>Follow-up examination: 10 min</li> </ul>

However, as colposcopy referral is based on cervical cytology results and the distribution of these results is likely to change substantially once the training and CQI programs have been implemented. Therefore, these estimates have been based on data from the Irish National Cervical Screening Program that was launched in September 2008 so the statistics come from a relatively unscreened population that will be more representative of the Moldovan population during the early years of program implementation:

- An colposcopy referral rate of 8.5%,
- 69.5% uptake of colposcopy,
- Each referral will generate an average of 1.6 colposcopy appointments (accounting for defaults),
- Each colposcopy clinic will be open for 220 days/year and conduct 4,400 colposcopies/year,
- Each colposcopy clinic will be staffed by 2 colposcopists, 2 nurses and 1 administrator.

Table 17 Est	timated col	poscopy clini	ic and staff	requirement	ts			
Coverage (%)	People Screened	Colposcopy Referrals	Colposcopy Appts.	Colposcopy Clinics	Colpo- scopists	Registered Nurses	Nurses	Admin Staff
35	198,512	16,874	18,763	5	10	5	5	5
45	255,229	21,694	24,124	6	12	6	6	6
55	311,947	26,515	29,485	7	14	7	7	7
65	368,665	31,337	34,846	8	16	8	8	8
75	425,382	36,157	40,207	10	20	10	10	10

In considering the estimates presented above, it is very important to remember they are based on the recommended *minimum* numbers for a program with well trained and experienced staff working in well-resourced clinics that have clearly defined clinical and administrative procedures. Therefore, until RM reaches a similar state, the number of colposcopies/clinic/ day will be considerably lower so the number of clinics and staff required will be considerably higher.

On this basis, RM should plan to develop the colposcopy capacity required for 75% coverage as quickly as possible so all women requiring follow-up during the early years of program implementation can be quickly seen without overburdening the newly trained colposcopists. Then, colposcopy capacity will progressively increase as the clinicians gain experience and this should accommodate the increased demand that will accompany the rollout of the screening program.

Therefore, the implementation of a cervical screening program in RM will require the:

- Preparation of a colposcopy training curriculum with certification criteria,
- Designation of colposcopy as a distinct medical specialty with a defined curriculum, CME requirements and certification/re-certification criteria,
- Design and implementation of a comprehensive colposcopy CQI system,
- Establishment of a colposcopy training facility that will:
  - Train new colposcopists to meet the needs of the screening program as it expands as well as the on-going needs of the program as clinicians retire, etc.
  - Run CME courses to maintain workforce skills,
  - Participate in the colposcopy CQI program by undertaking targeted training interventions to resolve quality issues that are related to staff skills.

#### 7.5.2 Colposcopy training and certification

#### 7.5.2.1 Colposcopy specialists

Primary responsibility for colposcopy training and certification in RM would be with the USFM, although the IO has the largest colposcopy clinic (≈15,000 patients/year) and the greatest concentration of colposcopy expertise. Therefore, a colposcopy training program would need to be established as a partnership of these 2 institutions with the USFM responsible for the curriculum, theoretical training and certification, while the IO would be responsible for the clinical training.

As for cervical cytology, RM can access substantial colposcopy expertise through partnerships with Western European organisations and the British Society of Colposcopy and Cervical Pathology (BSCCP) has developed exceptional training programs for both the practice as well as the teaching of colposcopy. However, the hands-on clinical training component of these programs would only be available to RM citizens who also hold a passport from Romania or another EU country. As this is unlikely to be a problem, a collaboration should be established between the USFM, the IO and the BSCCP as described in Section 7.1 and **Error! Reference source not found.**.

As the theoretical training is conducted in groups and much of the clinical training would be restricted to 1 trainee with the instructor, it would not be feasible to have one member of the group translate for the others. Therefore, the trainees will need to have a good knowledge of English to take advantage of this opportunity.

#### 7.5.2.2 Colposcopy nursing staff

As noted in Section 7.5.1, nursing staff are essential to the smooth running of colposcopy clinics and the cost-effective use of the colposcopists' time. The BSCCP recommends that each colposcopy clinic should have ≥2 nurses with one of these being a registered nurse who has also undertaken training in both colposcopy procedures and patient counselling.

The shortage of colposcopy capacity in RM creates a substantial barrier to the implementation of a cervical screening program. Therefore, introducing a training program that provides nurses with the skills to effectively support colposcopists in the clinic would help to overcome this barrier by increasing the number of patients each colposcopist could see per clinic session. The development of this training program could be included within the partnership described in Section 7.5.2.1.

## 7.5.3 Designating colposcopy as a distinct medical specialty

The quality of colposcopy will directly influence the safety and cost-effectiveness of the screening program so it is essential to ensure all colposcopists have the required training and skills. Therefore, colposcopy should be designated as a distinct medical speciality with a defined curriculum, CME requirements, and certification/recertification criteria, and with certification being mandatory to work in the field. In parallel with this, the RM MoH should officially recognise BSCCP certification as equivalent to national certification so people trained in the UK will not need to be recertified in RM.

#### 7.5.4 Evidence-based clinical guidelines and standard operating procedures

Evidence-based clinical guidelines and SOPs for each step in the colposcopic evaluation and treatment of the cervix are essential to ensure these service achieve the expected outcomes and are effectively integrated into the operation of screening program. Clinical guidelines and SOPs are also integral to the standard training curricula, certification criteria, performance standards and CQI processes. The clinical guidelines and SOPs relevant to colposcopy are set out in Table 18.

Table 18: Colposcopy clinical guidelines and SOPs
<ul> <li>Counselling women about abnormal Pap tests and colposcopy procedures,</li> </ul>
<ul> <li>Service provider operation of the cervical screening registry</li> </ul>
Colposcopic evaluation of the cervix
Colposcopically directed cervical biopsy

- Treatment of CIN: surgical techniques including cryocautery and excision
- Treatment of recurrent CIN
- Follow-up after colposcopy: duration, frequency, follow-up cytology
- Management of glandular abnormalities
- Clinico-Pathological Correlation (CPC)/Multidisciplinary Team (MDT) Meeting Guidelines,
- CQI for colposcopy.

The development of clinical guidelines and SOPs for RM can also draw upon work done in other countries. However, this should be coordinated with the colposcopy training described in Section 7.5.2 so the techniques and procedures taught to the trainees will be the same as the ones that will be adapted for use in RM.

## 7.5.5 Colposcopy facility and equipment specifications

As colposcopy hs not been classified as a speciality in RM, the facility and equipment specifications relating to the provision of colposcopy services will not reflect the revised clinicl guidelines, SOPs and performance standards recommended above. Therefore, the RM cervical screening Director of Clinical Services should work with the National Council for Evaluation and Accreditation in Health to review these specifications and revise them to comply with revised procedures.

## 7.6 Evidence-based performance indicators and standards

Performance indicators and standards for many health services in RM have already been established. However, because there are no organised cancer screening programs in RM, these indicators and standards do not include key aspects of 'program performance' that are required to optimise safety, quality and cost-effectiveness. Therefore, the RM cervical screening Director of Clinical Services should work with the Council for Evaluation and Accreditation in Health to review and revise relevant indicators and standards. The cervical screening performance indicators and standards recommended in the European Guidelines are presented in Appendix 11.

## 7.7 New technologies for cervical screening

Cervical screening has undergone many changes during the past 20 years and this has included the development of new technologies to complement or replace the Pap test. The best-characterised of these are liquid-based cytology (LBC) and HPV-testing, and it is important to consider these for use in RM. The benefits and drawbacks of each, compared to the Pap test, are summarised below.

# 7.7.1 The Pap Test

The Pap test is a procedure in which a small sample of cells is collected from the cervix using a spatula or brush and spread on a glass microscope slide that is preserved with a liquid fixative and sent to the laboratory. At the laboratory, the slide is stained to highlight cellular structures and it is examined microscopically for any abnormal cells that may indicate the presence of CIN. The Pap test has a pooled cross-sectional sensitivity for the detection of  $\geq$ CIN2 of  $\approx$ 77%. However, the sensitivity of a screening program based on the Pap test will be higher because cervical cancer takes  $\approx$ 10 years to develop so regular screening within a program allows multiple Pap tests to be conducted over this period. As a result, cervical screening programs can prevent <80% of cervical cancers but reductions of this magnitude are only achieve by organised cervical screening programs with strict quality control and high coverage of the target population.<sup>52,53</sup>

# 7.7.2 Liquid-Based Cytology (LBC)

LBC is a modification of the conventional Pap test in which the cells collected from the cervix are placed directly into a vial of liquid fixative instead of being spread on a microscope slide. The vial is then sent to the laboratory where cells are recovered and used to prepare a cell monolayer on a microscope slide that is stained and examined for abnormal cells.<sup>54</sup>

There are many systematic reviews and meta-analyses comparing the performance of LBC to the Pap test,<sup>55-62</sup> with one of the more widely cited studies concluding the sensitivity and specificity of LBC is not superior to the Pap test.<sup>63</sup> However, all the studies included in the analysis were conducted in expert laboratories where conditions are not representative of routine practice in many countries. As a result, the benefits of LBC are likely to be greater in the majority of countries where cervical cytology is of a lower standard. With regard to other aspects of LBC performance, there is substantial agreement that:<sup>64-66</sup>

- Cytopathologists and cytology screeners consistently prefer LBC because screening and interpretation are facilitated by the uniform presentation of the cervical cells,
- LBC reduces the number of inadequate samples in environments where this is a problem,
- LBC reduces the time required to screen each sample by  $\leq$  30%,
- LBC allows additional testing to be conducted on the preservative medium without the need to recall patients (such as HPV, chlamydia, etc.).

All of these characteristics can improve the operational efficiency of cervical screening programs. However, the cost of the reagents, supplies and equipment needed for LBC are higher than for the conventional Pap so it would be important for RM to undertake a cost-benefit analysis to see if the savings achieved through these efficiencies would offset higher costs. Unfortunately, it would not be possible to compare the cost-effectiveness of LBC to the Pap test in RM until there are reliable RM data on the costs of a conventional Pap test service. It is therefore recommended that RM should start with the development of a conventional Pap-test capacity but plan to evaluate LBC and/or other screening tests in the future.

#### 7.7.3 HPV Testing

High-risk HPV (hrHPV) infection is a necessary (but not sufficient) cause of cervical cancer and testing for hrHPV has therefore been proposed as a screening test for cervical cancer. However, because >90% of infections will resolve spontaneously, the detection of hrHPV only serves as a marker of risk and must be followed-up with another test (such as the Pap test) that has a higher correlation with the presence of clinically relevant CIN. In contrast, because cervical cancer will not develop in the absence of hrHPV infection, a negative HPV test result is an exceptionally strong marker for the absence of cervical disease (negative predictive value typically >99.9%) and longer screening intervals have therefore been proposed for hrHPV negative women.

HPV testing is not recommended for screening women under the age of 30 as the prevalence of transient HR-HPV infection in this group is too high and a large number of women would need to be followed-up unnecessarily. The prevalence of HR-HPV infection is lower in women aged  $\geq$ 30 so the use of HPV testing for primary screening in this age group would be more practical although it is still recommended to triage hrHPV positive women with the Pap test.

A number of large-scale, randomised controlled trails have been undertaken to evaluate test performance over 2 screening rounds. These studies demonstrated:<sup>67-71</sup>

- The sensitivity for the detection of ≥CIN2 of a single hrHPV test when used as a stand-alone primary screening test is 1.5-2.0 times higher than either a single Pap or LBC test,
- The specificity and positive predictive value of a single hrHPV test when used as a stand-alone primary screening test are lower than either a Pap or LBC test,
- Using cervical cytology to triage women with a positive HPV test (i.e. women with a positive hrHPV test subsequently have a Pap test and are referred to colposcopy only if the Pap test is also positive) improves the specificity and PPV of hrHPV testing so it is ≈ equivalent to the Pap test,
- Over 2 screening rounds, the sensitivity, specificity and PPV of hrHPV testing with cytology triage is ≈ equivalent to the Pap test or LBC although hrHPV testing identifies CIN earlier,
- The number of inadequate hrHPV tests is lower than the number of inadequate Pap tests.

As for LBC, the studies noted above were conducted within environments where the cervical cytology (either the conventional Pap test or LBC) would have been of very high quality and this will have minimised differences between hrHPV testing and cytology. As a result, the benefits of hrHPV testing may be greater in environments where the cytology quality is of a lower quality.

Further, these characteristics have implications for operational efficiency of cervical screening programs and it would be important for RM to conduct a cost-benefit analysis to see if the savings achieved through improved efficiencies would offset the higher costs of hrHPV testing. However, this would not be possible until there are reliable RM data on Pap-test provision so it is again recommended that RM start with the development of conventional Pap-test capacity but evaluate hrHPV testing, LBC or another technology in the future.

### 7.7.4 Economic considerations for the new technologies

A further consideration with using LBC and/or hrHPV testing is that all the reagents and equipment must be purchased outside RM while the reagents and equipment needed for the conventional Pap test either are or could be made in the country. Therefore, implementing a screening program using either of the new technologies would contribute to RM's current account deficit (7.0% of GDP in 2012<sup>72</sup>) and reduce scope for investment in public services. In contrast, a Pap test based program would contribute to the development of the local economy and to the equalization of wealth distribution in the country if the manufacturing facilities are either located or established in disadvantaged regions.

## 8. Actions for Implementing an Organised Cervical Screening Program

#### 8.1 Establish the Cervical Screening Coordination office

Actions	Time-Frame	Lead	Partners
Prepare CSO budget & obtain approval.	Yr 1 : Mo 1	CNAM	
Obtain authorisation to hire SCO core staff.			
<ul> <li>Prepare job descriptions for the core SCO staff:</li> <li>Cervical Screening Director (CSD),</li> <li>Director of Clinical Services (DCS),</li> <li>Director of Quality &amp; Risk Management (DQA),</li> <li>Head of IT &amp; Screening Registry Management (H-IT),</li> <li>Head of Communications &amp; Cervical Screening Promotion (H-Comm)</li> <li>Coordinator of PHC training (C-PHC).</li> </ul>	Yr 1 : Mo 1	CNAM	IO ECCA
Recruit SCO core staff.	Yr 1 : Mo 2-6	CNAM	

#### 8.2 Establish relationships for training exchange programs

Actions	Time-Frame	Lead	Partners
Organise RM government delegation visit to the principal partner country: • Liliana Palihovici, Deputy Speaker of the Parliament, • Valentina Stratan, Member of Parliament, • Andrei Usatîi, Minister of Health, • Mircea Buga, Director General CNAM, • Victor Cernat, Director, Institute of Oncology, • CSD.	Yr 1 : Mo 1-6	МоН	CNAM IO CSD ECCA
Undertake government visit to the principal partner country	Yr 1 : Mo 6		

#### 8.3 Initiate training exchange visits for SCO core staff

Actions	Time-Frame	Lead	Partners
Organise initial training exchange visits to the cervical screening program in the principal partner country where the SCO core staff can work directly with their counterparts in the WE screening program: • Cervical Screening Director, • Director of Quality & Risk Management, • Head of IT & Screening Registry Management, • Head of Communications & Cervical Screening Promotion.	Yr 1 : Mo 1-6	CSD	ECCA
Undertake training exchange visits	Yr 1 : Mo 6-9	CSD	ECCA

# 8.4 Establish the National Advisory Committee

Actions	Time-Frame	Lead	Partners
Prepare terms of reference for the Advisory Committee for the implementation & operation of the cervical screening program.	Yr 1 : Mo 1-2	МоН	CNAM IO
Obtain Ministerial Order to establish the Advisory Committee.	Yr 1 : Mo 1-2		
Appoint Advisory Committee members.	Yr 1 : Mo 2-6		
Convene quarterly meetings of the Advisory Committee during the planning and piloting of the cervical screening program.	Yr 1 : Mo 6,9,12 Yr 2 : Mo 3,6,9,12 Yr 3 : Mo 3,6,9,12	МоН	CNAM IO CSD
Convene biannual meetings of the Advisory Committee during the implementation of the cervical screening program.	Yr 4 : Mo 6,12 Yr 5 : Mo 6,12 Yr 6 : Mo 6,12 Yr 7 : Mo 6,12 Yr 8 : Mo 6,12	МоН	CNAM IO CSD

#### 8.5 Maintain the involvement of the stakeholder group

Actions	Time-Frame	Lead	Partners
Monitor activity within the health sector to identify additional organisations with an interest in cervical screening and recruit to the stakeholder group.	Continuous	CSD	Advistory Committee
Deliver all cervical screening program reports to the members of the stakeholder group.	Continuous	CSD	
Convene annual meetings of the stakeholder group for years 1-5 (and continue if requested)	Yr 1 : Mo 12 Yr 2 : Mo 12 Yr 3 : Mo 12 Yr 4 : Mo 12 Yr 5 : Mo 12	CSD	ECCA

## 8.6 Prepare & publish policy documents

Actions	Time-Frame	Lead	Partners
Identify & obtain examples of Cervical Cancer Prevention & Cervical Screening CQI policies from training exchange partner countries.	Yr 1 : Mo 1-6	CSD	DCS DQA ECCA
<ul> <li>Convene the first Advisory Group meeting to:</li> <li>Review the current situation with cervical cancer &amp; its prevention in RM</li> <li>Review the options for prevention &amp; assess compatibility with: <ul> <li>Existing capacities</li> <li>Health sector development plans</li> </ul> </li> <li>Discuss &amp; agree the key elements of the RM Cervical Prevention Policy,</li> <li>Prepare a draft RM Cervical Cancer Prevention Policy &amp; submit to the Advisory Committee for amendment or approval,</li> <li>Submit the final version to the MoH for approval.</li> </ul>	Yr 1 : Mo 6	МоН	
Review existing National policy documents relating to any aspect of cervical cancer prevention & amend or repeal as required to ensure consistency with the RM Cervical Cancer Prevention Policy.	Yr 1 : Mo 6-12	CSD	

#### 8.7 Implement the cervical screening registry

Actions	Time-Frame	Lead	Partners
Work with the WE partner to obtain copies of their cervical screening registry specifications & adapt these to RM for the preparation of the specification for the RM cervical screening registry together with the related IT systems.	Yr 1 : Mo 6	H-IT	National Center for Health Management CNAM-IT WE Partner
<ul> <li>Review legislation, regulations guidelines relating to the:</li> <li>Electronic collection, storage &amp; transfer of personal medical information,</li> <li>Service provider requirements for the collection, recording and/or reporting of the data required for the operation of the cervical screening program.</li> <li>Identify any barriers to the effective operation of the screening registry &amp;</li> </ul>	Yr 1 : Mo 6-12	H-IT	National Center for Health Management CNAM-IT
propose revisions as required.			
<ul> <li>Develop a survey tool to assess:</li> <li>Service provider IT requirements,</li> <li>Service provider training requirements to ensure effective utilisation of the screening registry,</li> <li>To be combined with surveys of service provider knowledge &amp; awareness of organised cervical screening program operation &amp; CQI.</li> </ul>	Yr 1 : Mo 6	H-IT	CNAM-IT WE partner
Undertake survey of service providers and analyse the results	Yr 1 : Mo 6-8	H-IT	CNAM-IT WE partner
Identify other health sector IT projects, assess compatibility/complementarity with the screening registry project & negotiate partnerships if considered appropriate.	Yr 1 : Mo 6-12	H-IT	MoH CNAM-IT
Prepare the cervical screening registry implementation budget & obtain approval.	Yr 1 : Mo 10-12	H-IT	CNAM-IT WE partner
Prepare a plan for the piloting & phased rollout of the cervical screening registry. To be coordinated with the piloting & rollout of the PHC training service as well as the development of the cytology laboratories & colposcopy services.	Yr 1 : Mo 10-12	H-IT	CNAM-IT WE partner
Together with the C-PHC, prepare a training module to teach service providers about the operation of the screening registry. To be included in the PHC outreach training service.	Yr 1 : Mo 10-12	H-IT C-PHC	WE partner
Implement the required modifications to the CNAM database, develop the SCO interface to perform the required operations & establish connections with the cancer registry as well as the death registry.	Yr 1 : Mo 10-12	CNAM-IT	H-IT
Implement the pilot project in 2 rayons to: • Test & refine the screening registry IT systems • Evaluate service provider registrey training program & modify as required.	Yrs 2 - 3	H-IT	CNAM-IT WE partner
To be coordinated with the piloting of PHC training as well as the development of the cytology laboratories & colposcopy services.			
Undertake quarterly progress reviews of the pilot projects and revise the plan as required.	Yr 2 : Mo 3,6,9,12 Yr 3 : Mo 3,6,9,12		
Inititate & undertake the phased roll-out of the cervical screening registry as part of the overall roll-out of the cervical screening program with quarterly reporting to the CSD.	Yrs 4 - 8	H-IT	CSD CNAM-IT WE partner
Undertake 6 monthly progress reviews of the cervical screening registry rollout. To be combined with meetings of the Advisory Committee.	Yr 4 : Mo 6,12 Yr 5 : Mo 6,12 Yr 6 : Mo 6,12 Yr 7 : Mo 6,12 Yr 7 : Mo 6,12 Yr 8 : Mo 6,12	H-IT	

# 8.8 Increase PHC capacity for cervical screening

Anthrop	<b>T</b>	Land	Devilue
Actions	Time-Frame	Lead	Partners
Establish a training exchange partnership with a cervical screening program in WE.	Yr 1 : Mo 1-6	CSD	ECCA
<ul> <li>Work with the WE partner to obtain copies of documents relating to the provision of cervical screening services in PHC, &amp; to adapt these to RM for the preparation of:</li> <li>PHC clinical guidelines &amp; SOPs for screening procedures,</li> <li>PHC screening performance indicators &amp; standards,</li> <li>PHC facilities &amp; equipment specifications,</li> <li>PHC screening CQI policy &amp; specification,</li> <li>Service specification for cervical screening procedures conducted in PHC.</li> </ul>	Yr 1 : Mo 6-9	DCS	MoH PHC Dept. NCEAH CNAM USMF Assoc. Fam-Phys Assoc. Nurses WE partner
Based on the adapted PHC screening CQI policy & specification, design & implement the PHC screening CQI program. To be coordinated with the development of the screening registry to ensure the required data are collected & analyses are performed.	Yr 1 : Mo 8-12	DQA	DCS H-IT WE partner
Review legislation & regulations relating to the delivery of cervical screening procedures by PHC staff, identify any barriers to the effective operation of the screening program & propose revisions as required.	Yr 1 : Mo 8-12	MoH Primary Care Dept.	DCS
Review CNAM contract conditions for PHC facilities & revise to comply with the new facilities, equipment & service specifications.	Yr 1 : Mo 8-12	DCS	CNAM
Review methodological norms for PHC providers under CNAM contract & revise to comply with new guidelines, SOPs, performance indicators, etc.			
Develop a survey tool to assess service provider knowledge & awareness about the operation of organised cervical screening programs. To be combined with surveys of service provider IT & training requirements.	Yr 1 : Mo 6	C-PHC	Assoc. Fam-Phys Assoc. Nurses WE partner
Undertake survey of service providers and analyse the results	Yr 1 : Mo 6-9		
Identify other health sector development projects, assess compatibility/complementarity with the PHC training & negotiate partnerships if appropriate.	Yr 1 : Mo 6-12	С-РНС	MoH PHC Dept. Assoc. Fam-Phys Assoc. Nurses
<ul> <li>The C-PHC will visit the WE partner country to</li> <li>Undertake their PHC training program,</li> <li>Adapt their PHC training curriculum &amp; educational materials to RM.</li> </ul>	Yr 1 : Mo 6-7	C-PHC	CSD ECCA
<ul> <li>Based on the adapted PHC training documents, the training exchange visit, the revised PHC clinical guidelines, SOPs, indicators &amp; standards, &amp; the survey results, define the structure, content, teaching methods, educational materials, evaluation &amp; certification procedures for:</li> <li>The family physician residency &amp; nurse training programs,</li> <li>The PHC outreach training service.</li> </ul>	Yr 1 : Mo 7-8	С-РНС	MoH PHC Dept. USMF DCS Assoc. Fam-Phys Assoc. Nurses WE partner
Design & produce the educational materials for the training of PHC staff including printed materials, teaching models, presentations, web-based distance-learning modules, etc.	Yr 1 : Mo 8-9	C-PHC	USMF Assoc. Fam-Phys Assoc. Nurses WE partner
Prepare the PHC training budget & obtain approval.	Yr 1 : Mo 10-12	C-PHC	CNAM
Work with the USMF & nursing college to implement cervical screening training modules into their programs.	Yr 1 : Mo 10	C-PHC	USMF Nursing College
Prepare job descriptions for the PHC outreach training service staff & undertake recruitment.	Yr 1 : Mo 10	C-PHC	CSD CNAM
Train the outreach training service staff.	Yr 1 : Mo 10-12	C-PHC	
Introduce measures requiring PHC staff to complete the training course as a prerequisite to participating in the cervical screening program. To be coordinated with the pilot projects & the cervical screening program rollout.	Yr 1 : Mo 10-12	МоН	CNAM
Plan & implement a pilot project for the PHC outreach training service in 2 rayons to evaluate the training program & modify as required. To be coordinated with the screening registry pilots as well as the development of the cytology laboratories & colposcopy services.	Yrs 2 - 3	C-PHC	DCS Assoc. Fam-Phys Assoc. Nurses WE partner
Undertake quarterly progress reviews of the pilot projects & revise plans as required.	Yr 2 : Mo 3,6,9,12 Yr 3 : Mo 3,6,9,12	C-PHC	CSD DCS
Prepare schedule & initiate the rollout of the PHC outreach training service so the training & certification of PHC staff is coordinated with the screening program rollout & development of cytology & colposcopy services.	Yrs 4 - 8	C-PHC	CSD DCS
Undertake 6 monthly progress reviews of the PHC outreach training service. To be combined with meetings of the Advisory Committee.	Yr 4 : Mo 6,12 Yr 5 : Mo 6,12 Yr 6 : Mo 6,12 Yr 7 : Mo 6,12 Yr 8 : Mo 6,12	С-РНС	


## 8.9 Increase cervical cytology & cytopathology capacity


Actions	Time-Frame	Lead	Partners
Introduce measures to ensure compliance with the recommended cervical screening age range & screening interval to reduce the volume of Pap testing.	Yr 1 : Mo 1-6	MoH CNAM	
Prepare inventory of each laboratory to characterize the quantity & quality of the facilities & equipment as well as staff number, qualifications & ages.	Yr 1 : Mo 6-9	Ю	MoH Path Comm CSD
Establish a training exchange partnership with a cervical screening program in WE.	Yr 1 : Mo 1-6	IO USMF	CSD ECCA
Work with the WE partner to undertake an external quality review of each cervical cytology laboratory	Yr 1 : Mo 6-9	Ю	CSD WE partner
Work with the WE partner to obtain copies of documents for the provision of gynae cytology, cytopathology & histopathology & adapt these to RM for the: • Cervical cytology & gynae pathology laboratory guidelines & SOPs, • Cervical cytology & gynae pathology performance indicators & standards, • Cervical cytology & gynae pathology CQI policy & specification, • Cervical cytology & gynae pathology facilities & equipment specification, • Service specification for cervical cytology & gynae pathology, • CPC/MDT Meeting Guidelines.	Yr 1 : Mo 6-9	10	MoH-Path Comm NCEAH Assoc. of Pathologists CSD ECCA WE partner
Based on the adapted cervical cytology & gynae pathology CQI policies & specifications, design & implement the RM cervical cytology & gynae pathology CQI programs. To be coordinated with the development of the screening registry to ensure the required data are collected.	Yr 1 : Mo 8-12	DQA	DCS H-IT WE partner
Review legislation, regulations guidelines relating to the delivery of cervical cytology & gynae pathology, identify any barriers to the effective operation of the screening program & propose revisions as required.	Yr 1 : Mo 8-12		
Based on these documents & the inventory results, prepare a plan & budget for the reorganisation of the RM cervical cytology service & obtain approval.	Yr 1 : Mo 10-12	Ю	CSD CNAM
<ul> <li>Work with the WE partner to create a RM nucleus of expertise in cervical cytology screening &amp; cytopathology using the Papanicolaou technique:</li> <li>A WE cytopathologist will visit RM to review the provision of cervical cytology &amp; work with RM experts to prepare plans for: <ul> <li>The phased introduction of the Papanicolaou technique,</li> <li>Converting the IO cervical cytology laboratory to the Papanicolaou technique,</li> <li>Converting the IO cervical cytology training facility within the IO laboratory,</li> </ul> </li> <li>While work is being done on the IO laboratory, 2 cytopathologists &amp; 7 cytotechnicians will go to the WE partner country to: <ul> <li>Be trained in Papanicolaou cytopathology &amp; cervical cytology Screening,</li> <li>Adapt the WE training curricula &amp; certification criteria to RM,</li> <li>1 of the RM trainees will receive additional training in cytology CQI,</li> <li>1 of the RM traines will receive additional training in managing cervical cytology laboratories as part of an organised cervical screening program.</li> </ul> </li> <li>The WE cytopathologist will travel to RM together with the RM trainees to: <ul> <li>Provide support with introducing the Papanicolou technique &amp; CQI,</li> <li>Monitor the quality of services during the initial phase of operation using the Papanicolou technique.</li> </ul> </li> <li>The WE cytopathologist will travel home but maintain contact with the RM staff to monitor performance indicators &amp; intervene as required.</li> <li>The WE cytopathologist will travel to RM to support the RM staff in conducting a full quality review of the IO laboratory. This will service both to assess the quality of the IO laboratory services &amp; to reinforce RM staff skills for undertaking quality reviews of other RM laboratories.</li> </ul>	Yr 1 : Mo 6-12 Yr 1 : Mo 6-12	IO USMF IO USMF	CSD ECCA WE partner
<ul> <li>RM trainees will work with the WE trainers to adapt their training program &amp; teaching materials to RM,</li> <li>Once the Papanicolou technique has become routine in the IO laboratory, the WE cytopathologist will travel to RM to support the staff: <ul> <li>Running the first RM cytology training session using Papanicolaou staining,</li> <li>Reviewing &amp; revising the cervical cytology screening training program.</li> </ul> </li> </ul>			WE partner
Prepare schedule for the training & certification of cytotechnicians. To be coordinated with the plan for reorganisation of cervical cytology services in RM, the implementation of the cervical screening pilots & the phased rollout of the cervical screening program.	Yr 1 : Mo 11-12	IO USMF	CSD
Review & revise relevant instruments to designate cervical cytology screening as a distinct laboratory specialty with a defined training curriculum & certification criteria together with CME & re-certification requirements.	Yr 1 : Mo 11-12 Yr 2 : Mo 1-2	MoH CNAM	CSD
Launch the cervical cytology screening training program with: • Biannual reporting to the IO & CSD, • Periodic progress reviews & modification of the program and/or schedule.	Ongoing as required	IO USMF	CSD CNAM
<ul> <li>Work with the WE partner to establish a cervical cytopathology training facility in the IO:</li> <li>RM cytopathologists will work with the WE partners to adapt their cytopathology training program &amp; teachning materials to RM,</li> <li>The WE cytopathologist will travel to RM to: <ul> <li>Support the RM cytopathologists to run the first cervical cytopathology training session based on the Papanicolaou technique &amp; evaluate trainees,</li> <li>To participate in a CPC/MDT with the colposcopy service.</li> </ul> </li> </ul>	Yr 1 : Mo 7-12	IO USMF	CSD ECCA WE partner

# 8.10 Increase colposcopy capacity

Actions	Time-Frame	Lead	Partners
Prepare an inventory of each colposcopy facility to characterize the quantity & quality of their facilities & equipment as well as staff number, qualifications & ages (gynaecologists, nurses & admin).	Yr 1 : Mo 6-9	MoH CNAM	DCS
Establish a training exchange partnership with a cervical screening program in WE.	Yr 1 : Mo 1-6	IO USMF	CSD DCS ECCA WE partner
Work with the WE partner to obtain copies of documents relating to the provision of colposcopy services & adapt these documents to RM for the preparation of: • Colposcopy clinical guidelines & SOPs, • Colposcopy facility & equipment specifications, • Colposcopy performance indicators & standards, • Colposcopy service specification, • Colposcopy CQI policy & specification, • CPC/MDT Meeting Guidelines.	Yr 1 : Mo 6-9	DCS	ECCA WE partner
Based on the adapted colposcopy CQI policy & specification, design & implement the RM colposcopy CQI program. To be coordinated with the development of the screening registry to ensure the required data are collected & analyses are performed.	Yr 1 : Mo 8-12	DQA	DCS H-IT WE partner
Review legislation, regulations guidelines relating to the delivery of colposcopy services, identify any barriers to the effective operation of the screening program & propose revisions as required.	Yr 1 : Mo 8-12		
Based on the inventory results, prepare a plan & budget for the phased development of colposcopy services in RM & obtain approval.	Yr 1 : Mo 10-12	DCS CSD	MoH CNAM
<ul> <li>Work with the WE partner to create a RM training facility for colposcopists &amp; for colposcopy nurses in the IO:</li> <li>3 RM gynaecologists (who also have a Romanian/EU passport) will attend the WE partner's training courses for colposcopy practice &amp; for the teaching of colposcopy,</li> <li>1 of the RM trainees will undertake an additional training exchange to learn about colposcopy CQI methods &amp; procedures,</li> <li>1 of the RM trainees will undertake an additional training exchange to learn about colposcopy service management &amp; the effective coordination of these services with the operation of a cervical screening program,</li> <li>WE partner colposcopy trainers will visit RM &amp; work with RM trainees to: <ul> <li>Evaluate the IO colposcopy facilities &amp; prepare plans for the establishment of a national training facility for colposcopists &amp; colposcopy nurses,</li> <li>Review the WE partner's colposcopy training curricula, teaching materials, examination methods &amp; certification criteria. &amp; adapt these to RM.</li> </ul> </li> <li>Once the facilities have been prepared, WE partner colposcopy trainers will return to support RM staff: <ul> <li>To run the first training sessions for both colposcopists &amp; colposcopy nurses, &amp; to evaluate the trainees,</li> <li>To refine the colposcopy trainers will maintain contact with the RM colposcopists to: <ul> <li>Include them by video-conference in CPC/MDT meetings,</li> <li>Provide advice &amp; support as required,</li> <li>Monitor performance indicators to identify problems as they arise &amp; recommend remedial action,</li> </ul> </li> <li>The WE partner colposcopy trainers will travel to RM to support the RM staff in conducting a full quality review of the IO colposcopy services. This will both assess the quality of these services &amp; reinforce RM staff skills for undertaking quality reviews of other RM colposcopy services. This will both assess the quality of these services &amp; reinforce RM staff skills for undertaking quality reviews of other RM colposcopy services. This will</li></ul></li></ul>	Yr 1 : Mo 6-12	IO DCS	CSD ECCA WE partner
Prepare schedule for the training & certification of colposcopists & colposcopy nurses. To be coordinated with the plans for development of colposcopy services & the reorganisation of cervical cytology services in RM, the implementation of the cervical screening pilots & the phased rollout of the cervical screening program.	Yr 1 : Mo 11-12	DCS	CSD IO USMF
Review & revise relevant instruments to designate colposcopy as a distinct medical specialty with a defined training curriculum & certification criteria together with CME & re-certification requirements,	Yr 1 : Mo 11-12 Yr 2 : Mo 1-2	МоН	CSD DCS
<ul> <li>Launch the colposcopy training program with:</li> <li>Biannual reporting to the IO &amp; CSD,</li> <li>Periodic progress reviews &amp; modification of the program and/or schedule as required.</li> </ul>	Ongoing as required		

#### 8.11 Implementation actions Gantt chart





Appendix 1: Legislation & orders affecting cervic	al screening
Law/regulation	Provisions dealing with cervical screening
1995	
RML № 411-XIII of 28 March 1995	Article 3 specifies preventive health care as a fundamental principle to ensuring public health.
1997 MHO № 200 of 19 August 1997, "On primary health care reform in Moldova"	Guarantees all Moldovan citizens access to PHC services
GD №1134 of 9 December 1997, "On the development of primary health care"	Guarantees people's access to PHC services and specified measures for improving the quality of PHC services.
1998	
MHO №163 of 21 May 1998, "On reforms of primary health care physician profiles"	Specifies measures to accelerate reform of the health system and facilitates the introduction of a new form of PHC. Appendix 3 includes examinations for breast and cervical cancers within the specified duties of family physicians.
GD № 1269 of 25 December 1998	Approves the national program to fight cancer for 1998-2003.
1999 MHO № 57 of 1 March 1999, "On the improvement of cytology."	
2001	
RML Nº185-XV of 24 May 2001, "On reproductive health and family planning" 2002	Article 7(1) states, "Everyone has the right to receive reproductive health care services and family planning services"
GD № 156 of 11 February 2002, "On the approval of the organization and funding of actions and events that promote healthy lifestyles and reduce the risk of disease." GD № 594 of 14 May 2002, "On the approval of the regulation on carrying out preventive measures (screening)	
for early detection of disease."	
MHO № 141 of 29 May 2002	<ul> <li>Approved additional programs for control and prevention of reproductive tract cancers and established specific measures to combat breast and cervical cancers including:</li> <li>Create a special educational program on the prevention of breast and cervical cancers for gynaecologists, doctors and nurses in PHC,</li> <li>Create multidisciplinary teams of oncologists, surgeons, cytologists and radiologists for the 1° and 2° prevention of breast and cervical cancers,</li> <li>Increase availability of cytology screening as for the prevention of cervical cancer and improve cytology quality assurance measures,</li> <li>Increase family physician participation in breast and cervical cancer prevention.</li> </ul>
Guidelines for Oncology Prophylactic Checks of the Female Population in Moldova. Prof D Sofroni d.h.ş.m., Dr V Cernat d.h.ş.m.; Dr I Lazarev d.h.ş.m., Dr I Iacovlev d.h.ş.m., Prof N Godorogea d.h.ş.m. and Dr L Sofroni d.ş.m.	<ul> <li>Recommends:</li> <li>Annual preventive gynecological examinations for all women aged ≥20 and for sexually active women aged &lt; 20.</li> <li>Pap test once every 2 years for all women aged ≥ 20, taken by CMM nurse, midwife or doctor. In women aged &lt;20, a Pap test is indicated only in the case of visible cervical pathology.</li> </ul>
2005	
MHO №68 of 10 March 2005, "On measures directed to improve cytology services."	Establishes the Republican Cytology Laboratory within the IO with authority for national cytology services delivered through laboratories located in regional medical institutions: SR Cahul, SR Causeni, SR Edineţ, SR Hincesti, SR Orhei, SR Soroca, SR Ungheni, Department of Health for the Municipality of Chişinău, Department of Health for the Municipality of Bălţi, Department of Health for the Municipality of Gagauzia
GD № 913 of 26 August 2005, "Approval of the National Reproductive Health Strategy for 2005-2015" 2006	Approves the National Reproductive Health Strategy (see below for details of the strategy)
MHO № 46 of 31 January 2006, "On the organization in the IMSP Republican, a subdivision for the monitoring and evaluation of medical services."	<ul> <li>Created a new organisation for the monitoring and evaluation of health services including those provided by the IO:</li> <li>Monitor and evaluate the quality of medical services delivered in medical institutions at the municipal and district levels</li> <li>Advise on monitoring and data collection to medical institutions</li> </ul>
MHO № 425 of 12 October 2006, "On the creation of municipal Reproductive Health Offices and Women's Health Centres"	<ul> <li>Introduces the reorganisation of family planning and reproductive health services, with clinics required to provide more services including:</li> <li>Primary and secondary preventive measures for cancer of the reproductive organs in women</li> <li>Diagnostic services for the prevention of breast and cervical cancer</li> <li>Cytologic screening to detect precancerous &amp; cancerous lesions</li> <li>Counselling women with precancerous processes</li> </ul>
2007	· · · ·
GD № 886 of 6 August 2007, "On the approval of the National Health Policy 2007-2021"	Approves the National Health Policy 2007-2021 which includes provisions for the prevention of non-communicable diseases (see below for details)

Appendix 1: Legislation & orders affecting cervic	
Law/regulation	Provisions dealing with cervical screening
GD №1387 of 10 December 2007, "On the single program of mandatory health insurance"	<ul> <li>funding all public health care services in RM. The health insurance regulations specify that:</li> <li>Primary care services will include annual prophylactic medical examination for all persons aged 18+ years,</li> <li>Prophylactic examinations, in accordance with MoH regulations, include</li> </ul>
	CBE and a gynaecological examination with a Pap test.
2008	1
MHO № 504 of 12 October 2008, "On medical prophylactic examination of the population"	<ul> <li>Specifies that prophylactic medical examinations are the responsibility of PHC doctors and must include:</li> <li>Yearly preventive gynecological examination for all women aged ≥15,</li> <li>A Pap test every 2 years for all women ≥20 years of age,</li> <li>CBE every year for women of all ages.</li> </ul>
2009	- concerv year for women of an ages.
MHO/CNAM № 522/207 of 24 December 2009,	Extends annual prophylactic medical examinations conducted in PHC to all Moldovan citizens, whether or not they are registered with CNAM, starting in 2012. Paragraph 26 states, "Prophylactic examinations, including early detection of breast and cervical cancer (CBE and Pap test), are to be provided for all people registered with a GP, established by legislation in force."
2010	1
Ministry Health Order № 695 of 13 October 2010, "On Primary Health Care in Moldova"	<ul> <li>Specifies that:</li> <li>Primary care services can be conducted in: family physician centres, health centres (including autonomous health centres), family physician cabinets, health offices,</li> <li>Family physicians must be able to perform cervical pathology screening with cytology smear collection and interpretation of the results of the cytological analysis; perform screening for mammary gland pathology,</li> </ul>
	<ul> <li>Nurses must be able to perform gynecological examinations and take Pap tests,</li> <li>The facilities note above must have a gynaecological examination couch and vaginal speculums.</li> </ul>
MHO № 722 of 28 October 2010	Authorises HPV vaccination for the female population aged 10 to 18 years. (20,790 doses of Gardasil were received for the vaccination of 6,930 girls. ≈2.5% of the target population was vaccinated.)
2011	
2011 - The MoH - draft regulations for preventive examinations conducted in gynecological cabinets.	<ul> <li>Specifies:</li> <li>Procedure for conducting CBE,</li> <li>Procedure for examining the cervix and taking a Pap test,</li> <li>Minimum equipment required to conduct the examinations (vaginal speculums, vaginal spatula for taking Pap tests, forceps, colposcope),</li> <li>Qualifications (minimum training requirements) for health workers conducting screening examinations.</li> </ul>
MHO № 550 of 30 June 2011, "On Approval the National Clinical Protocol for Cervical Cancer Prevention"	Approves the National Clinical Protocol for Cervical Cancer Prevention. (Amended 4 October 2011)
MHO №743 of 4 October 2011, "On amending and repealing certain orders of the Ministry of Health."	Approved a new list of prophylactic medical examinations of the population including ecto and endocervical cytology once every 2 years for all women aged 20+.
2012	
MHO/CNAM Nº 302/70A of 30 March 2012, "On approval of medical service performance indicators."	<ul> <li>Sets-out PHC performance indicators including:</li> <li>Providing a preventive gynecological examination with cytology sampling once in every 2 year period for each woman registered on the GP list,</li> <li>Payments to GPs are based on validation of the performance indicators and are paid "per service."</li> </ul>
MHO № 722 of 16 July 2012, "On improvement of activity and cytological pathomorphologic services in Moldova."	Recommends the organisational structure of cytology services and confirms authority of the Republican Cytology Laboratory in the IO over all national cytology services.

Appendix 2: Guidelines & protocols affecting	
Strategy/guideline	Provisions dealing with cervical screening or cancer
2002	
Guidelines for Prophylactic Oncology Checks of the Female Population in Moldova. Sofroni D, Cernat V, Lazarev I, Iacovlev I, Godorogea N and Sofroni L.	Recommends a Pap test once every 2 years for all women aged ≥20, taken by a nurse, midwife or doctor. For women aged <20, a Pap test is indicated only in case of visible cervical pathology.
2005	
The National Reproductive Health Strategy for 2005- 2015	<ul> <li>Sets priority areas within the health system for improvement including:</li> <li>Improve the legal framework to facilitate the early diagnosis of breast and cervical cancers,</li> <li>Increase public access to diagnostic services for the prevention of breast and</li> </ul>
	cervical cancer,
	<ul> <li>Improve cytology screening for precancerous lesions and cervical cancer,</li> <li>Provide training in the early detection of breast and cervical cancer to health care providers and specifically to obstetrician-gynaecologists and nurses in rural areas,</li> </ul>
	<ul> <li>Public health education programs to increase public awareness about preventing breast and cervical cancers,</li> </ul>
	• Targets for cervical screening in which the detection rate of cervical cancers in stage 0 will exceed 25.0% and stages I-II will exceed 45.0%.
2007	
National Health Policy 2007-2021 (approved by GD № 866 of 6 August 2007).	Specifies provisions for promoting healthy lifestyles and the prevention of non- communicable diseases.
The Early Detection of Cancer and Precancerous Conditions as Performance Indicators for Family Physicians. CNAM 2007	Set the number of Pap tests conducted as the indicator for the provision of preventive gynaecological examinations with cytology sampling.
2008	
National Program Against Oncologic Diseases in Moldova 2008-2012 (not approved)	Recommended • Annual detection of cancer and precancerous lesions with the support of family
	<ul><li>doctors, regional oncologists and medical specialists.</li><li>Modernizing and popularizing cytology screening for cervical cancer,</li></ul>
2009	Implementation of new methods of pathomorphological detection.
Ghidul Naționala de Profilaxie a Cancerului de col uterin	Recommended:
/ National Guidelines for the Prevention of Cervical Cancer. Authors: Codreanu NP, Friptu VG, Strătilă M, Cernat V. Universitatea de Stat de Medicină și Farmacie	Preventive gynecological examinations, including the Pap test, for all women aged 25-65, once every 3 years for women aged 25-49 and once every 5 years for women aged 50-65.
N.Testemiţeanu. Chişinau 2009	(Was not approved only by gynaecology scientific council.)
2010	
Strategia Naționala de Dezvoltare în Sănătate 2008- 2017 / National Health System Development Strategy 2008-2017	<ul> <li>This strategy specified:</li> <li>Primary care services could be conducted in Centrele Medicilor de Familie, Centrele de Sănătate, Oficiile Medicului de Familie and Oficiile de Sănătate.</li> <li>Family physicians must be able to: <ul> <li>Perform cervical screening with Pap smear collection and be able to interpret the results,</li> </ul> </li> </ul>
	<ul> <li>Perform breast screening.</li> <li>Primary care nurses must be able to perform gynecological examinations including the taking of Pap tests,</li> <li>Facilities conducting PHC must have the equipment required to conduct breast and cervical cancer screening including a gynaecological examination couch</li> </ul>
2014	and vaginal speculums.
	<b>7</b> 1. 1. 1. 1
Cancerul Cervical. Protocol Clinic Naţional/ National Cervical Cancer Clinical Protocol (Approved by the MH)	<ul> <li>This states:</li> <li>PHC institutions are responsible for primary cervical cancer prevention by HPV vaccination of girls aged 11-12 and for the education of girls aged 11-12 about cervical cancer prevention (i.e. safe sex, etc.)</li> </ul>
	<ul> <li>Cervical cancer screening should start with the commencement of sexual activity and continue until the age of 65</li> <li>Pap tests are to be conducted once every 3 years to the age of 30 and once</li> </ul>
	<ul> <li>Pap tests are to be conducted once every 5 years to the age of 50 and once every 5 years from the age of 30 if preceded by 3 normal Pap tests</li> <li>Women with increased risk of cervical cancer are to be screened annually.</li> </ul>
Programul Național de Control al Cancerului in Moldova / National Cancer Control Program in Moldova	
2012	
Strategia Națională de Dezvoltare 2012-2015/National Development Strategy 2012-2015.	Includes recommendations for improving cancer prevention and early detection of breast and cervical cancer.

					ted cervi			ap Tests/Y		
	Total №	Women		Coverag				Coverage		
	Females	Aged 25-64	45%	55%	65%	75%	45%	55%	65%	75%
Chişinău	418,435	233,300	52,493	64,158	75,823	87,488	57,742	70,573	83,405	96,23
Chişinău	352,291	196,422	44,195	54,016	63,837	73,658	48,614	59,418	70,221	81,02
Codru	6,254	3,487	785	959	1,133	1,308	863	1,055	1,247	1,43
Cricova Durlesti	4,558 9,752	2,541 5,437	572 1,223	699 1,495	826 1,767	953 2,039	629 1,346	769 1,645	909 1,944	1,04
Singera	4,187	2,334	525	642	759	2,039	578	706	835	2,24
Vadul lui Voda	2,544	1,418	319	390	461	532	351	429	507	58
Vatra	1,802	1,005	226	276	327	377	249	304	359	414
Chişinău-villages	37,047	20,656	4,648	5,680	6,713	7,746	5,112	6,248	7,384	8,52
North	529,406	295,173	66,414	81,173	95,931	110,690	73,055	89,290	105,524	121,75
Bălți Bălți	80,406 77,760	44,831 43,355	10,087	12,328	14,570 14,091	16,812 16,258	11,096 10,730	13,561	16,027	18,493 17,884
Balţi Bălţi-villages	2,646	43,355	9,755 332	11,923 406	479	553	365	13,115 446	15,500 527	17,88
Briceni	39,533	22,042	4,959	6,061	7,163	8,266	5,455	6,668	7,880	9,092
Briceni	5,198	2,898	652	797	942	1,087	717	877	1,036	1,195
Lipcani	2,940	1,639	369	451	533	615	406	496	586	676
Briceni-villages	31,395	17,504	3,938	4,814	5,689	6,564	4,332	5,295	6,258	7,223
Donduseni	24,083	13,428	3,021	3,693	4,364	5,035	3,323	4,062	4,800	5,539
Donduseni Donduseni-villages	5,714 18,370	3,186	717	876	1,035	1,195	788 2,535	964	1,139	1,314
Donduseni-villages Drochia	18,370 47,212	10,242 26,324	2,304 5,923	2,817 7,239	3,329 8,555	3,841 9,871	2,535	3,098 7,963	3,662 9,411	4,225
Drochia	47,212	5,960	1,341	1,639	1,937	2,235	1,475	1,803	2,131	2,459
Drochia-villages	36,523	20,363	4,582	5,600	6,618	7,636	5,040	6,160	7,280	8,400
Edineţ	43,688	24,359	5,481	6,699	7,917	9,134	6,029	7,368	8,708	10,048
Edineţ	9,697	5,406	1,216	1,487	1,757	2,027	1,338	1,635	1,933	2,230
Cupcini	4,005	2,233	502	614	726	837	553	676	798	921
Edineţ-villages	29,986	16,719	3,762	4,598	5,434	6,270	4,138	5,057	5,977	6,897
Fălești	47,782	26,641	5,994	7,326	8,658	9,990	6,594	8,059	9,524	10,989
Fălești Fălești-villages	8,669 39,113	4,833 21,808	1,087 4,907	1,329 5,997	1,571 7,087	1,812 8,178	1,196 5,397	1,462 6,597	1,728 7,796	1,994 8,996
Floresti	46,800	26,094	5,871	7,176	8,480	9,785	6,458	7,893	9,328	10,764
Floresti	8,008	4,465	1,005	1,228	1,451	1,674	1,105	1,351	1,596	1,842
Ghindesti	988	551	124	151	179	207	136	167	197	227
Marculesti	1,040	580	130	159	188	217	144	175	207	239
Floresti-villages	36,764	20,498	4,612	5,637	6,662	7,687	5,073	6,201	7,328	8,455
Glodeni	32,250	17,981	4,046	4,945	5,844	6,743	4,450	5,439	6,428	7,417
Glodeni Glodeni-villages	6,096 26,154	3,399 14,582	765 3,281	935 4,010	1,105 4,739	1,275 5,468	841 3,609	1,028 4,411	1,215 5,213	1,402
Ocnita	29,565	16,484	3,709	4,533	5,357	6,181	4,080	4,986	5,893	6,800
Ocnita	4,901	2,733	615	751	888	1,025	676	827	977	1,127
Otaci	4,480	2,498	562	687	812	937	618	756	893	1,030
Frunza	896	500	112	137	162	187	124	151	179	206
Ocnita-villages	19,288	10,754	2,420	2,957	3,495	4,033	2,662	3,253	3,845	4,436
Rîşcani	36,540	20,373	4,584	5,603	6,621	7,640	5,042	6,163	7,283	8,404
Rîşcani Costesti	6,995 1,305	3,900 728	877 164	1,072 200	1,267 236	1,462 273	965 180	1,180 220	1,394 260	1,609
Rîşcani-villages	28,240	15,745	3,543	4,330	5,117	5,905	3,897	4,763	5,629	6,495
Sîngerei	47,821	26,663	5,999	7,332	8,665	9,999	6,599	8,065	9,532	10,998
Sîngerei	7,475	4,168	938	1,146	1,355	1,563	1,032	1,261	1,490	1,719
Biruinta	2,150	1,199	270	330	390	450	297	363	429	495
Sîngerei-villages	38,195	21,296	4,792	5,856	6,921	7,986	5,271	6,442	7,613	8,785
Soroca	51,405	28,661	6,449	7,882	9,315	10,748	7,094	8,670	10,246	11,823
Soroca Soroca-villages	19,149 32,445	10,677	2,402	2,936	3,470	4,004	2,642	3,230	3,817	4,404
Center	32,445 544,088	18,090 303,359	4,070 68,256	4,975 83,424	5,879 98,592	6,784 113,760	4,477 75,081	5,472 91,766	6,467 108,451	7,462
Anenii Noi	42,547	23,722	5,338	6,524	7,710	8,896	5,871	7,176	8,481	9,785
Anenii Noi	4,403	2,455	552	675	798	921	608	743	878	1,013
Anenii Noi-villages	38,144	21,267	4,785	5,849	6,912	7,975	5,264	6,433	7,603	8,773
Calarasi	40,188	22,407	5,042	6,162	7,282	8,403	5,546	6,778	8,011	9,243
Calarasi	8,262	4,607	1,036	1,267	1,497	1,727	1,140	1,393	1,647	1,900
Calarasi-villages	31,926	17,800	4,005	4,895	5,785	6,675	4,406	5,385	6,364	7,343
Criuleni	37,354	20,827	4,686	5,727	6,769	7,810	5,155	6,300	7,446	8,593
Criuleni Criuleni-villages	4,241	2,365	532	650 5.077	769 6 000	887 6 922	585	5 5 8 5	845 6 600	97
Criuleni-villages Dubasari-villages	33,113 17,917	18,462 9,990	4,154 2,248	5,077 2,747	6,000 3,247	6,923 3,746	4,569 2,472	5,585 3,022	6,600 3,571	7,610
Hincesti	61,732	9,990 34,419	7,744	2,747 9,465	3,247 11,186	3,746 12,907	8,519	10,412	12,305	4,12.
Hincesti	8,501	4,740	1,066	1,303	1,180	12,907	1,173	1,434	1,694	1,955
Hincesti-villages	53,231	29,679	6,678	8,162	9,646	11,130	7,346	8,978	10,610	12,243

	population					_		uirement		
ſ			v		eened/Yea	r	F	Pap Tests/Y		
	Total №	Women		Coverag				Coverag		
	Females	Aged 25-64	45%	55%	65%	75%	45%	55%	65%	75%
Ialoveni	50,343	28,069	6,315	7,719	9,122	10,526	6,947	8,491	10,035	11,57
laloveni ulauni villagas	7,874 42,469	4,390	988	1,207	1,427	1,646	1,087	1,328	1,569	1,81
laloveni-villages	33,868	23,679 18,883	5,328 4,249	6,512 5,193	7,696 6,137	8,880 7,081	5,860 4,674	7,163 5,712	8,465 6,751	9,763 7,789
Nisporeni Nisporeni	7,402	4,127	4,249	1,135	1,341	1,548	4,674	1,248	1,475	1,70
Nisporeni-villages	26,465	14,756	3,320	4,058	4,796	5,533	3,652	4,464	5,275	6,08
Orhei	65,468	36,502	8,213	10,038	11,863	13,688	9,034	11,042	13,049	15,057
Orhei	17,420	9,713	2,185	2,671	3,157	3,642	2,404	2,938	3,472	4,006
Orhei-villages	48,048	26,789	6,028	7,367	8,707	10,046	6,630	8,104	9,577	11,053
Rezina	26,773	14,928	3,359	4,105	4,851	5,598	3,695	4,516	5,337	6,158
Rezina	6,872	3,831	862	1,054	1,245	1,437	948	1,159	1,370	1,580
Rezina-villages	19,902	11,096	2,497	3,052	3,606	4,161	2,746	3,357	3,967	4,577
Straseni	46,472	25,911	5,830	7,125	8,421	9,716	6,413	7,838	9,263	10,688
Straseni	10,333	5,761	1,296	1,584	1,872	2,160	1,426	1,743	2,060	2,376
Bucovat	662	369	83	101	120	138	91	112	132	152
Straseni-villages	35,477	19,781	4,451	5,440	6,429	7,418	4,896	5,984	7,072	8,159
Soldanesti	22,170	12,361	2,781	3,399	4,017	4,635	3,059	3,739	4,419	5,099
Soldanesti Soldanesti villagos	3,891	2,170	488	597	705	814	537	656	776	895
Soldanesti-villages	18,278	10,191	2,293	2,803	3,312	3,822	2,522	3,083	3,643	4,204
Telenesti Telenesti	37,397 4,133	20,851 2,304	4,691 518	5,734 634	6,776 749	7,819 864	5,161 570	6,307 697	7,454 824	8,601 951
Telenesti-villages	33,264	18,547	4,173	5,100	6,028	6,955	4,590	5,610	6,630	7,650
Ungheni	59,170	32,990	7,423	9,072	10,722	12,371	4,350 8,165	9,980	11,794	13,608
Ungheni	19,202	10,706	2,409	2,944	3,480	4,015	2,650	3,239	3,828	4,416
Cornesti	1,361	759	171	2,344	247	285	188	230	271	313
Ungheni-villages	39,909	22,251	5,007	6,119	7,232	8,344	5,507	6,731	7,955	9,179
South	276,536	154,184	34,691	42,401	50,110	57,819	38,161	46,641	55,121	63,601
Basarabeasca	15,038	8,385	1,887	2,306	2,725	3,144	2,075	2,536	2,997	3,459
Basarabeasca	6,438	3,589	808	987	1,167	1,346	888	1,086	1,283	1,481
Basarabeasca-villages	8,601	4,795	1,079	1,319	1,558	1,798	1,187	1,451	1,714	1,978
Cahul	64,646	36,044	8,110	9,912	11,714	13,516	8,921	10,903	12,886	14,868
Cahul	20,565	11,466	2,580	3,153	3,726	4,300	2,838	3,468	4,099	4,730
Cahul-villages	44,082	24,578	5,530	6,759	7,988	9,217	6,083	7,435	8,787	10,138
Cantemir	31,400	17,507	3,939	4,814	5,690	6,565	4,333	5,296	6,259	7,222
Cantemir	3,000	1,673	376	460	544	627	414	506	598	690
Cantemir-villages	28,400	15,835	3,563	4,355	5,146	5,938	3,919	4,790	5,661	6,532
Causeni	47,073	26,246	5,905	7,218	8,530	9,842	6,496	7,939	9,383	10,826
Causeni Cainari	10,149	5,659	1,273 294	1,556 360	1,839 425	2,122 491	1,401 324	1,712 396	2,023 468	2,334
Causeni-villages	2,346 34,578	1,308 19,279	4,338	5,302	6,266	7,230	324 4,772	5,832	6,892	7,953
Cimişlia	31,405	17,510	3,940	4,815	5,691	6,566	4,334	5,852	6,260	7,333
Cimişlia	7,228	4,030	907	1,108	1,310	1,511	997	1,219	1,441	1,662
Cimişlia-villages	24,178	13,480	3,033	3,707	4,381	5,055	3,336	4,078	4,819	5,561
Leova	26,954	15,028	3,381	4,133	4,884	5,636	3,719	4,546	5,373	6,199
Leova	5,461	3,045	685	837	990	1,142	754	921	1,088	1,256
largara	2,405	1,341	302	369	436	503	332	406	479	553
Leova-villages	19,088	10,643	2,395	2,927	3,459	3,991	2,634	3,219	3,805	4,390
Stefan Voda	36,022	20,084	4,519	5,523	6,527	7,532	4,971	6,075	7,180	8,285
Stefan Voda	4,359	2,430	547	668	790	911	601	735	869	1,002
Stefan Voda - villages	31,663	17,654	3,972	4,855	5,738	6,620	4,369	5,340	6,311	7,282
Taraclia	22,144	12,347	2,778	3,395	4,013	4,630	3,056	3,735	4,414	5,093
Taraclia	7,465	4,162	936	1,145	1,353	1,561	1,030	1,259	1,488	1,717
Taraclia-villages	14,679	8,185	1,842	2,251	2,660	3,069	2,026	2,476	2,926	3,376
UTA Gagauzia	80,511	44,889	10,100	12,345	14,589	16,833	11,110	13,579	16,048	18,51
Comrat	12,675	7,067	1,590	1,943	2,297	2,650	1,749	2,138	2,527	2,915
Ciadir-Lunga	11,537	6,432	1,447	1,769	2,091	2,412	1,592	1,946	2,300	2,653
Vulcanesti UTA Gagauzia-villages	8,532 49,824	4,757	1,070	1,308 7,639	1,546 9,028	1,784 10,417	1,177 6,875	1,439	1,701	1,962
UTA Gagauzia-villages	43,024	27,780	6,250	7,059	9,028	10,417	0,075	8,403	9,931	11,459

Appendix 4: Health facili	tv staff	ing levels in 2011	(% of required staff	levels)	
District	Í	РНС	Hospitals	Specialists	Total
Comrat		100.00	96.20	86.10	87.40
Drochia		98.60	97.60	95.50	97.70
Ceadîr-Lunga	- 0%	97.80	88.20	92.70	84.60
Edineț	≥95.0%	97.10	97.00	95.20	96.80
Chişinău		96.30	95.50	94.50	94.10
Donduseni		95.00	99.20	97.30	96.80
Sîngerei		94.60	98.30	78.30	91.60
Bălți		94.50	99.00	92.10	95.40
Rîşcani		94.10	91.60	91.50	92.70
Ialoveni		93.80	94.50	89.80	88.30
Ocnita	、 。	93.30	91.20	93.20	93.40
Soroca	95%	93.10	95.60	88.60	93.20
Anenii Noi	V I	92.30	98.30	90.60	89.50
Taraclia	90% - <95%	92.10	93.60	76.20	83.20
Telenesti	6	90.90	88.00	84.50	83.00
Vulcanesti		90.50	78.00	79.40	78.20
Straseni		90.40	98.20	77.20	83.50
Briceni		90.20	85.50	82.30	87.30
Dubasari		90.10			81.40
Glodeni		89.70	84.80	79.00	85.50
Cahul		89.10	82.40	83.60	83.20
Calarasi		88.80	88.20	79.20	81.50
Floresti	%	87.50	93.70	85.70	90.20
Soldanesti	80% - %08	85.80	89.70	91.30	82.50
Ungheni	- %	82.90	88.20	89.80	80.40
Basarabeasca	80	82.40	96.10	80.60	82.90
Criuleni		82.00	82.50	86.20	81.00
Cimişlia		81.50	85.60	77.50	75.90
Causeni		81.00	91.10	87.20	78.70
Stefan Voda		76.50	95.70	70.70	76.40
Orhei		74.20	91.30	94.80	82.40
Leova		73.00	99.20	80.80	77.10
Fălești	<80%	72.50	97.40	68.70	76.40
Hincesti	86	71.90	91.90	99.60	81.30
Rezina		71.70	91.00	94.70	79.40
Nisporeni		70.90	89.10	56.60	68.70
Cantemir		52.50	86.60	59.90	62.80

Append	ix 5: Estimate e	eligible num	ber vs. r	eported r	number c	of wome	n screened/	year
		Est. Annual	Repo	rted № Woi	men Screer	ned/Yr	Coverage of	Comments
		Target Population	CMF/	CS/ CDC	OMF	OS	Target Population	
	Chicinău Control	98,211	AMT				Population	
	Chişinău Central AMT Botanica	98,211	12,000					Own lab – 26,840 Paps/yr
	AMT Buiucani		13,200	19,200				Cytology →AMT Centru
	AMT Centru		26,400	26,400				Own lab – 40,054 Paps/yr
	AMT Ciocana		10,800	9,600				Own lab – 20,400 Paps/yr
	AMT Rîşcani		14,400	5,280				Own lab – 16,076 Paps/yr
	Codru	1,743						
	Cricova	1,271						Cytology →AMT Centru
	Durlesti	2,719						Cytology →AMT Centru
	Singera	1,167						
	Vadul lui Voda	709						Cytology →AMT Centru
	Vatra	502						Cytology →AMT Centru
	Chişinău-villages	10,328						
Chişinău		116,650	76,800	60,480			117.7%	
North								
Bălți		22,415		5,7	760		25.7%	Own lab – 42,130 Paps/yr
	Bălți	21,678	3,600					
	Bălți -villages	738		960	1,200			
Briceni		11,021	0.057	3,3	360		30.5%	→Edineţ
	Briceni	1,449	3,360					
	Lipcani Brigani villagas	820						
Dent	Briceni-villages	8,752			140		04.451	1
Donduseni	<b>.</b>	6,714	4 000	5,4	48		81.1%	
	Donduseni Dondusoni villagos	1,593	4,800	480	120	48		
Duashia	Donduseni-villages	5,121				48	F1 10/	
Drochia	Drochia	13,162 2,980	4,800	6,7	20		51.1%	
	Drochia-villages	10,182	4,800	960	960	0		
Edinat	DIOCIIIa-Villages			900		0	92.6%	Own lab – 17,346 Paps/yr
Edineţ	Edineț	12,179 2,703	7,200	11,	280		92.6%	Own lab – 17,346 Paps/yr
	Cupcini	1,117	7,200					
	Edineţ-villages	8,360		3,600	480	0		
Fălești	Luncy Muges	13,320		2.8	380		21.6%	→CDR
i alcști	Fălești	2,417	1,440	2,0			21.070	
	Făleşti-villages	10,904	1,110	960	480	0		
Floresti		13,047			180		26.7%	→CDR
	Floresti	2,232	2,400					
	Ghindesti	275						
	Marculesti	290		960	120	0		
	Floresti-villages	10,249						
Glodeni		8,991		7,2	200		80.1%	→CDR, Bălți
	Glodeni	1,699	2,400					
	Glodeni-villages	7,291		2,400	2,400	0		
Ocnita		8,242		4,3	320		52.4%	
	Ocnita	1,366	1,920		240	0		
	Otaci	1,249						
	Frunza	250		1,920	240	0		
	Ocnita-villages	5,377						
Rășcani		10,187		9,8	340		96.6%	→CDR
	Rășcani	1,950	4,800	ļ				
	Costesti	364		2,400	2,640	0		
-	Rășcani -villages	7,873						
Sîngerei		13,331			540		64.8%	→ Bălți
	Sîngerei	2,084	5,280	960	720	480		
	Biruinta Sîngoroj villagos	599		1,200				
Core	Sîngerei-villages	10,648		1	200		CD 201	Ourplab 25 150 Dece fr
Soroca	C	14,330	7 200	9,7	780		68.3%	Own lab – 25,158 Paps/yr
	Soroca Soroca-villages	5,338	7,200	2 400	100	0		
Conter	Soroca-villages	9,045		2,400	180	0		
Center Anonii Noi		11.001		1	20		36.90/	
Anenii Noi	Anonii N-i	11,861	2 400	3,1	180		26.8%	→10
	Anenii Noi Anenii Noi villages	1,228	2,400	720	60	0		
Călăra -:	Anenii Noi-villages	10,634		720	1	U	21.0%	
Călărași	Călărași	11,204 2,303	2,400	2,4	+24		21.6%	
	Călăraşi-villages	2,303	2,400		24	0		
Criuleni	Cararaşı-villages	10,413		1 1	24 40	U	11.0%	
Chalefil	Criuleni	10,413	1,200	1,1			11.0%	
	Criuleni-villages	9,231	1,200	240		0		
	Chaleni-villages	1 د کر د	I	240	1	U	1	1

Appendix 5: Estimate e							year
	Est. Annual		ted № Wo			Coverage of	Comments
	Target Population	CMF/ AMT	CS/ CDC	OMF	OS	Target Population	
Dubasari-villages	4,995	2,880	240	240	0	67.3%	
Hincesti	17,209	_,		40	-	29.3%	
Hincesti	2,370	4,800	-,-	-			
Hincesti-villages	14,840		240	0	0		
Ialoveni	14,034		5,0	40		35.9%	
laloveni	2,195	3,840					
Ialoveni-villages	11,839		960	240	0		
Nisporeni	9,442	1 0 0 0	9,6	00		101.7%	
Nisporeni Nisporeni-villages	2,064 7,378	4,800	2,400	1,920	480		
Orhei	18,251		2,400	-	460	32.9%	→CDR
Orhei	4,856	2,400	0,0	00		32.376	
Orhei-villages	13,395	2,100	720	1,680	1,200		
Rezina	7,464		9,6		,	128.6%	→CDR
Rezina	1,916	6,000	,				
Rezina-villages	5,548		720	1,920	960		
Straseni	12,955		1,4	40		11.1%	
Straseni	2,881	1,200					
Bucovat	184		240	0	0		
Straseni-villages	9,890			60		02.2%	
Soldanesti Soldanesti	6,180 1,085	1,440	5,7	υU		93.2%	
Soldanesti-villages	5,096	1,440	2,400	720	1,200		
Telenesti	10,425			00	1,200	57.6%	→CDR
Telenesti	1,152	3,360	0,0			57.670	
Telenesti-villages	9,273		720	1,920	0		
Ungheni	16,495		7,6	80		46.6%	Own lab – 35,698 Paps/yr
Ungheni	5,353	6,000					
Cornesti	379		960	480	240		
Ungheni-villages	11,126						
South						00.00/	
Basarabeasca Basarabeasca	4,192 1,795	1,200	3,3	60		80.2%	→10
Basarabeasca-villages	2,398	1,200	720	720	720		
Cahul	18,022		6,8		720	38.0%	Own lab – 38,128 Paps/yr
Cahul	5,733	6,000	0,0			50.070	
Cahul-villages	12,289		720	120	0		
Cantemir	8,754		12,	000		137.0%	
Cantemir	836	7,200					
Cantemir-villages	7,917		2,400	2,400	0		
Căuşeni	13,123		5,5	20		42.1%	Own lab – 12,477 Paps/yr
Căușeni	2,829	4,800					
Cainari Căuseni -villages	654 9,640		480	240	0		
Cauşeni -vinages Cimişlia	9,640 8,755		7,6	80		87.7%	→10
Cimişlia	2,015	2,400	1,200	720	720	07.770	
Cimişlia-villages	6,740	-,	1,200	720	720		
Leova	7,514		3,0			39.9%	→IO, RDC, Cahul
Leova	1,522	2,400					
largara	670		480	72	48		
Leova-villages	5,321				-70		
Ştefan-Vodă	10,042	2	8,4	00		83.7%	
Ştefan-Vodă	1,215	2,400	2,600	2.400	0		
Ştefan-Vodă - villages Taraclia	8,827		3,600 2,6	2,400	0	43.4%	
Taracila Taraclia	6,173 2,081	1,920	2,6	0		43.4%	
Taraclia-villages	4,092	1,520	480	240	36		
UTA Găgăuzia	22,445			048		53.7%	
Comrat	3,534	5,520	_,				
Ciadir-Lunga	3,216	3,600	2,400	0	0		
Vulcanesti	2,379	480	24	24	0		
UTA Găgăuzia-villages	13,890						
Total	515,615	206,640	125,544	26,400	6,852	70.9%	
.000	,010		365	676			

Laboratory	Status	laboratory staffing Cyto-technicians	Cyto-pathologists	Pathologists	Spe	cimens/yr	
Institute of	Operational	5 x FTE	5 X FTE		Result	Nº	%
Oncology	Operational	JAFIE	JAFIE	-	Normal	48,854	77.25%
JICOlogy					Inflammation	9,818	15.53%
					ASC-US	2,574	4.07%
					AGC	136	0.22%
					ASC-H	384	0.61%
					LSIL	1,168	1.85%
					HSIL	286	0.45%
					Carcinoma	18	0.03%
					Total	63,238	100.0%
Republic Diagnostic	Operational	3 FTE	3 FTE	-	Result	Nº	%
Centre					Normal	31,451	73.29%
					Endocervicoză	830	1.93%
					Inflamation	10,400	24.23%
					AGC	ND	ND
					LSIL (+ASC-US)	76	0.18%
					HSIL (+ASC-H)	124	0.29%
					Susp. Carc.	8	0.02%
					Carcinoma	22	0.05%
					Total	42,891	100.0%
AMT Botanica	Operational	1 x FTE	0.5 FTE	-	Result	Nº	%
					Normal	21,162	78.84%
					Endocervicoză	1,605	5,97%
					Inflamation	3,815	14,21%
					AGC	-	
					LSIL (+ASC-US)	113	0,42%
					HSIL(+ASC-H)	98	0,36%
					Susp. Carc.	47	0,17%
					Carcinoma	-	
					Total	26,840	100,0%
AMT Buiucani	Not operational,	contracts services from	AMT Centru				
AMT Centru	Operational	2 x FTE	2 x FTE		Result	Nº	%
					Normal	26,753	66,79%
					Inflamation	10,816	27,00%
					AGC	15	0,03%
					LSIL (+ASC-US)	238	0,59%
					HSIL (+ASC-H)	110	0.27%
					Carcinoma	22	0.05%
					Total	40,054	100.0%
AMT Ciocani	Operational	1 x FTE	0.5 FTE		Result	N♀	%
					Normal	20,088	98.47%
					Inflamation	147	0.72%
					ASC-US	10	0.04%
					AGC	ND	ND
					LSIL	12	0.05%
					HSIL (+ASC-H)	8	0.03%
					Carcinoma	3	0.014%
					Total	20,400	100.0%
AMT Rîşcani	Operational	0.5 FTE	1 x FTE		Result	Nº	%
					Normal	13,597	84.57%
					Endocervicoză	1,090	6.80%
					Inflamation	1,340	8.33%
					AGC	ND	ND
					LSIL (+ASC-US)	11	0.68%
					HSIL (+ASC-H)	32	0.19%
					Carcinoma	6	0.037%
					Total	16,076	100.0%
Anenii Noi	Not operational.	Contracts services from	the IO & RDC?				
Bălți	Operational	4.5 FTE	1 FTE		Result	2012	%
parti		4.3 FIE	TLIC		Normal		- /0
					Trihomoniaza	349	- 0.8%
					Endocervicoză	1149	2.7%
					Inflamation	4975	2.7%
					AGC	-	11.070
					LSIL (+ASC-US)	608	1.44%
					HSIL (+ASC-US)	35	0.08%
							5.50/0
							0.35%
					Susp. Cr. Carcinoma	148 33	0.35% 0.07%

Laboratory	Status	Cyto-technicians	Cyto-pathologists	Pathologists	Spee	cimens/yr	
Basarabeasca	Not operational. Cor						
Briceni	Stopped operations						
Bricem	in 2013						
Cahul					Cutologios: 25	120	
					Cytologies: 35,2		
Căușeni	Operational	1 FTE	1 FTE	1 FTE	Result Normal	№ 12,180	% 97.61%
					Endocervicoză	154	1.23%
					Inflammation	125	1.00%
					ASC-US	ND	ND
					AGC	ND	ND
					ASC-H	ND	ND
					LSIL HSIL	 15	0.12%
					Carcinoma	3	0.12%
					Total	12,477	100.0%
Cimiclia	Not operational. Con	tracts convisos from	the IO			,	1
Cimişlia	Not operational. Cor						
Drochia	Not operational. Cor		T T				
Edineţ	Operational	1 FTE	1 FTE		Result	NՉ	%
					Normal	14,848	85.6%
					Inflamation	2,387	13.8%
					Endocervicoză ASC-US	78 17	0.45%
					AGC	ND	0.09%
					ASC-H	ND	ND
					LSIL	5	0.03%
					HSIL	5	0.03%
					Susp. Carc.	11	0.06%
					Carcinoma	6	0.03%
					Total	17,346	100.0%
Glodeni	Not operational. Cor	ntracts services from	Bălți				
Leova	Not operational. Cor	ntracts services from	the IO & RDC				
Sîngerei	Not operational. Cor	ntracts services from	Bălți				
Soroca	Operational	1 FTE	1 FTE		Result	Nº	%
					Normal	20,486	81.43%
					Inflamation	2,803	11.14%
					Endocervicoză	1.829	7.27%
					ASC-US	ND	ND
					AGC	ND	ND ND
					ASC-H LSIL	ND 16	0.03%
					HSIL	26	0.08%
					Susp. Carc.	-	-
					Carcinoma	9	0.02%
					Total	25,158	100.0%
Ungheni	Operational	1.25 x FTE	1 x FTE		Result	N⁰	%
					Normal	29,070	81.43%
					Inflamation	3,976	11.14%
					Endocervicoză ASC-US	2,596 ND	7.27% ND
					AGC	ND	ND
					AGC ASC-H	ND	ND
					LSIL	10	0.03%
					HSIL	27	0.08%
					Susp. Carc.	11	0.03%
					ouspi ourer		0.0070
					Carcinoma	8	0.02%

Appendix 7: Sei	rvices	& eq	uipm	ent fo	r foll	ow-u	p of a	bnori	nal Pap	tests 8	cervica	l surge	ery	
	Colposcopy	Cervical Surgery	Gynaecological Couch	Vaginal Speculums	Endocervical Speculums	Biopsy Forceps	ECC Curette	Forceps	Autoclave/steriliser	Colposcope	LEEP	Cryo	DEC*	Refer to IO
Chişinău														
AMT Botanica	~	?												
CS Femeii "Dalila"	~	~												
AMT Buiucani	~	~	1	D	-	2	1	T 5 NT 5 Sp 10		1xDoM				?
AMT Centru	~	~	12	D	-	2		T 32 NT 8	1x1989 1x1989	1x2010 1x2010	0	0		?
AMT Ciocani	~	~	14	D	-	2	260	T 5 NT 5 Sp 10	1x2006	1x2002	0	0		?
AMT Rîşcani	~	~	26	D	-	3	0	0	3x1988 1x2008 4x2009	1x1984 1x1987 1x2003 1x2010	0	0	1x1975 1x1978 1x1982 1x2010	?
North			10	-				-		4 9999				
Bălți CMF	<b>~</b>	Х	18	D	0	0	0	0	0	1x2003				-
CS Briceni	~		2	D	0	0	0	0	0	1x1989	0	0	0	?
Briceni (Auto) CS Lipcani			6	D	0	0	0	0	0	0	0	0	0	Briceni
Donduşeni CMF	Х	Х	1	?	30	0	0	0	1xDoM	1x2005	0	0	0	~
Dondușeni (Auto) CS Sudarca	~	~	7	D	0	0	0	0	1x2009	1x1998	0	0	1x2009	IO & Bălți
Drochia CMF	~	~	14	D	?	8	2	Т5 NT5 Sp2		1xDoM				
Edineţ CMF	~	х	44	D	0	0	0	0	0	1x2008	0	0		IO & Bălți
Făleşti CMF	Х	Х	3							1x2009				
CS Chetriş														
CS Briceni	Х	Х												
Florești CMF	х	x	19	L 20 M 30 S 20						1x2004				~
Glodeni CMF	х	x	5	L 5 M 16 S 30	0	2	2	T 2 NT 7	1xDoM 1x2009	1x2004	1xDoM		1xDoM	~
Ocniţa CMF	х	х	9	L 10 M 10 S 10	0	0	0	0	1x2009					~
CS Rîşcani	~	Х	28	D	0	0	0	0	1x2003	1x2003	-	-	-	~
CS Sîngerei Noi	~	~	15	L 10 M 20 S 30	0	0	0	10	0	1x2003	?	0	1x1990	?
Soroca CMF	~	~	15							1x2005			1xDoM	?
Center														
Anenii Noi CMF	~	~	10	D	0	0	0	0	-	1x2004	1xSoviet	0	1xSoviet	~
Călărași CMF	~	~	25	D	0	10	10	0	0	3x2003	?	0	1x1976	~
CS Pirljolteni	х	х	1	L 30 M 23 S 12	0	0	1	0	0	0	0	0	0	?
Criuleni CMF	~	X	9	L 10 M 15 S 2	0	0	0	0	0	1x2004	0	0	0	?
Dubăsari CMF	Х	Х	10											?
Hînceşti CMF	Х	Х	21	D	0	0	0	0	0	1x2006	0	0	-	?

	Colposcopy	Cervical Surgery	Gynaecological Couch	Vaginal Speculums	Endocervical Speculums	Biopsy Forceps	ECC Curette	Forceps	Autoclave/steriliser	Colposcope	LEEP	Cryo	DEC*	Refer to IO
										(NF)				
Ialoveni CMF	~	~	17	L 20 M 40 S 20						1xDoM			1xDoM	
CS Nisporeni	~	~	18	D	0	20	10	0	0	1x2007		0	1xDoM	?
Orhei CMF	Х	Х	29	D	0	0	0	0						
CS Teleșeu (Auto)		?	1										1xDoM	
Rezina CMF	х	~	2	L 8 M 29 S 7						1x2006 (NF)	1x2011			
Strășeni CMF	No Staff	No Staff	14	D						1xDoM	1xDoM			
Şoldăneşti CMF	Х	Х	2		9.									
Teleneşti CMF	х	Х		L 8 M 26 S 4										
Ungheni CMF	~	~	16	D	0	0	0	0	1x2012	1x2000	?	0	1xDoM	?
South														
Basarabeasca CMF	х	Х	2	L 7 M 13 S 3	0	0	0	0	0		1x1983	0	1x1983	?
Cahul CMF	Х	Х	17	0	0	0	0	0	0	0		1xDoM		
Cantemir CMF	•	Х	44	D	1	0	0	0	1x2003	1x2006	0	0	0	?
Căuşeni CMF	Х	Х	34	-	0	0	0	0	0	0	0	0	1xDoM	?
Cimişlia CMF	Х	Х	33	D	0	0	0	0	4	1x2005	0	0	1xDoM	?
Leova CMF	Х	Х	1	D	0	0	0	0	0	0	1x2009	0	0	?
CS Ştefan-Vodă	~	~	21	L 12 M 15 S 10	0	0	0	T 5 NT 5 Sp 10	0	1x2005	1x2011	0	1x2009	~
CS Taraclia	No Staff	No Staff	14							1x2011				
UTA Găgăuzia														
Comrat CMF	~	~	11	-	0	0	0	0	1xDoM	1x2006	1x1979	0		
Ceadîr-Lunga CMF	Х	Х	9	D	0	0	0	0	0	0	0	0	0	?
CS Copciac	Х	Х		D	0	0	0	0	1xDoM		0	0	0	?
Vulcănești CMF	No Staff	No Staff	1	D	0	0	0	0	2xDoM	1x2005	0	0	0	?
Totals:	24	17							Total:	37	8	1	18	
									≥2000	29	3		3	
									≥2000NF	2				
									<2000	4	3	0	7	
								1	???	4	2	1	8	

\*Diathermic electroconisation

	CNAM	Database			sc	O/Scree	ening Registry	
	Data Source		ent to SCO		SCO Actio		Data Out	
	<ul> <li>Sources outside the cervical screening program</li> </ul>	<ul> <li>Identification women eligib</li> <li>Details of all F colposcopy cl participating i screening pro</li> </ul>	details of all le for screening PHC and inics and staff in the cervical gram aboratories and ting in the	<b>→</b>	<ul> <li>Characterize the sc population by area</li> <li>Characterize the ne clinics and laborate participating in the</li> <li>Identify screening g by clinic catchmeni</li> <li>Calculate CQI perfc clinic &amp; staff memt</li> <li>Target CME progra members based on performance</li> <li>Identify under-scree populations</li> </ul>	reening etwork of pries program: population area prmance by per ms to staff CQI	<ul> <li>each clinic, laboratory and staff</li> <li>each clinic, laboratory and staff</li> <li>CME recommendations for each staff member</li> </ul>	
•	<ul> <li>PHC</li> <li>Cytopathology</li> <li>Colposcopy</li> <li>Histopathology</li> </ul>	See below		<b>&gt;</b>	•		<ul> <li>Monthly lists of women to be screened:</li> <li>Routine screening recall (2 years)</li> <li>Short recall (6 months)</li> <li>Repeat Pap test (3 months)</li> <li>Pap test results with follow-up recommendations</li> <li>Lists of women who have defaulted from screening or referra</li> <li>Operate failsafe system to flag process discrepancies for</li> </ul>	
	Other I	Databases					investigation	
•	Cancer Registry	<ul> <li>Identification developing or cervical cance</li> <li>Cervical cance mortality</li> </ul>	dying from er	$\rightarrow$	functioning of the	orogram	ify & resolve problems with the ce & track progress over time	
		women who l			eligible for cervical	Ser cering.		
				PH	0			
	Data Sent to CN	AM		PHC PHC Ac		[	Data Received from SCO	
	Data Sent to CN Clinic identification Staff identification (for each I		  •			[	Data Received from SCO	
	Clinic identification	Pap test) ampling I aginal vault eened	Identify & recru	PHC Ac	tions	<ul> <li>Monthly</li> <li>Routine</li> <li>Short red</li> </ul>	Data Received from SCO (lists of women to be screened screening recall (2 years) call (6 months) Pap test (3 months)	
	<ul> <li>Clinic identification</li> <li>Staff identification (for each l</li> <li>Women screened</li> <li>Satisfactory/unsatisfactory sz</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or va</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Women attended but not scr</li> <li>Women invited but refused</li> </ul>	Pap test) ampling I aginal vault eened	Identify & recru screened	PHC Act uit eligib	le women to be	Monthly     Routine     Short rei     Repeat F	(lists of women to be screened screening recall (2 years) call (6 months) Pap test (3 months) result – unsatisfactory, repeat Pap	
	<ul> <li>Clinic identification</li> <li>Staff identification (for each l</li> <li>Women screened</li> <li>Satisfactory/unsatisfactory sz</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or va</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Women attended but not scr</li> <li>Women invited but refused</li> </ul>	Pap test) ampling I aginal vault eened	Identify & recrustions of the screened     Council womenhave a repeat i     Notify women	PHC Ac uit eligib	le women to be	<ul> <li>Monthly</li> <li>Routine</li> <li>Short ref</li> <li>Repeat F</li> <li>Pap test test in 3</li> </ul>	<ul> <li>result – unsatisfactory, repeat Pap months</li> </ul>	
	<ul> <li>Clinic identification</li> <li>Staff identification (for each l</li> <li>Women screened</li> <li>Satisfactory/unsatisfactory sz</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or va</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Women attended but not scr</li> <li>Women invited but refused</li> </ul>	Pap test) ampling I aginal vault eened	<ul> <li>Identify &amp; recrustive screened</li> <li>Council womer have a repeat i</li> <li>Notify women about 2 year re</li> <li>Council womer</li> </ul>	PHC Ac uit eligib about r n 3 mon of result call	tions le women to be results & the need to ths s and remind them results the need to be	<ul> <li>Monthly Routine</li> <li>Short rei</li> <li>Repeat F</li> <li>Pap test test in 3</li> <li>Pap test routine</li> </ul>	<ul> <li>result – unsatisfactory, repeat Pap months</li> </ul>	
	<ul> <li>Clinic identification</li> <li>Staff identification (for each l</li> <li>Women screened</li> <li>Satisfactory/unsatisfactory sz</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or va</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Women attended but not scr</li> <li>Women invited but refused</li> </ul>	Pap test) ampling aginal vault eened ed, not found py or for further	Identify & recrusscreened     Council womenhave a repeat i     Notify womenabout 2 year re     Council womenre-screened in	PHC Ac uit eligib n about r n 3 mon of result call n about r 6 month n about f	tions le women to be results & the need to ths s and remind them results the need to be s	<ul> <li>Monthly Routine</li> <li>Short rei</li> <li>Repeat F</li> <li>Pap test test in 3</li> <li>Pap test routine i</li> <li>Pap test months</li> <li>Pap test referral cytopatt</li> </ul>	result – unsatisfactory, repeat Pap months	
	<ul> <li>Clinic identification</li> <li>Staff identification (for each I</li> <li>Women screened</li> <li>Satisfactory/unsatisfactory sa</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or va</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Women attended but not scr</li> <li>Women invited but refused</li> <li>Women known to have move</li> <li>Women referred to colposco investigations at the IO</li> <li>Women referred but refused</li> <li>Women moved out of the are</li> </ul>	Pap test) ampling aginal vault eened ed, not found py or for further ea copy	Identify & recruscreened     Council womer have a repeat i     Notify women about 2 year ree     Council womer re-screened in     Council womer the required for     Council default	PHC Ac uit eligib about r n 3 mon of result call about r 6 month about p llow-up ers abou to comp	tions le women to be results & the need to ths s and remind them results the need to be is Pap test results and procedures	<ul> <li>Monthly Routine</li> <li>Short rei</li> <li>Repeat F</li> <li>Pap test test in 3</li> <li>Pap test routine i</li> <li>Pap test referral cytopath informat</li> <li>Women</li> </ul>	<ul> <li>(lists of women to be screened screening recall (2 years) call (6 months)</li> <li>Pap test (3 months)</li> <li>result – unsatisfactory, repeat Pap months</li> <li>result – no abnormalities found, recall</li> <li>results requiring re-screening in 6</li> <li>results requiring referral, with recommendations and nologist contact details for further</li> </ul>	

## Appendix 8: Screening registry data requirements and flows

	Cytopathology	
Data Sent to CNAM	Use	Data Received from SCO
<ul> <li>Laboratory identification</li> <li>Staff identification (for each Pap test)</li> <li>Specimen type</li> <li>Squamous cell results</li> <li>Endocervical cell results</li> <li>Other/non-cervical cell analysis</li> <li>Follow-up recommendations</li> </ul>	<ul> <li>Anticipate sample receipt and initiate tracing of Pap tests that do not arrive at lab</li> <li>Investigate and resolve failsafe notices</li> <li>Allows laboratory staff and managers to understand how their performance compares to agreed standards, other laboratories and program averages to:         <ul> <li>Identify sub-standard performance so targeted remedial action can be taken to resolve problems</li> <li>Introduce competition for quality of services and thereby motivate laboratory staff to achieve and exceed the standards.</li> </ul> </li> </ul>	<ul> <li>Pap tests taken and date sent to lab</li> <li>Previous Pap test results</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or vaginal vault</li> <li>Appearance of cervix</li> <li>Additional clinical comments</li> <li>Failsafe notices to be investigated</li> <li>CQI reports comparing program, laboratory and staff performance: <ul> <li>Time from receipt of Pap test to reporting of results</li> <li>Proportion of unsatisfactory results</li> <li>Proportion of positives</li> <li>Distribution of cytology results</li> </ul> </li> </ul>
	Colposcopy & Cervical Surgery	1
Data Sent to CNAM	Use	Data Received from SCO
Clinic identification     Colposcopist identification     Appointment attendance <del>Colposcopic opinion     Colposcopic opinicolposcopic opinion     Colposcopic opinico     Colposcopic opinio</del>	<ul> <li>Anticipate patient appointment and initiate tracing of defaulters</li> <li>Ensures access to referral Pap test result and related clinical information</li> <li>Investigate and resolve failsafe notices</li> <li>Allows colposcopy staff and clinic managers to see how their performance compares to agreed standards and other clinics: <ul> <li>Identify sub-standard performance so targeted remedial action can be taken to resolve problems</li> <li>Introduce competition for quality of services and thereby motivate staff to achieve and exceed the standards.</li> </ul> </li> </ul>	<ul> <li>Women referred and date of referral</li> <li>Referring clinic/clinician identification</li> <li>Referral Pap test result and/or clinical indications</li> <li>Pap test history</li> <li>Additional clinical comments</li> <li>CQI reports for colposcopy clinic and staff performance:         <ul> <li>Time from referral to appointment</li> <li>Biopsy rate</li> <li>Proportion of women treated after screen detected CIN1</li> <li>Proportion of women treated after screen detected ≥CIN2</li> <li>Proportion of women having a hysterectomy after screen detected CIN</li> <li>Positive predictive value of colposcopy referral</li> <li>Distribution of histology results</li> <li>Cancer incidence after treatment for CIN</li> </ul> </li> </ul>
	Histopathology	
Data Sent to CNAM	Use	Data Received from SCO
<ul> <li>Specimen adequacy</li> <li>Margin status</li> <li>Histology result</li> <li>Pathologist's recommendations</li> </ul>	<ul> <li>Anticipate patient appointment and initiate tracing of defaulters</li> <li>Ensures access to required clinical information</li> <li>Investigate and resolve failsafe notices</li> <li>Allows laboratory staff and managers to understand how their performance compares to agreed standards, other laboratories and program averages to:         <ul> <li>Identify sub-standard performance so targeted remedial action can be taken to resolve problems</li> <li>Introduce competition for quality of services and thereby motivate laboratory staff to achieve and exceed the standards</li> </ul> </li> </ul>	<ul> <li>Specimen referred and date of referral</li> <li>Referring clinic/clinician identification</li> <li>Colposcopic opinion and clinical details</li> <li>CQI reports: <ul> <li>Time from receipt of sample to reporting of results</li> <li>Proportion of unsatisfactory results</li> <li>Proportion of positives</li> <li>Distribution of histology results</li> </ul> </li> </ul>

Appendix 9: SCO -	- Key staff positions, responsibilities & qualifications
Position	Responsibilities & Qualifications
Cervical Screening Director	Overall responsibility for the costs, service delivery and quality of the cervical screening program when operating together with overall responsibility for program implementation. The principal duties include:
	• Convene and coordinate the working groups required to develop the various policy, planning and service documents.,
	<ul> <li>Establish the Advisory Committee, facilitate its operation and initiate actions as required to implement thier recommendations,</li> </ul>
	<ul> <li>Liaise with the MoH and other government agencies, other CNAM departments as well as regional and municipal agencies to facilitate the implementation and operation of the screening program,</li> <li>Liaise with the IO, USFM and professional associations as required to facilitate the implementation and operation of the cervical screening program,</li> </ul>
	<ul> <li>Manage the operation of the SCO, including the recruitment, selection, day-to-day management, appraisal and development of the SCO staff,</li> </ul>
	• Prepare the cervical screening program implementation plan, supervise its progressive implementation and intervene as required to facilitate progress, monitor implementation progress and report to the MoH and CNAM,
	• Monitor and evaluate the provision of cervical screening services where the program is operational to identify and characterise substandard services and initiate remedial actions,
	• Develop new policies, directives and strategic changes to improve service quality and efficiency, with the support of external partners as required, and initiate their implementation
	<ul> <li>Prepare and submit budgets to CNAM, monitor and manage expenditure,</li> <li>Represent the cervical screening program to all external organisations and the public.</li> </ul>
	This person must be a medically qualified professional with clinical experience in some or all of the health services involved in cervical screening (PHC, cytology, colposcopy and cervical surgery, gynae-oncology) as well as experience in the administration of a cancer screening service or similar population health program within RM as a detailed knowledge of the RM health system will be essential. In addition, fluency in English is required, as the CSD will need to communicate effectively with a wide range of organisations in Western Europe to facilitate training exchanges.
Clinical Director, Colposcopy	As colposocopy is specific to cervical screening, the cervical screening program must be responsible for coordinating this service through the Clinical Director, Colposcopy (CDC). The CDC will also be responsible for clinical procedures conducted by PHC staff for the cervical screening program, while cervical cytology screening will continue to be coordinated by the IO.
	Therefore, the Clinical Director, Colposcopy will have overall responsibility for ensuring the colposcopy service and cervical screening related clinical procedures conducted by PHC staff are of high quality and comply with international recommendations and best practice. The principal duties of the CDC will include:
	<ul> <li>Monitor international recommendations and best practice for relevant clinical services, assess their applicability to RM and make recommendations to the CSD and Advisory Committees,</li> <li>Work with the IO, USFM and professional associations to develop or revise relevant curricula and certification criteria, guidelines and SOPs, indicators and standards,</li> </ul>
	<ul> <li>Work with the PHC, Pathology and Colposcopy Advisory Committees to ensure their recommendations comply with the RM screening policy and international recommendations,</li> <li>Monitor the delivery of relevant clinical services to identify substandard performance and initiate remedial action,</li> </ul>
	<ul> <li>Support the Cervical Screening Coordinators to identify and resolve issues relating to the provision or coordination of clinical services,</li> </ul>
	<ul> <li>Maintain direct contact with clinical staff to identify &amp; resolve issues before they become problems,</li> <li>Serve as the spokesperson for the cervical screening program on clinical issues.</li> </ul>
	This person must be a medically qualified professional with training and clinical experience colposcopy together with a detailed knowledge of the operation of an organised cervical screening program and the provision of clinical services within the RM health system. In addition, fluency in English is required, as the CDC will need to communicate effectively with a wide range of
	organisations in Western Europe to facilitate training exchanges.

Appendix 9: SCO -	- Key staff positions, responsibilities & qualifications
Position	Responsibilities & Qualifications
Director of CQI and Risk Management	CQI and risk management are essential to achieving and maintaining the required quality standard for all the administrative and health services involved in the delivery of the cervical screening program. Therefore, responsibility for CQI and risk management must be at Director level to ensure this person has sufficient authority to ensure all the component services comply with the CQI and Risk Management (CQIRM) policy.
	The Director of CQI and Risk Management will have overall responsibility for ensuring the CQIRM policy is fully and continuously implemented at all levels of the cervical screening program. The principal duties include: • Monitor and evaluate international CQIRM recommendations for cervical screening to assess their
	<ul> <li>applicability to RM and make recommendations to the CSD and Advisory Committees,</li> <li>Lead the preparation of the CQIRM policy by facilitating the participation of the MoH, CNAM, IO, USMF and professional associations together with NGOs/CSOs representing the public perspective,</li> <li>Participate in the preparation of relevant curricula and certification criteria, guidelines and SOPs,</li> </ul>
	<ul> <li>performance indicators and standards to ensure these are coordinated with the CQIRM policy,</li> <li>Monitor the delivery of relevant services to identify non-complicance with the CQIRM policy and initiate remedial action to resolve the problem,</li> <li>Monitor indicate communications with corporation program and clinical staff to identify and resolve</li> </ul>
	• Maintain direct communications with screening program and clinical staff to identify and resolve issues before they become problems.
	This person requires professional qualifications in health services quality and/or risk management together with experience in the health field. A detailed knowledge of the structure and operation of an organised cervical screening program will be required.
Head of IT and Screening Registry Management	<ul> <li>The Head of IT and Screening Registry Management will have overall responsibility for the design, implementation and operation of the IT systems needed for effective operation of the cervical screening program, centered on the cervical screening registry. The principal duties include:</li> <li>Prepare the specification for the RM cervical screening program registry and associated IT systems including the CQI programs for each component service,</li> </ul>
	<ul> <li>Work with the Head of the CNAM Department of Information Systems to develop the cervical screening registry as a component of the CNAM database and implement required modificatons,</li> <li>Manage the piloting and implementation of the screening registry including the installation of the field-based components required to submit and receive data,</li> <li>Oversee the ongoing operation of the screening registry and associated systems, and make</li> </ul>
	<ul> <li>Oversee the ongoing operation of the screening registry and associated systems, and make modifications as required to accommodate new policies and procedures,</li> <li>Undertake special data queries as required for reports, analyses, audits, etc.</li> </ul>
	This position requires specialist qualifications and experience in database design, operation and maintenance as well as the collection, verification and analysis of confidential health data. In addition, a detailed knowledge of the operation and data requirements of an organised cervical screening program will be required.
Head of Communications and Cervical	The Head of Communications and Cervical Screening Promotion will have overall responsibility for informing, educating and encouraging women to participate in the cervical screening program. Duties will include:
Screening Promotion	<ul> <li>Monitor and evaluate international recommendations and best practice for cancer screening program communications and promotion,</li> <li>Commission the design and implementation of advortising comparison</li> </ul>
	<ul> <li>Commission the design and implementation of advertising campaigns,</li> <li>Commission the design and launch of the cervical screening program website,</li> </ul>
	<ul> <li>Work with the Advisory Groups to prepare/confirm the content of any educational or promotional materials (such as advertising campaigns, the website, brochures, posters, etc.)</li> </ul>
	<ul> <li>Prepare and publish educational materials for the general public</li> <li>Identify and characterise underserved groups, and develop mechanisms to encourage these women to attend for screening,</li> </ul>
	<ul> <li>Work with the MoH, CNAM, other government agencies, NGOs, etc. to ensure relevant educational, promotional or outreach activities are well coordinated with the screening program,</li> <li>Work with NGOs/CSOs to encourage and facilitate their participation in campaigns to raise</li> </ul>
	awareness of the cervical screening program and promote screening attendance.
	Cancer screening program communications and promotion is a highly complex field so this position will require specialist qualifications in health communications and/or health psychology. In addition, a detailed knowledge of the factors influencing cancer screening program recruitment will be essential.

Appendix 9: SCO -	<ul> <li>Key staff positions, responsibilities &amp; qualifications</li> </ul>
Position	Responsibilities & Qualifications
Cervical Screening Coordinators	<ul> <li>An organised cervical screening program requires the efficient coordination of 3 key services: PHC, pathology and colposcopy. Therefore, a Cervical Screening Coordinator should be appointed for each service to:</li> <li>Be the single point of contact with the cervical screening program for each group of service providers so they can easily get a rapid response to any questions or issues that may arise,</li> <li>Maintian regular communications with the service providers to identify and resolve performance issues as they arise and promote best practice within each service,</li> <li>Communicate program updates to the service providers and work with them to ensure changes are smoothly integrated into practice in the field,</li> <li>Record and report any problems that have been identified so the related procedures can be amended to prevent recurrence or improve performance,</li> <li>Support other screening program staff, such as the CDC, Coordinator of PHC Training, etc. to facilitate their interactions with the service providers.</li> </ul>
	The 3 Cervical Screening Coordinators should be located within the same office so they can work closely together as many of the issues they will handle will involve more than 1 service.
	The Clinical Screening Coordinators require a good knowledge of their respective services, such as that obtained through a nurse or laboratory technician training program, together with very good organisational, communications and problem solving skills. In addition, a detailed knowledge of the operation of an organised cervical screening program will be required.
Coordinator of PHC	The Coordinator of PHC Training will responsible for CME training of PHC staff. The principal duties will include:
Training	<ul> <li>Interact with the CDC, IO, USFM and other partners to prepare or revise the training curriculum for PHC staff,</li> <li>Organise and implement CME training sessions for PHC staff to ensure they have the knowledge and skills (administrative, counseling and clinical) required to fulfill their roles in the cervical screening program,</li> <li>Organise and implement special training programs to introduce changes or new developments in</li> </ul>
	the cervical screening program to PHC staff,
	<ul> <li>Work with the Cervical Screening Coordinators to resolve issues relating to training of PHC staff,</li> <li>Organise and implement targetted training intervations to resolve issues identified by the CQI program.</li> </ul>
	This position requires a good knowledge of PHC service delivery within the RM health system, such as that obtained through a nurse training program with subsequent practical clinical experience in PHC, gynaecology or RH services, and good communications skills and/or teaching experience. In addition, a detailed knowledge of the operation of an organised cervical screening program will also be required.

Appendix 10: Minimum data reporting requirements			
Facility	Data		
PHC – Pat test submission <sup>73</sup>	<ul> <li>Patient surname</li> <li>Patient forename</li> <li>Patient surname at birth and any previous surnames</li> <li>Patient address + postcode</li> <li>Patient correspondence address (if different from registered address)</li> <li>Patient date of birth</li> <li>Patient health insurance number</li> <li>Clinic name, address and registration number</li> <li>Staff name and registration number (the person who took the cervical sample</li> <li>Date of last menstrual period</li> <li>Type of sample: cervical or vaginal vault</li> <li>Appearance of cervix: normal, suspicious, or not seen</li> <li>Confirmation that the cervix was fully visualised and a 360° sample was taken</li> <li>Previous Pap test results</li> </ul>		
Cytopathology	<ul> <li>Additional clinical comments</li> <li>Specimen type</li> <li>Squamous cell results</li> <li>Endocervical cell results</li> <li>Other/non-cervical cell analysis</li> <li>Follow-up recommendations</li> </ul>		
PHC – Colposcopy referral	<ul> <li>Referral indication: abnormal screening cytology; abnormal smear after colposcopy; clinically suspicious cervix; suspicious symptoms; other</li> <li>@@ervical cytology: no cytology; negative (normal cytology); inadequate; ASC-US; ASC-H; AGUS; LSIL, HSIL; ? invasive cancer; ? glandular neoplasia</li> </ul>		
Colposcopy & Cervical Surgery <sup>74</sup>	<ul> <li>Attendance: attended; defaulted (cancelled by patient in advance; cancelled by patient on the day; cancelled by clinic; did not attend - no advance warning; arrived late; left without being seen)</li> <li>Improvement of lesion: ectocervix; extends into endocervical canal (upper limit seen); extends into endocervical canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); extends onto vagina</li> <li>Improvement canal (upper limit not seen); value (upper limit seen); extends (upper limit not seen); extends (upper limit not seen); extends (upper limit not seen); value (upper limit not seen); value (upper limit not seen); extends (upper limit not seen); extends (upper limit not seen); extends (upper limit no</li></ul>		
Histopathology (biopsy, excised tissue)	<ul> <li>Biopsy adequacy: satisfactory; unsatisfactory</li> <li>Histology: unsatisfactory/inadequate; normal (no HPV or cervicitis); HPV or cervicitis; CIN 1; CIN 2; CIN 3; invasive squamous (la1); invasive squamous (la2); invasive squamous (lb+); CGIN; invasive adenocarcinoma; VaIN 1; VaIN 2; VaIN 3; invasive vaginal carcinoma,</li> <li>Margin status (not applicable to punch biopsies): incompletely excised at endocervical margin; completely excised at endocervical margin; excision status not specified; not applicable</li> </ul>		

	pendix 11: Performance indicators for cervical screening <sup>23</sup> Indicator	Calculation
4		
1	Program extension/coverage calculated regionally and nationally	N <sup>o</sup> targeted women
		in catchment area
		N <sup>o</sup> targeted women in
		the region or country
2	Program recruitment during the screening interval, stratified by 5 year age groups	$N^{\circ}$ women screened in
		the screening interval
		N <sup>°</sup> targeted women
		living in catchment area
3	Compliance to invitation (within six months after the end of the screening interval)	N <sup>o</sup> invited women screened
5		N° women invited
	Properties of eligible women receiled within the coreoning interval	<u>N° women recalled</u>
	Proportion of eligible women recalled within the screening interval	
		N <sup>o</sup> women eligible for recall
	Compliance to recall invitation (within six months of the end of the screening	N° recalled women screened
	interval)	N <sup>o</sup> women recalled
6	Time (in working days) between:	
	<ul> <li>screening test and reporting of result to patient</li> </ul>	
	<ul> <li>positive screening test result and offer colposcopy appointment</li> </ul>	
	<ul> <li>colposcopy appointment and reporting of results to patient</li> </ul>	
	colposcopy/biopsy result and offer of appointment for treatment	0
7	Pap tests/woman screened (include only the initial Pap test, not repeat tests such as	N° Pap tests in the interval
	those conducted after unsatisfactory tests or for follow-up)	$N^{\circ}$ women screened in the
		interval
8	Proportion of women requiring repeat Pap tests (calculate for initial screening	N° women requiring repeat Pap
-	appointment & recall screening appointment)	N <sup>o</sup> women screened
9	Compliance with repeat Pap testing (calculate for the initial screening appointment	<u>N° women having repeat Pap</u>
9		N <sup>o</sup> women referred for repeat Pa
	& recall screening appointment)	
10	Proportion of screen positive women (calculate for the initial screening	N° women with a positive Pap
	appointment & recall screening appointment)	N <sup>o</sup> women screened
11	Distribution of cytology results (calculate for the initial screening appointment &	N° of each cytological diagnosis
	recall screening appointment)	N <sup>o</sup> women screened
12	Referral rate to colposcopy (calculate for the initial screening appointment & recall	N° women referred to colposcop
	screening appointment)	N <sup>°</sup> women screened
12	Compliance with referral to colposcopy (Calculate for 3 months after referral, 6	N <sup>o</sup> women attending colposcopy
13	months after referral and by referral cytology)	N° women referred to colposcopy
4.4		$N^{\circ}$ women having a biopsy
14	Biopsy rate (calculate for the initial screening appointment & recall screening	
	appointment)	N <sup>°</sup> women having colposcopy
15	Proportion of women treated after screen detected CIN1	N° women with CIN1 treated
		N <sup>o</sup> women with CIN1
16	Proportion of women treated after screen detected ≥CIN2	N° women with CIN2/3 treated
		N° women with CIN2/3
17	Proportion of women having a hysterectomy after screen detected CIN	N <sup>o</sup> women with CIN
1/	Proportion of women naving a hysterectomy after screen detected city	
		having a hysterectomy
		N <sup>o</sup> women with CIN
18	Positive predictive value of colposcopy referral (Calculate overall and for referral	<u>N<sup>°</sup> women with ≥ CIN1</u>
	cytology, initial screening appointment, recall screening appointment & for grade of	N <sup>o</sup> women referred
	CIN)	to colposcopy
19	Distribution of histology results (Calculate for histology result, initial screening	N <sup>°</sup> women with CIN+
-	appointment & recall screening appointment)	N <sup>°</sup> screened women
20		N <sup>o</sup> women having
20	Cancer incidence after normal cytology (Calculate for interval from index cytology	
	and by cancer morphology)	cancer after normal cytology
		N <sup>o</sup> person-years of screened
		women for same period

#### **References:**

- 1 Beginning with the end in mind: planning pilot projects and other programmatic research for successful scaling up. World Health Organization 2011
- 2 Don de Savigny and Taghreed Adam (Eds). Systems thinking for health systems strengthening. Alliance for Health Policy and Systems Research, WHO, 2009
- 3 Atun R. Health systems, systems thinking and innovation. Health Policy and Planning 2012;27:4-8
- 4 Atun RA, Kyratsis I, Jelic G, et al, Diffusion of complex health innovations--implementation of primary health care reforms in Bosnia and Herzegovina. Health Policy Plan 2007;22:28-39
- 5 International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Vol. 7. Breast Cancer Screening. Lyon: IARC Press, 2003
- 6 International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Vol. 10: Cervix Cancer Screening. Lyon, France: IARC Press, 2005
- 7 Kramer BS: The science of early detection. Urol Oncol 2004;22(4):344-7
- 8 Ferlay J, Boyle P, et al. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488
- 9 Levi F. Inequalities in health in Europe, Brit Med J 2001;322:798
- 10 Munoz N, Bosch FX, de Sanjose S, et al. Epidemiological Classification of Human Papillomavirus Types Assocaited with Cervical Cancer. N Engl J Med 2003;348:518-27
- 11 Winer RL, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26
- 12 Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am 2005;19:439-58
- 13 Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;19:182-92
- 14 De Vuyst H, Clifford GM, Li N and Franceschi S. HPV Infection in Europe. Eur J Cancer 2009;45:2632-9
- 15 OS GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8
- 16 Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of HPV persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24
- 17 Rodriguez AC, Burk R, Herrero R, et al. The natural history of HPV infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis. 2007;34:494-502
- 18 Nasiell K, Roger V and Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9
- 19 Nash JD, Burke TW, Hoskins WJ. Biologic course of cervical human papillomavirus infection. Obstet Gynecol 1987;69:160-2
- 20 Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35
- 21 Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8
- 22 International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Vol. 10: Cervix Cancer Screening. Lyon, France: IARC Press 2005
- 23 European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening (Second Edition). Office for Official Publications of the European Communities, Luxembourg (2008)
- 24 Solomon D, Davey D, Kurman R, et al.: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9
- 25 Solomon D, Davey D, Kurman R, et al.: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9
- 26 Melnikow J, Nuovo J, Willan AR, et al: Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92 (4 Pt 2): 727-35, 1998
- 27 Arends MJ, Buckley CH, Wells M: Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 51 (2): 96-103, 1998
- 28 Holowaty P, Miller AB, Rohan T, et al: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91 (3): 252-8, 1999
- 29 McCredie MR, Sharples KJ, Paul C, et al.: Natural history of cervical neoplasia and risk of invasive cancer in women with CIN 3: a retrospective cohort study. Lancet Oncol 9 (5): 425-34, 2008
- 30 Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35
- 31 Arends MJ, Buckley CH, Wells M: Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998;51: 96-103
- 32 Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91 (3): 252-8, 1999
- 33 Sadler L, Saftlas A, Wang W, et al.: Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 291 (17): 2100-6, 2004
- 34 Lindeque BG. Management of cervical premalignant lesions. Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):545-61

- 36 Gramma R, Spinei L, Buffalo A and Jemma S. Analysis of the health of the population of Moldova in terms of statistical indicators. Study prepared under the project, "Strengthening the National Statistical System," UNDP, Moldova, 2010
- 37 Cancer Registry, Republic of Moldova
- 38 European health for all database. Copenhagen, WHO Regional Office for Europe (<u>www.euro.who.int/en/what-we-do/data-and-evidence/databases/european-health-for-all-database-hfa-db2</u>)
- 39 Ministerul Sănătății al Republicii Moldova, Centrul Național de Management în Sănătate, Anuarul statistic al sistemului de sănătate din Moldova, anul 2011, Chişinău, 2012
- 40 National Centre of Health Management, 2011
- 41 Quality assurance guidelines for the cervical screening programme. NHSCSP 1996.
- 42 Working Party of the Royal College of Pathologists. Achievable standards , benchmarks for reporting , criteria for evaluating cervical pathology. Cytopathology 1995;6:301–3.
- 43 Buntinx, Knottnerus J, Crebolder H, et al. Does feed-back improve the quality of cervical smears? a randomised controlled trial. The British journal of general practice : the journal of the Royal College of General Practitioners 1993;43:194–8
- 44 Cecchini S, Ciatto S, Lossa A, et al. Effective cytological sampling [letter]. The Lancet 1989;ii:393.
- 45 CNAM Institutional Development Strategy 2013-2017, 13 November 2012.
- 46 Martin-Hirsch PPL, Jarvis GG, Kitchener CS, Lilford R. Collection devices for obtaining cervical cytology samples. Cochrane Database of Systematic Reviews 2000, Issue 3. Art. №: CD001036
- 47 Sadler L, Saftlas A, Wang W, et al.: Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 291 (17): 2100-6, 2004
- 48 Lindeque BG. Management of cervical premalignant lesions. Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):545-61
- 49 CNAM Institutional Development Strategy 2013-2017, 13 November 2012.
- 50 Best Practice Guidance for Colposcopy Clinic Staffing and Workload. Version 2. February 2012. http://www.neyhgarc.nhs.uk/LinkClick.aspx?fileticket=cGGX4be4ONs%3D&tabid=93&mid=926
- 51 Colposcopy and Programme Management Guidelines for the NHS Cervical Screening Programme. Second edition. NHSCSP Publication No 20 May 2010. <u>http://www.cancerscreening.nhs.uk/cervical/publications/ nhscsp20.pdf</u>
- 52 Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65
- 53 Franco EL, Duarte-Franco E and Rohan TE. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect Prev. 2002;26:350-61
- 54 Hutchinson ML, Isenstein LM, Goodman A, et al: Homogeneous sampling accounts for the increased diagnostic accuracy using ThinPrep Processor. Am J Clin Pathol 1994;101:215-219
- 55 Karnon J, Peters J, Platt J, et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8(20):73-8
- 56 Noorani HZ, Brown A, Skidmore B, Stuart GCE. Liquid-based cytology and human papillomavirus testing in cervical cancer screening [Technology report no 40]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Available at: www.cadth.ca/media/pdf/197\_cervical\_cancer\_tr\_e.pdf
- 57 Goblirsch G, Kastner T, Madden J, et al. Liquid-based cervical cytology [ICSI technology assessment report no 76]. Bloomington (MN): Institute for Clinical Systems Improvement; 2003. Available at: www.icsi.org/technology\_assessment\_reports\_-\_active/ta\_liquid-based\_cervical\_cytology.html
- 58 Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185(2):308-17
- 59 Klinkhamer PJ, Meerding WJ, Rosier PF, Hanselaar AG. Liquid-based cytology. Cancer 2003;99(5):263-71
- 60 Sulik SM, Kroeger K, Schultz JK, et al. Are fluid-based cytologies superior to the conventional Papanicolaou test? A systematic review. J Fam Pract 2001;50(12):1040-6
- 61 Moseley RP, Paget S. Liquid-based cytology: is this the way forward for cervical screening? Cytopathology 2002;13(2):71-82
- 62 Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-32
- 63 Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167-77
- 64 Moss SM, Gray A, Legood R, Henstock E. Evaluation of HPV/LBC. Cervical screening pilot studies. First report to the Department of Health on evaluation of LBC (December 2002). Institute of Health Sciences (Oxford); 2003.
- 65 Sherman ME, Schiffman MH, Lorincz AT, et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 1997;81:89-97
- 66 Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:S7–11.
- 67 Ronco, G. et al. efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–257

<sup>35</sup> Globocan 2008

- 68 Kotaniemi-Talonen L, Anttila A, Malila N, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer. 2008;44:565-71
- 69 Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72.
- 70 Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
- 71 Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTisTiC): a randomised controlled trial. Lancet Oncol. 2009;10:672-82
- 72 Moldova Economic Update 2013, World Bank: www.worldbank.org/content/dam/Worldbank/document/eca/Moldova-Economic-Update.pdf
- 73 British Society for Clinical Cytology, Recommended Code of Practice for Laboratories Participating in the UK Cervical Screening Programmes, 2010
- 74 BSCCP Revised Minimum Dataset for Colposcopy Services, 2006